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Alzheimer’s disease (AD), Vascular Dementia (VaD), Mixed dementia 
(MIX), Parkinson’s Disease Dementia (PDD) and Dementia with Lewy 
Bodies (DLB) are common brain diseases affecting the aging population. 
N-methyl-D-Aspartate (NMDA) receptor and α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors are important in 
dementia because of their roles in cognitive function and fast excitatory 
neurotransmission respectively. However, while glutamatergic 
dysfunction has been fairly well characterized in AD, their status in VaD, 
MIX, PDD and DLB is unclear.  
Methodology: Postmortem brain tissues samples of VaD, MIX, PDD and 
DLB as well as age-matched control subjects which were obtained from 
established longitudinal studies in United Kingdom and United States of 
America were subjected to measurements of NMDA and AMPA receptor 
protein levels. Clinical data such as cognitive and behavioral assessments, 
obtained from our collaborators were then used in correlative analysis 
with NMDA and AMPA receptor changes observed. 
Results and conclusion  
Lewy body dementia (Chapter 3) 
Using a clinically well-characterized cohort of patients with Lewy body 
dementias (DLB and PDD), it was reported that moderate losses of AMPA 
receptor GluA2/3/4 subunits in the parahippocampal gyrus region 
correlated with pre-death Hoehn and Yahr scores and with longer 
Parkinson’s disease duration before dementia onset.  In this cohort, 
GluA2/3/4 immunoreactivities did not correlate with pre-death MMSE 
scores or cortical LB scores; and also did not appear to be affected by 
senile plaque or neurofibrillary tangle burden. This suggests that GluA 
subunit changes in Lewy body dementia which could lead to 
corticostriatal dopamine–glutamate imbalances may be a neurochemical 
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marker of severity or chronicity of parkinsonism. This findings also 
suggest that although clinically defined PDD and DLB are two aspects of 
the same entity and share similar brain changes, PDD appears to be 
characterized by higher GluA2/3/4 losses, and also manifests more 
severe motor disability and longer duration of parkinsonism.  This data 
suggest caution in extending therapeutic rationales of Parkinson’s Disease  
such as AMPA receptor antagonist  to lewy body dementias in view of 
altered levels of receptor drug targets. Further studies to elucidate the 
relationships between parkinsonism, dementia and GluA neurochemical 
alterations are needed.  
Cerebrovascular-associated dementia (Chapter 4) 
Using a clinically well-characterized cohort of patients with subcortical 
ischemia vascular dementia (SIVD) and MIX, it was found that GluA2 
immunoreactivity and mRNA were up-regulated in temporal cortex of 
SIVD, but remained unchanged in MIX. Furthermore, higher GluA2 
immunoreactivity was associated with milder cognitive impairment and 
lower concentrations of Aβ42 peptide and phosphorylated tau. This 
suggests that GluA2 up-regulation may be an adaptive process in SIVD, 
and that this process is repressed in the presence of concomitant AD in 
mixed dementia. Also, there was a significant reduction of NMDA receptor 
GluN1 only in MIX, while significant upregulation of GluN2A and GluN2B 
were found only in SIVD. Furthermore, GluN1 loss and GluN2A/2B 
upregulation was associated respectively with higher Braak stages and 
lacunar infarct scores. This suggest that the differential alterations of 
NMDA/AMPA receptor  subunits in SIVD and MIX may result from 
separate, interacting disease processes, and suggest  potential utility of 
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GLUTAMATERGIC SYSTEM IN CENTRAL NERVOUS 
SYSTEM 
1.1 INTRODUCTION 
The glutamatergic system is the most widespread neurotransmitter 
system in the Central Nervous System (CNS); it plays an important role in 
physiological excitatory synaptic transmission and the normal functioning 
of the nervous system. Glutamate is an excitatory neurotransmitter which 
activates post synaptic receptors causing a depolarization and promotes 
the generation of action potential (Curtis et al., 1959).  
As a primary excitatory neurotransmitter, glutamate plays a major role in 
allowing the nervous system to rapidly convey sensory information and 
complex motor commands from one part of body to another and also in 
the formation of thoughts and memories. Glutamate is involved in Long 
Term Potentiation (LTP), which is a form of a synaptic strengthening that 
last for a long time and is caused by repeated short and high frequency 
stimuli.  During LTP, the post-synaptic neuron is more sensitive to the 
same pre-synaptic stimuli, thus increasing the amplitude of the excitatory 
postsynaptic current (EPSC). LTP is thought to be responsible for learning 
and memory (Baudry and Lynch, 2001) . 
As the major and most abundant excitatory neurotransmitter, glutamate 
can cause damage in the brain when there is excess in the synaptic cleft.  
Glutamate excitotoxicity is known to occur in stroke, brain injury and 




The excessive glutamate found in the synaptic cleft will bind to the α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 
and N-methyl-d-aspartate (NMDA) receptors, causing depolarization in 
the former and excessive calcium influx in the latter.  It is therefore of 
interest to investigate the status of the glutamatergic system in other 
neurodegenerative diseases which are not as well studied such as 
cerebrovascular disease mediated Vascular Dementia(VaD) and Mixed 
dementia (MIX) as well Lewy Body mediated disease such as Parkinson’s 
Disease with Dementia(PDD) and Dementia with Lewy Bodies (DLB).  
 
1.2 Glutamate synthesis 
Similar to all amino acid, glutamate has a carboxyl, an amino functional 
group and a side chain attached to the same carbon. The non-essential 
amino acid glutamate can be found ubiquitously and in high 
concentration in different parts of the brain. Glutamate, which is widely 
found in neurons and glia, serves a number of roles in the mammalian 
brain; (1) it is a neurotransmitter and also a precursor of the inhibitory 
neurotransmitter γ-aminobutyric acid (GABA); (2) an important 
component of metabolic functions such as protein synthesis and 
intermediatary metabolism; (3) serves an energy substrate. Because of its 
different roles, glutamate is found in separate pools; neurotransmitter 
glutamate is found in the vesicles of glutamatergic terminals, glutamate 
that act as a precursor of GABA is located in GABAergic neurons and that 
of precursor of glutamine is located in glial, while metabolic pool of 
glutamate is present in all cells as it is the byproduct of energy 
metabolism. These pools communicate with each other to ensure 
adequate supply of glutamate. An imbalance of glutamate regulation may 
thus cause the essential amino acid to be toxic. 
 As glutamate does not cross the blood-brain barrier, it must be 
synthesized in neurons from local precursors. The most prevalent 
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precursor for glutamate synthesis is glutamine which is released by glial 
cells. Once released, glutamine is taken up into presyanaptic terminals 
and metabolized to glutamate by enzyme glutaminase in mitochondria. 
Another source of glutamate synthesis by transamination of α-
ketoglutarate, an intermediate of the tricarboxylic acid cycle(TCA) 
(Meldrum, 2000). After synthesis, glutamate is packaged into synaptic 
vesicles by transporter called VGLUTs and is released from pre-synaptic 
neurons to post synaptic neurons. Depending on a proton gradient that 
VGLUTs created by hydrolysing Adenosine Triphosphate (ATP) with the 
vacuolar H(+) ATPase(V-ATPase), VGLUTs allow the flow of hydrogen 
ions into synaptic vesicles thus generating pH gradient across the 
membrane.  At least three different VGLUT genes have been identified 
VGLUT1-3 in mammals. VGLUT1 and VGLUT2 are largely found in the CNS 
and are considered markers of excitatory terminals, while VGLUT3 is less 
abundant in CNS, it is found to be localised with non-glutamatergic 
neurons(Liguz-Lecznar and Skangiel-Kramska, 2007). Glutamate binds to 
glutamate receptors on the postsynaptic cell once released. The glutamate 
released in the synaptic cleft can be either inactivated by enzymatic 
degradation or reuptake into neurons and/or glial cells by active 
transport system. There are five different types of high affinity glutamate 
transporters also known as excitatory amino acid transporter (EAATs1-5) 
in glial cells and all presynaptic terminals. These membrane-bound 
pumps act by binding onto glutamate and transferring them into the cell. 
High glutamate uptake activity takes place in the brain in order to 
maintain low extracellular space levels (Shigeri et al., 2004).  Glutamate is 
then taken up by glial cells and converted into glutamine by enzyme 
glutamine synthetase; glutamate is then transported out of the glial cells 
and into the nerve terminals. This sequence of events is called the 
glutamate-glutamine cycle where synaptic terminals co-operate with glial 
cells to maintain adequate supply of glutamate neurotransmitter (refer to 
Figure 1.1).   
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Maintenance of cortical excitability requires a balance of glutamate 
(excitatory) and GABA (inhibition) metabolism. Glutamate is a metabolic 
precursor of GABA, which will subsequently be recycled through TCA to 
synthesize glutamate by enzyme glutamic acid decarboxylase.  As 
opposed to glutamate, the activation of post synaptic receptor by 
inhibitory neurotransmitter GABA causes hyperpolarization and 
depresses action potential generation (Petroff, 2002). 
 
 
Figure 1.1:  Schematic diagram of the glutamate/GABA-glutamine cycle 
The schematic representation outlines the glutamate-glutamine cycle in 
glutamatergic synapse (A) and GABA-glutamine in a GABAergic synapse (B). 
Glutamate is packed into vesicles by VGLUTs and is released upon action 
potential. In the glutamatergic synapse, released neurotransmitter glutamate is 
predominantly taken up into the glial cells by EAATs where it is converted to 
glutamine by glutamine synthetase using free ammonia and return to the 
neurons. In the GABAergic synapse (B), the released neurotransmitter GABA is 
taken up by EAATs into both the surrounding glial and the pre-synaptic terminal. 
In the glial, GABA is metabolized into two steps to succinate, which is further 
metabolized in the TCA cycle to α-ketoglutarate, which is translocated out of the 
mitochondria and and subsequently to converted to glutamate. Thereafter, the 
steps are similar to the glutamatergic synapse.  
 
Abbreviations: GABA,γ-aminobutyric acid; VGLUT,vesicular glutamate transporter; 
EAAT;excitatory amino acid transporter; TCA,tricarboxylic acid; NH4,free ammonia.  
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1.3 Excitotoxicity of Glutamate  
As a primary excitatory neurotransmitter, glutamate plays a major role in 
regulating how the nervous system rapidly convey sensory information 
and complex motor commands from one part of body to another and also 
in the formation of thoughts and memories. Glutamate is involved in 
higher cognitive functions such as the LTP, which is a form of a synaptic 
strengthening that last for a long time and is caused by repeated short 
and high frequency stimuli.  During LTP, the post-synaptic neuron is more 
sensitive to the same pre-synaptic stimuli, thus increasing the amplitude 
of the EPSC. LTP is thought to be responsible for learning and memory 
(Baudry and Lynch, 2001). 
Glutamate has the ability to cause cell death when either there is an 
excessive amount of glutamate released or the excessive time period of 
glutamate exposure. The phenomenon of cell death caused by glutamate 
was first observed by Lucas and Newhouse (Lucas and Newhouse, 1957), 
where glutamate was found to  damage  neurons of the inner layer of the 
retina.     Subsequently the term excitotoxicity was coined by John Olney 
et al when he discovered such toxicity was not limited to only the retina of 
the mouse but were also present in peripheral and central neurons in 
mice, rats, rabbits and rhesus monkeys. Excitoxicity describes the 
pathological process that occur when neurons are damaged or killed by 
the overactivation of glutamate receptors by either binding of excitoxins 
such as NMDA or exceptionally high glutamate levels, causing entry of 
high levels of calcium ions (Ca2+). The Ca2+ influx into the cell will activate 
enzymes such as endonucleases, proteases and calpain which will 
subsequently damage membrane, cytoskeleton and DNA (Olney, 1969; 
Olney and Ho, 1970).  
Studies have shown that excitotoxicity may be involved in stroke, 
traumatic brain injury and neurodegerative diseases of the CNS such as 
Alzheimer’s Disease.  Insults as observed in stroke and neurodegenerative 
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diseases can lead to excessive release of glutamate within the nervous 
system.  Injury (head or spinal cord injury) can lead to large amount of 
glutamate released from injured cells. The excessive glutamate exposed to 
cells which survived the original injury depolarized them, leading to 
swelling, lysis and death by necrosis. The lysed cells release more 
glutamate which leads to a cascade of destructive events and progressive 
cell death which can last for hours and days after the original injury. 
Evidence indicates the presence of glutamatergic dysfunction in AD, 
which has a strong correlation with cognitive decline (Francis et al., 
1993). A more detailed literature review of excitoxicity in various 
neurodegeration diseases is provided in the individual chapters.  
 
1.4 Post-synaptic glutamate receptors 
Glutamate released from presynaptic cells, binds to the postsynaptic 
glutamate-gated receptor which leads to the production of an EPSC.  The 
glutamate receptors can be classified according to the mechanism by 
which their activation produces a postsynaptic current. Ionotropic 
glutamate receptors (iGluRs) directly form an activated ion channel pore 
when glutamate binds. In contrast, metabotropic glutamate receptors 
(mGluRs) are linked to G-protein and  operate by either releasing second 
messengers such as adenylyl cyclase and phospholipase C or indirectly 
modulate ion channels found on the plasma membrane through signalling 
cascades that involve G-protein subunits (Conn and Pin, 1997).  This 
difference in activation mechanism allows iGluRs to relay information 
faster than mGluRs. Glutamate is not the exclusive ligand to glutamate 
receptors and in most cases other agonist is required for receptor 
activation.         
mGluRs are made up of seven-transmembrane domains with an 
extracellular N-terminal and intracellular -COOH terminal. mGluRs are 
divided into groups according to their activation mechanism; Group I 
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receptors activate phospholipase C, producing diacylglycerol and inositol 
triphosphate as second messengers. Groups II and III are negatively 
coupled to adenylyl cyclase (Conn and Pin, 1997). 
In contrast, iGluRs are ligand-gated nonselective cation channels which 
allow the flow of potassium (K+), sodium (Na+) and sometimes calcium 
(Ca2+) in response to glutamate binding. These fast excitatory cation 
channels consist of, N-methyl D-aspartate (NMDA) receptors and non-
NMDA receptors. NMDA receptors are made up of α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) receptors and kainate (KA) 
receptors. Upon binding of agonist, the ion channels of the iGluRs are 
directly stimulated, allowing ion flow and causing EPSC. Following the 
depolarizing EPSC, if enough iGluR is activated, action potential in the 
postsynaptic neuron is triggered.  Although all of the iGluRs produce 
EPSC, the different types of iGluRs produce the current at different speed 
and duration. The presence of an Mg2+ ion site creates a voltage-
dependent block which can be removed by outward flow of positive 
current. To open, NMDA receptors rely on EPSC produced by AMPA as a 
source of outward flow of positive current.   
The NMDAR are homogenously Ca2+-permeable, playing an important and 
well–recognised role in synaptic plasticity as well as disease. Long term 
potentiation (LTP) and long term depression (LTD) are thought to be 
caused by the calcium Ca2+ entering through the NMDA receptor, 
suggesting the importance of NMDA receptor playing an important role in 
signalling cascades and gene expression.  The  AMPA receptor and some 
KA receptors are largely Ca2+-impermeable, but Ca2+-permeable AMPA 
receptors also exist at some synapse and are thought to play a role in 
synaptic plasticity and disease  (Gorter et al., 1997; Liu and Zukin, 2007; 
Pellegrini-Giampietro et al., 1997). 
For the purposes of this study, only the post-synaptic iGluR will be 




1.4.1 Ionotrophic receptors of glutamatergic system  
In the glutamatergic system, the ionotrophic receptors are fast 
responding compared to the metabotropic receptors as they are directly 
linked to ion receptor channels. These receptors are characterised by two 
functional domains: an extracellular site that binds neurotransmitters, 
and a membrane-spanning domain that forms an ion channel. These 
ligand-gated ion channels receptors are multimers which made up of at 
least four or five individual protein subunits, each of which contributes to 
the pore of the ion channel (Dingledine et al., 1999). In this thesis, the 
status of two main ionotrophic receptors namely α-amino-3-hydroxy-5-
methyl-4-isoxazolepropionicacid (AMPA) receptors and N-methyl D-
aspartate (NMDA) receptors will be studied in neurological diseases apart 
from AD. 
 
1.5. N-methyl-d-aspartate (NMDA) receptors 
1.5.1 Introduction 
NMDA receptors are excitatory ionotropic receptors responsible for fast 
excitatory synaptic transmission in the brain and its modulation is 
important for neurodevelopment as well as the synaptic plasticity. 
Together with the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic 
acid (AMPA) receptor, NMDA receptor has cation channels which are 
capable of converting chemical signal in the form of pre-synaptically 
released glutamate to electrical signal resulting in membrane voltage 
change due to cation flow though the channels.  
This section will describe how the NMDA receptor are synthesized, sorted 
and trafficked to the membrane, exocytosed, stabilized at the synapse and 
removed from cell surface via internalization. Studying NMDA receptor 
might give us better understanding of the molecular mechanisms that 
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modulate NMDA receptor subcellular localization and signaling, hence 
contributing to the development of novel therapies for ameliorating 
NMDA receptor dysfunction in multiple disease states. 
 
1.5.2 NMDA receptor structure, assembly and function 
NMDA receptors are integral membrane proteins consist of four large 
subunits that form a central ion channel pore selective for cations (Na+, K+ 
and Ca2+). There are seven NMDA receptor subunits, namely GluN1 
(formerly denoted as NR1), GluN2A–GluN2D (formerly denoted as NR2A-
D) and GluN3A–GluN3B (formerly denoted as NR1-3).  Most of the NMDA 
receptors are diheterotetrameric complexes containing two GluN1 and 
two GluN2 subunits where the dimers of GluN2 can be made up of 
identical or different GluN2 subunits.  
The activation of these conventionally requires the binding of glutamate 
(binding site found on GluN2) and co-agonist glycine/D-serine (binding 
site found on the GluN1), thereafter making these NMDA receptor 
permeable for both Ca2+ and Na+ (Dingledine et al., 1999; Hollmann and 
Heinemann, 1994). The GluN3 subunits are the last of the NMDA receptor 
to be cloned and its properties are not fully understood. NMDA receptor 
which are made up of GluN1 and GluN3 subunits are exclusively activated 
by glycine due to both receptors’ possession of glycine binding sites, thus 
triggering influx of Na+ (Pachernegg et al., 2012). Tri-heteromeric 
receptors (GluN1/GluN2/GluN3) also exist although they are rare (Pérez-
Otaño et al., 2006). The expression of the NMDA subunit expression varies 
regionally as well as developmentally.  
Each subunit consists of four discrete domains : an extracellular  N-
terminal domain (NTD; 380 amino acid) which  forms part of the S1; an 
extracellular  loop between M3 and M4(forming  S2);  the agonist-binding 
domain (ABD; 300 amino acids);  a membrane domain made of three 
transmembrane segments (M1, M3 and M4) with  a short re-entrant loop 
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(M2) which forms the ion channel; and lastly an  intracellular C-terminal 
tail, highly variable in length depending upon the subunit, and which is 
involved in receptor trafﬁcking, anchoring the receptor to the post-
synaptic density and which facilitates cytoplasmic protein–protein 
interactions. The interacting partners of the NMDA receptor are 
determined by the different amino sequence of its C-terminal. The 
NMDAR also has other modulatory sites such as the zinc and polyamine 
binding site which affect receptor function (Paoletti and Neyton, 2007). 
The N terminal is found to be extracellular due to its glycosylated 
sequence. The C terminal is found to be cytoplasmic due to the presence 
of hydrophilic protein sequence and consensus sequence for kinases. At 
resting membrane potentials, the NMDA receptor is blocked by 
magnesium ion in the the pore. Since NMDA receptor is both ligand-gated 
and voltage-gated, opening of NMDA receptor requires depolarisation by 
the AMPA receptor as well as activation by glutamate and either 
glycine/D-serine (depending on location of GluN1).  
Glutamate binds to ABD found between S1 and S2 of the GluN2, while the 
co-agonist, glycine or D-serine binds to the S1 and S2 of the GluN1. This 
will allow the flow of calcium and sodium ions into the channel and 





Figure1.2 Schematic diagram of structure and composition of NMDA 
receptor 
The NMDA receptor is made up from four subunits. Most of the NMDA receptors 
are diheterotetrameric complexes containing two GluN1 and two GluN2/GluN3 
subunits where the dimers of GluN2 can be made up of identical or different 
GluN2 subunits.  The individual subunit is composed of four transmembrane 
domain(M1-4). Each subunit consists of four discrete domains : an extracellular  
N-terminal domain which  forms part of the S1; an extracellular  loop between 
M3 and M4 (forming  S2);  the agonist-binding domain (ABD);  a membrane 
domain made of three transmembrane segments (M1, M3 and M4) with  a short 
re-entrant loop (M2) which forms the ion channel; and lastly an  intracellular C-
terminal tail, highly variable in length depending upon the subunit, and which is 
involved in receptor trafﬁcking, anchoring the receptor to the post-synaptic 
density and which facilitates cytoplasmic protein–protein interactions. The 
interacting partners of the NMDA receptor are determined by the different 
amino sequence of its C-terminal. The NMDAR also has other modulatory sites 
such as the zinc and polyamine binding site which affect receptor function. At 
resting membrane potentials, the NMDA receptor is blocked by magnesium ion 
in the the pore. Since NMDA receptor is both ligand-gated and voltage-gated, 
opening of NMDA receptor requires depolarisation by the AMPA receptor as well 
as activation by glutamate and either glycine/D-serine (depending on location of 
GluN1). This will allow the flow of calcium and sodium ions into the channel and 
potassium ions out of the channel.  
 











1.5.3 Determination of channel properties by NMDA receptor 
subunit composition 
The specific combinations of the subunits determine the functional 
properties of the NMDA receptor.  Heterogeneity of the NMDA receptor 
can also be caused by alternative splicing (Cull-Candy et al., 2001). Both 
the NMDA receptor composition (Farrant et al., 1994; Liu et al., 2004; 
Quinlan et al., 1999) as well as the GluN1 alternative splicing  (Laurie and 
Seeburg, 1994; Prybylowski and Wolfe, 2000) are  developmentally 
regulated.  
The large GluN1 subunit which is composed of 22 exons of which 3 (exon 
5, 21 and 22) undergo alternative splicing resulting in 8 isoforms of 
GluN1.  These splice variant are generated by insertion of exon 5 in the N 
terminus (forming splice cassette N1), deletion of exon 21 in the C 
terminus (forming splice cassette C1), and use of an alternative splice 
acceptor site in the C-terminus (forming splice cassette C2). Splicing of 
the C2 removes a first stop codon which will result in an unrelated and 
alternative C-terminal cassette called C2’ which contain PDZ-interacting 
domain. (Standley et al., 2000).  Thus all isoforms lacking C2 has C2’.  The 
switching of C2 to C2’ increases NMDA receptor trafficking and increased 
cell surface expression (Mu et al., 2003; Standley et al., 2000).  
The splicing of GluN1 at the C- or N-terminal can affect NMDAR trafficking 
and protein interactions (Carroll and Zukin, 2002; Ehlers et al., 1995; 
Okabe et al., 1999; Wenthold et al., 2003), as well as receptor function 
(Cull-Candy et al., 2001), resulting in different distinct 
electrophysiological and well as pharmacological properties . The type of 
the GluN1 splice variant involved during receptor assembly influences 
features such as the inhibition by protons, potentiation by polyamines 
and the inhibition by Zn2+. For example, proton sensitivity is directly 




In addition, GluN2 is also important in determining many biophysical and 
pharmacological properties of the receptor which influence downstream 
signalling and trafficking mechanism of the NMDA receptor (Cull-Candy 
and Leszkiewicz, 2004).  GluN1 combined with different GluN2 subunits 
vary in properties   including affinity for glutamate, modulation by 
sensitivity, Mg2+ sensitivity as well as channel desentization kinetics. 
Using recombinant (Vicini et al., 1998; Wyllie et al., 1998) as well as 
native NMDA receptor (Cathala et al., 2000; Misra et al., 2000) , it is 
shown that the deactivation time to glutamate differs depending on the 
type of GluN2 receptor subunit present. GluN1-GluN2A receptors which 
predominate in many mature synapses) display the fastest 
desensitization, followed by similar rate of desentization of GluN1-2B and 
GluN1-GluN2C. GluN1-GluN2D produces the slowest decay time of 4-5s. 
Different subunits of GluN2 composition also produce different single 
channel conductance and Mg2+ block as observed in patch clamp studies 
using native and recombinant NMDA receptor. GluN2A and GluN2B-
containing receptors are associated with of high conductance as well as 
high sensitivity Mg2+ block. In contrast, those with GluN2C and GluN2D 
are of low conductance with low sensitivity to Mg2+ block. (Farrant et al., 
1994; Momiyama et al., 1996; Wyllie et al., 1998) 
Although GluN3 subunit is not necessary for the formation of the 
functional NMDA receptor, there is evidence that GluN3A might play a 
role in regulating early development. GluN1-GluN3A or GluN1-GluN3B 
receptors form an excitatory glycine receptor (selectively activated by 
glycine) that is permeable to Ca2+, resistant to Mg2+, and unaffected by 
glutamate. Tri-heteromers composed of GluN1/2/3 regulate surface 
expression and reduces Ca2+ permeability and Mg2+ sensitivity,  as well as 




1.5.4 Trafficking and surface expression of the NMDA receptor 
By observing the live imaging of the GFP-tagged GluN1 using time-lapse 
imaging and fluorescence recovery after photo bleaching (FRAP), it is 
suggested that the receptors are trafficked in vesicular form to the sites of 
developing synaptic sites (Washbourne et al., 2002) and in a gradual 
manner as observed in (Bresler et al., 2004). Since NMDA receptor are 
membrane proteins, its transportation to the synaptic membrane occur 
via the vesicular intermediate. Fast delivery of the NMDA receptor into 
the post-synaptic membrane is observed to occur through PKC-activated 
and soluble N-ethylmaleimide-sensitive factor attachment protein 
receptors (SNARE)-dependent exocytosis (Lan et al., 2001).  
 
1.5.4.1 GluN1 required in trafficking NMDA receptor out of the 
Endoplasmic Reticulum(ER) 
GluN1 and GluN2 differ in their roles during intracellular trafficking and 
surface expression of receptors. Assembled GluN1-GluN2 complex as well 
as some individual subunits can be exported from the endoplasmic 
reticulum (ER). GluN2A and GluN2B receptors are unable to be trafficked 
to the cell surface unless co-assembled with GluN1, suggesting the 
importance of GluN1 in the release of NMDA receptor from ER.  Knockout 
of GluN1 is observed to lead to the retention of GluN2 within the cell and a 
reduction of GluN2A/GluN2B in the dendrites (Fukaya et al., 2003). The 
splice variants of the GluN1 differ in their synaptic targeting to the cell 
surface (Y. Mu, 2003). The splice variant of the GluN1 is also important in 
trafficking. Those that contain the C1 cassette have the ER retention 
motifs that prevent surface expression of such variants. Shielding of the 
C1 cassette promotes forward trafficking to the surface  while the 





1.5.4.2  Exocytosis of NMDA receptor 
In contrast, GluN2 regulates the advanced stages of NMDA receptor 
delivery to the cell membrane which includes dendritic transport, 
synaptic localization and receptor trafficking (Wenthold et al., 2003). The 
interaction between C-terminal tail of GluN2 and PDZ domains of 
scaffolding proteins and kinase is most important. Membrane-associated 
guanylate kinases (MAGUKs) which include PSD-93, PSD-95, SAP-97, SAP-
102, and chapsyn-110 is a family of such scaffolding protein responsible 
for binding and stabilizing NMDARs in the plasma membrane. GluN2 
receptor subunits differentially bind to PSD 95 and SAP102 for surface 
delivery. After the synthesis of the GluN2B in the ER, the receptor is 
delivered to the cell surface by its interaction with SAP-102 and exocyst 
protein Sec8. The delivery of GluN2A, by contrast, involves binding of its 
C-terminal tail to PSD-95.  
Other important feature of NMDA receptor trafficking is the GluN C-
terminal tail for trafficking. Studies have used mutant mice with truncated 
C-terminal tails to further study the interaction of the NMDA receptor 
with intracellular scaffolding proteins. The truncation of the GluN2A C-
terminal tails is not lethal unlike GluN2B-truncated mice, but it leads to 
decrease in GluN2A expression levels and resulted in reduction of LTP in 
CA3-CA1 synapse (Steigerwald et al., 2000). There are further evidence 
that the truncation of the GluN2A and GluN2C C terminal tail decreases 
the open-channel probability of the NMDA receptor component of the 
EPSCs, resulting in a decrease in LTP at the cerebellar mossy fibre–






1.5.4.3 Endocytosis of the NMDA receptor  
In addition to synaptic delivery, the subunit composition of NMDA 
receptor also regulates the receptor internalization. The endocytic motif 
encoded in the distal c termini of GluN2A and GluN2B results in 
interaction with clathrin adaptor complexes with differing affinities. The 
GluN2B is found to undergo a more robust endocytosis compared to 
GluN2A in mature culture(Lavezzari et al., 2004). Both the NMDA and 
AMPA receptor can be internalized by the activation of the metabotropic 
glutamate receptors (mGluRs) (Snyder et al., 2001). The binding of 
glycine to the NMDA receptor prepare the receptor for internalization 




1.5.5 Developmental GluN2B to GluN2A switch in NMDA 
receptor 
During the second post-natal week in cortex and hippocampus, the 
GluN2A replaces GluN2B as the predominant GluN2 subunit (Barria and 
Malinow, 2002) . High sensitivity of the EPSCs to the selective GluN2B 
inhibitors ifenprodil and CP101, 606 in immature synapses showed that 
the GluN1/2B di-heteromers are the primary type of NMDA receptor 
expressed. Ifenprodil sensitivity is reduced and the kinetic decay of the 
EPSCs is faster in mature synapses compared to younger synapses which 
coincide with the predominantly GluN2A-containing NMDA receptor 
(Bellone and Nicoll, 2007; Rauner and Köhr, 2011). The GluN2B to 
GluN2A shift is evolutionarily conserved in many animals including frogs, 
birds and mammals in many parts of the brain including the cortex, 
hippocampus, amygdala and cerebellum (Dumas, 2005). Although the 
timing of the switch varies in different parts of the brain, the switch 
results in an increase in associative learning abilities and is suggested to 
be involved in the refinement of the neuronal circuits.  
 
The exact mechanism of the development GluN2 subunit switch is not 
confirmed (Barria and Malinow, 2002). The reasoning behind the switch 
of GluN2B to GluN2A leading to refinement of neuronal circuitry is still 
not understood. As development progress, there is an increase in PSD-95 
expression which results in the elevated expression of GluN2A and a 
reduction of GluN2B at the synapse (Sans et al., 2000).  This may be a 
suggested cause of the critical GluN2B to GluN2A switch during the 
initiation of synaptic activity during the development of cortical neuron. 
The GluN2 subunit switch is found to be reduced in the mouse lines that 
are lacking in PSD-95(Béïque and Andrade, 2003) or both PSD-95 and 
PSD-93 (Elias 2008). However, it is still unknown how these scaffolding 
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proteins aid in the insertion of newly synthesized GluN2A into the 




1.5.6 Roles of differentially located NMDA receptor 
1.5.6.1 Synaptic, perisynaptic and extra synaptic NMDA receptor 
NMDA receptors are localized in different location on the plasma 
membrane namely the perisynaptic (pNMDAR), extra synaptic (eNMDAR) 
as well as the post synaptic (sNMDAR). These differentially localised 
NMDA receptors have unique properties and distinct functions. The extra 
synaptic NMDARs (eNMDARs) are localized at sites further from the post 
synaptic density(PSD) which is on the spine neck, the dendritic shaft or 
soma (Groc and Choquet, 2006; Newpher and Ehlers, 2008; Kenneth R. 
Tovar and Westbrook, 2002). Perisynaptic NMDARs(pNMDAR) are 
located on the plasma membrane within 200–300 nm of the PSD (Petralia 
et al., 2005; Zhang and Diamond, 2006) and are  only activated by high 
glutamate concentrations in the synaptic cleft (Groc et al., 2009). The 
perisynaptic region may contain mobile receptors that are in transit to 
and from the PSD since receptors diffuse between synaptic and extra 
synaptic sites (Groc et al., 2004; Groc and Choquet, 2006; Kenneth R 
Tovar and Westbrook, 2002). Endocytic zones (EZs) located outside of 
PSD (Blanpied et al., 2002), may facilitate clathrin-dependent NMDAR 
endocytosis at both peri- and extra synaptic sites (Petralia et al., 2003)  
 
Lastly, there are the post synaptic NMDA receptor(sNMDAR) that are 
found on the PSD which is a cytoskeletal network that allows the 
anchoring of the postsynaptic glutamate receptors such they can be 
efficiently activated by presynaptic glutamate release and signalled to 
effector proteins (Newpher and Ehlers, 2009). The macromolecular 
NMDAR complex (NRC), which is made up of scaffolding, adaptor as well 
as effector proteins which is involved in activation of downstream 
signalling cascades and regulation of NMDAR function, membrane 
stability and trafficking, is formed at the postsynaptic density (PSD). 
Visualization of the assembly of PSD using single molecule imaging 
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methodologies, shows that the glutamate receptors are confined and 
stabilized by specific ‘slots’ that are dependent on close association and 





1.5.6.2 Mobility of Synaptic and extra synaptic sites 
The mobility of the NMDA receptor allows lateral diffusion between 
synaptic and extra synaptic sites to occur with ease (Groc et al., 2009), 
resulting in cytoskeletal reorganization, alterations in surrounding 
scaffolding and signaling complexes and modulation of NMDA receptor 
posttranslational modifications. As the sNMDA receptor and the eNMDA 
receptor differentially signal to cell survival or apoptotic pathways 
(Hardingham and Bading, 2010; Papadia and Hardingham, 2007), a 
balance between them proves critical. Imbalances of these receptors can 
lead to early cognitive dysfunction as well as onset of neurodegenerative 
diseases (Levine et al., 2010; Milnerwood and Raymond, 2010). 
 
1.5.6.3 Influence of synaptic and extra synaptic NMDA receptor on 
intracellular signalling cascade  
There are new evidences showing that the sNMDA and eNMDA receptor 
forms functionally distinct pool of receptors which are gated by different 
exogenous co-agonist D-serine and glycine respectively (Papouin et al., 
2012).  Activation of the synaptic and extra synaptic NMDA receptor leads 
to different intracellular signalling. While the activation of sNMDA 
receptor results in  intracellular signalling cascade leading to cell survival, 
the calcium entry of calcium, through the eNMDA receptor trigger 
neuronal cell death through excitotoxicity (Hardingham and Bading, 
2010).   
Regardless of subunit composition of the NMDA receptor, the sNMDA 
activation is thought to induce the phosphorylation of the cyclic-AMP 
response element binding protein (CREB) transcription factor that plays 
well-known roles in neuronal survival and plasticity (G E Hardingham et 
al., 2002; Léveillé et al., 2008).  Activation of sNMDA receptor is also 
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thought to block the transcription of several pro-apoptotic and oxidative 
genes (such as Puma and APAF1 or Txnip, respectively) (Léveillé et al., 
2010). In contrast, activation of eNMDA receptor shut off cell survival 
pathways (Giles E. Hardingham et al., 2002)  and  results in neuronal 
death mediated by a variety of pathways, including CREB 
dephosphorylation, ERK1/2 inactivation, induce mitochondrial 
dysfunction (Gouix 2009)   and activation of pro-apoptotic genes (Léveillé 
et al., 2010)  
 Activation of the eNMDA receptor has been observed in pathologically in 
ischemia. However it is unknown whether this pool of NMDA receptor can 
be activated under the physiological conditions. Moreover, it is also not 
known whether the GluN2 subunit composition of eNMDA receptor 
determines the intracellular signalling cascade or its deleterious effect of 








1.6 α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid 
(AMPA) receptors  
1.6.1 Introduction 
AMPA receptors are excitatory ionotropic receptors responsible for fast 
excitatory synaptic transmission in the brain and its modulation is 
important for neurodevelopment as well as the synaptic plasticity. 
Together with the NMDA receptor, AMPA receptor has cation channels 
which are capable of converting chemical signal in the form of pre-
synaptically released glutamate to electrical signal resulting in membrane 
voltage change due to cation flow though the channels.  
This section will describe how the AMPA receptor are synthesized, sorted 
and trafficked to the membrane, exocytosed, stabilized at the synapse and 
removed from cell surface via internalization. Studying AMPA receptor 
might give us better understanding of the molecular mechanisms that 
modulate AMPA receptor subcellular localization and signaling, hence 
contributing to development of novel therapies for ameliorating AMPA 
receptor dysfunction in multiple disease states. 
 
1.6.2 Structure, assembly and function 
α-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid (AMPA) 
receptors mediate the majority of fast, excitatory synaptic transmission in 
the CNS.  Unlike the NMDA receptor which remains silent at resting 
potential, the AMPA receptor possesses the ability to mediate excitatory 
currents during basal neuronal activity. There are 4 types of AMPA 
receptor subunit: GluA1-4 (previously known as the GluA1-4), each 
encoded by different genes (Dingledine et al., 1999; Hollmann and 
Heinemann, 1994) . The AMPA receptor was first cloned amongst all the 
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other glutamate receptors by screening a rat brain cDNA library for the 
expression of kainate activated ion channels in xenopus laevis oocytes. 
The GluA1 subunit of the AMPA receptor was first cloned after screening 
an expression library and subsequently, the remaining GluA2, GluA3 and 
GluA4 homologues was revealed using standard cDNA homology screens. 
Each AMPA receptor subunit has a molecular weight of between 105 to 
116 kDa and 70 % sequence homology amongst the subunits (Hollmann 











Figure 1.3 Schematic diagram of structure and composition of GluA2 subunit 
of AMPA receptor.  AMPA receptor are heterotetramic consisting of ‘dimers of 
dimers’ of GluA2 and either GluA1,3,4. The schematic diagram above depict the 
composition of GluA2 subunit which regulate the calcium permeability of the 
AMPA receptor. Each subunit consists of four discrete domains(M1-M4) : an 
extracellular  N-terminal domain which  forms part of the S1; an extracellular  loop 
between M3 and M4(forming  S2);  the agonist-binding domain (ABD) or ligand-
binding domain;  a membrane domain made of three transmembrane segments 
(M1, M3 and M4) with  a short re-entrant loop (M2) which forms the ion channel; 
and lastly an  intracellular C-terminal tail, highly variable in length depending 
upon the subunit, and which is involved in receptor trafﬁcking, anchoring the 
receptor to the post-synaptic density and which facilitates cytoplasmic protein–
protein interactions. The interacting partners of the AMPA receptor are 
determined by the different amino sequence of its C-terminal. The calcium 
permeability of the AMPA receptor involves the Q/R RNA editing site of the GluA2. 
The presence of the edited GluA2(R) subunit will render the AMPA receptor 
calcium impermeable. Another important aspect of the GluA2 is the flip/flop 
alternative splice site. The flip/flop sequence determines the speed of receptor 
desensitisation and resensitisation while the NSF/AP2 binding domain play an 
important role in the stabilization of GluA2 at the synapses. Other important 
features of the GluA2 which affect receptor function includes R/G RNA editing site, 
phosphorylation sites, , phosphorylation sites.   
 
Abbreviation: NSF/AP2,N-ethylmaleimide-sensitive fusion protein/adaptor protein2 ; 




1.6.2.1  AMPA receptor expression 
Despite residing in the same synapses in most regions of the brains, the 
AMPA and NMDA receptor reach their synaptic destinations through 
different pathways. While the NMDA receptor are expressed soon after 
birth in the hippocampus (Durand et al., 1996; Hsia et al., 1998; Shi et al., 
1999)  as well as other parts of the brain (Losi et al., 2002; Wu et al., 
1996), AMPA receptor are only expressed gradually over the postnatal 
development course. The delivery of the AMPA receptor is known to be 
regulated by the activation of NMDA receptor, thus playing a role in 
synaptic plasticity (Barry and Ziff, 2002; Malinow and Malenka, 2002; 
Song and Huganir, 2002). 
 
The various combinations of these subunits depend on their location in 
the brain. GluA1, GluA2 and GluA3 are widely distributed and are found in 
abundance in the CNS including brain area such as the hippocampus, 
outer layer of cortex, basal ganglia, olfactory regions, lateral septum, and 
amygdala. For example within the hippocampus and cerebral neocortex , 
the majority of AMPAR contains GluA2 , which predominantly  forms 
heteromers with GluA1 (Greger et al., 2002; Wenthold et al., 1996). 
 The expression of the GluA4 is lower throughout the CNS except in the 
cerebellum, thalamus and brain stem. The expression of the AMPA 
receptor subunits is developmentally regulated. For example, GluA4 
subunit is expressed predominantly during early postnatal period, and its 
abundance decreases as  development progresses (Zhu et al., 2000) while 





1.6.2.2 The constituents of the AMPA receptor  
Each subunit is made up of an extracellular N-terminus domain, an 
intracellular C-domain and three transmembrane domains (M1, M3, and 
M4). The second membrane domain (M2) consists of a hairpin structure 
that changes direction within the membrane and loop back to the 
intracellular side of the cell.  The N-terminal contains lobe-like regions D1 
and D2, which houses the site for ligand binding (McFeeters and Oswald, 
2004) in the cleft between them, while the C-terminal contains NSF and 
PDZ binding domains, which is involved in protein interactions during 
AMPA receptor trafficking (Dong et al., 1999). M2 domain of the AMPA 
receptor subunits joins together to form the ion-permeable pore (Refer to 
Figure 1.3). 
 
The agonist-binding site on each subunit is formed by the N-terminal and 
the extracellular loop between M3 and M4 (Szénási et al., 2008). The 
binding of an agonist caused the two extracellular loops get closer to each 
other, thus opening the pore (McFeeters and Oswald, 2004). The pore 
opens when at least two binding sites occupied and the current increases 
as more binding sites being occupied.  Once the agonist dissociates, the 
channels deactivate quickly.  A change of the angle of a small part of the 
agonist binding site is thought to cause the reduction of current in the 
presence of high levels of agonist, resulting in  fast desensitization 
(Armstrong et al., 2006). 
 
1.6.2.3 Splicing and RNA editing of the AMPA receptor and their 
consequences  
AMPA receptor made up of GluA1-4 combine in varying stoichiometries, 
resulting in ion channel with distinct functional properties (Hollmann and 
Heinemann, 1994). Although the AMPA receptor subunits have similar 
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extracellular and transmembrane region, they differ considerably in their 
cytoplasmic tails. The alternative splicing of the C terminal domain 
resulted in subunits with either long or short intracellular C-termini. 
GluA2 and GluA4 exhibit both long and short forms with the short form 
being homologous to the C-terminus of GluA3 and the long isoform to that 
of GluA1.  In vivo, over 90% of GluA2 is expressed as the short alternative 
splice variant. Different isoforms of GluA4 are expressed preferentially in 
differing areas of the brain with the GluA4short found mostly in the in 
cerebellar granule cells and Bergmann glial cells. To date, GluA1 has only 
been found as the long-form splice variant in vivo and GluA3 as the short 
form. GluA1, GluA4 and GluA2long with long cytoplasmic tails, are activity 
dependent and play a part in LTP. GluA2, GluA3 and GluA4short which 
contains the short cytoplasmic tail, are constitutively recycled in and out 
of the synapse. Expressions of these subunits are developmentally 
regulated and brain region-specific. The alternative splicing of the C-
terminal domain is responsible for the binding of the subunits to specific 
interacting protein as well as regulation of the receptor by receptor 
phosphorylation (Song and Huganir, 2002). 
 
All of the four AMPA receptor subunits exist in two alternatively splice 
forms namely Flip and Flop. The flip flop region is an alternative splice site 
with an interchangeable sequence of 38 amino acid encoded by exons 14 
and 15,  and forms part of the extracellular ligand-binding domain (LBD) 
The flip and flop splicing event which is regulated both developmentally 
as well as regionally in different parts of the brain (Hollmann and 
Heinemann, 1994),  vary  in their speed of desensitization and 
resensitization in response to glutamate and their rates of channel 
closing, as well as pharmacologic properties. Thus, the kinetic properties 
of the subunit differ depending on the splice variants with the flip form 
giving a more sustained current compared to the flop form which 
desensitised more easily (Szénási et al., 2008). For example, the flop 
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variants of GluA2-4 desensitised faster than the flip variants, but takes a 
longer time to recover (Sommer et al., 1990). The GluA1 flip and flop 
variant on the other hand desensitise at an equal rate depending on the 
glutamate concentration (Mosbacher et al., 1994).  
 
The AMPA receptor are also regulated by RNA editing at amino acid 607 
of GluA2 (Q/R editing) and 745 of GluA1-4(R/G). The arginine to glycine 
(R/G) of the S2 loop at amino acid 745 changes the resentisization 
kinetics, with the edited G form recovers from desensitization faster than 
the R form.  The M2 domain of the GluA2 forms part of the lining of the 
channel pore and undergoes the RNA editing at amino acid 607.   The 
editing of GluA2 from single amino-acid change from neutral-charged 
glutamine (Q) to negatively arginine (R) prevents Ca2+ entry and   function 
as the retention motif in the endoplasmic reticulum(ER).  RNA edited 
Ca2+-impermeable GluA2 (R607) is the major form of GluA2 in the CNS 
(Blakemore et al., 2006) and is responsible for the linear rectifying 
properties of a GluA2-containing AMPA receptor (Burnashev et al., 1992), 
Such an arrangement is  hypothesised to provide protection against 





1.6.2.4 Transcriptional Regulation of GluA2 
The mRNA of AMPA receptor is found only in neurons and some glial cells 
such as the Bergmann glial in the cerebellum and the oligodendrocytes 
precursor cells throughout the brain (Bergles et al., 2000) Research has 
shown that the GluA2 promoter region has the regulatory element for 
RE1 silencing transcription factor (REST1). The transcription of the GluA2 
is monitored by REST1 which silences the GluA2 in non-neuronal cells 
(Borges and Dingledine, 2001).  Most of the mRNA is translocated into the 
dendrites (where translation machineries such as the ribosomes, 
elongation and initiation factor reside) for translation to occur.   
 
1.6.2.5 Biosynthesis of AMPA receptor 
1.6.2.5.1 Biosynthesis of AMPA receptor in the Endoplasmic Reticulum 
Like all eukaryotic cells, the assembly of transmembrane proteins in 
neurons is in the ER is highly conserved. The four AMPAR subunits, 
GluA1–4, assemble in different combination to form tetrameric channels 
(Rosenmund et al., 1998). Most AMPA receptor are heterotetramers 
consisted of one pair of dimers of two AMPA receptor subunits. Almost all 
AMPA receptor complexes contain GluA2 subunit, dimerized with one of 
GluA1, GluA3 or GluA4 subunit (Shi et al., 2001; Wenthold et al., 1996) In 
the hippocampus of mature adult brain, GluA1-GluA2 and GluA2-GluA3 
heteromers  are the predominant receptor types,  whereas the GluA4-
containing AMPA receptor are expressed mainly in the early postnatal 
development .  GluA1 monomers are less abundant (Shi et al., 2001; 
Wenthold et al., 1996; Zhu et al., 2000). The formation of GluA1 
homomeric receptors give rise to  unique ion permeation properties and  
are thought to be expressed only in selective neuronal populations. The 
numbers and percentage of combinations vary in different brain regions 
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and during development. AMPA receptor with different subunit 
compositions form ion channels with distinct functional properties, with 
varying in pharmacological properties such as preference of agonist and 
cation, opening and closing kinetics, regulation of synaptic trafficking, etc. 
(Hollmann and Heinemann, 1994; Nardone et al., 2008). 
 
AMPA receptors are firstly assembled in the endoplasmic reticulum. 
Attachment of a high-mannose glycosylation replaces the N-terminal 
signal sequence which is cleaved at the first extracellular domain at 
specific asparagine residues during the start of the assembly began in the 
ER. The mechanism which is involved in the assembly of different AMPA 
receptor subunit is still not well understood but it is largely understood 
that it involve luminal interactions between N-terminal domains (NTDs) 
of the subunits (Kuusinen et al., 1999; Leuschner and Hoch, 1999). 
 
Through the usage of recombinant and native receptors, it is observed 
that AMPA receptor assemble as dimer-of dimers in a two-step manner.  
The monomers firstly interact through the NTD to form dimers, which 
will then combine through the membrane domains to form the tetramer.  
Other brain regions, such as the membrane region and S2 loop, are also 
found to be necessary for the formation of the mature tetrameric receptor 
(Ayalon and Stern-Bach, 2001) .The transition from dimer to tetramer 
require the interaction between the ligand binding domains(LBDs) of the 
AMPA receptor subunits (Greger et al., 2006) . Although the NTD  is 
required for the preferential assembly of the heteromers (Ayalon et al., 
2005), it is not required for the assembly of homomers.  
 
GluA1-GluA2 heteromers exit the ER rapidly unlike GluA2-GluA3 
heteromers which are more likely to be retained in the ER. The difference 
in the time needed for the different combination of subunits to exit from 
the ER can be accounted for by presence of arginine(R) at amino acid 607 
of GluA2.  Evidence has shown that the presence of R607 provided an ER 
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retention motif for GluA2 (Greger et al., 2002)  . The GluA1, GluA3 and 
GluA4 mRNAs are not edited at amino acid 607, thus do not undergo 
retention at the ER. The GluA1-GluA2 heteromers are trafficked out at a 
faster pace due to the presence of GluA1 which overrule that of the GluA2. 
The GluA2-GluA3 complex and GluA2 homomer is retained longer in the 
ER and act as the GluA2 homomer. The retention of mature GluA2 the 
subunits in the ER allows efficient exit in heteromeric complex. Knockout 
mice without GluA2 form GluA1-GluA3 heteromers as well as GluA1 and 
GluA3 homomers which are poorly translocated  to synapses (Sans et al., 
2003). 
 
Other than Q/R editing at amino acid 607 at GluA2, the editing at R/G at 
amino acid position 743 in the S2 domain also influence the formation of 
GluA2 homomers. The edited variant prevent the formation of homomers 
(Greger et al., 2006). The flip and flop forms of the AMPA receptor also 
traffick differently to the surface. The flop form of homomers AMPA 
receptor accumulate in the ER whereas those of the flip form trafficked  to 
the cell surface efficiently (Coleman et al., 2006).   
 
It is still unknown which exact protein  interacting with R607 is 
responsible for the retention of immature GluA2 in ER, but  GluA2  is 
found to be co-localized extensively with  BiP and calnexin (Rubio and 
Wenthold, 1999). Such interactions with these ER chaperones may 
control the ER retention. GluA2 also has other properties which regulate 
ER retention and exit in early intracellular trafficking. The GluA2 C 
terminus has a PDZ consensus motif (SVKI) that interacts with several 
PDZ domain–containing proteins, such as  the protein interacting with C 
kinase 1 (PICK1) (Xia et al., 1999), which is thought to be necessary for 
the exit of GluA2 from the ER (Greger et al., 2002). The GluA1 terminus 
has the consensus motif (ATGL) that interacts with the synapse-
associated protein 97 (SAP97) (Leonard et al., 1998) .Immature GluA1 
interact with SAP97 during early secretory pathway  in the ER (Sans et al., 
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2001) . While it is known that the GluA1-SAP97 is needed for the correct 
synaptic targeting, it is not clear whether such interaction is necessary for 
AMPA receptor’s exit out of the ER   
 
The normal expression of the AMPA receptor requires the glutamate 
binding and the ion permeation through the pore. Mutants that cannot 
bind glutamate and block ion permeation is known to decrease 
surface/synaptic expression and are most likely be retained in the ER 
(Grunwald and Kaplan, 2003). Thus, there may be a mechanism which 
acts as surveillance in the ER such that only correctly folded and active 
channels are allowed to exit.   
 
1.6.2.5.2 Biosynthesis of AMPA receptor in the Golgi  
Proteins trafficking through the secretory pathway can exit via soma and 
dendritic sites (Horton and Ehlers, 2004). Proteins that are translated 
locally in the dendrites can be post-translationally modified in these Golgi 
outposts. Although most of the AMPA receptor contains N-glycosylation 
sites, these became fully glycosylated only in the Golgi. The interaction of 
postsynaptic density(PSD) with the c-tail of the stargazin  help the exit of 
the AMPA receptor out of the Golgi (Cuadra et al., 2004).  
 
Lipid modification of proteins such as palmitoylation which is important 
in the synaptic function also occur in the Golgi (El-Husseini et al., 2002; 
Huang and El-Husseini, 2005). Palmitoylation is a reversible process that 
occurs by attaching palmitate via thioester bonds to cytosolic cysteine 
residues covalently and is regulated by the balance of palmitoyl acyl 
transferase (PAT) and palmitoyl thioesterase activities.  
 
Further study showed that the AMPA receptor palmitolytion at two sites 
is important for correct AMPA receptor trafficking (Hayashi et al., 2005). 
Palmitolytion occur at two sites of the AMPA receptor; 1) the 
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transmembrane 2 domain which is around 3 amino acid away from the 
RNA editing site and 2) the cysteine at the C-terminal of the final 
transmembrane. The second site leads to the accumulation of the Golgi. 
AMPA receptor interaction with the 4.1N protein, which stabilizes AMPA 
receptor surface expression, is inhibited by the palmitolytion of the C-
terminal domain  (Shen et al., 2000a). Inhibition of regulated endocytosis 
of the AMPA receptor and increased association of GluA1 to protein 4.1N 
is resulted from the mutation of the palmitoylation sites(Hayashi et al., 
2005). AMPA receptor accumulation at the synapses required the 
palmitolytion of the scaffolding protein PSD-95 (El-Husseini et al., 2002). 
Other AMPA receptor-interacting proteins important for membrane 
trafficking of the AMPA receptor, such as the glutamate receptor–
interacting proteins GRIP1b and GRIP2b, are also palmitoylated (DeSouza 
et al., 2002; Yamazaki et al., 2001) 
 
1.6.3 Trafficking and the surface expression of AMPA receptor  
1.6.3.1 AMPA receptor trafficking along the cytoskeletal tracks in 
dendrites and spines 
As most of the mRNA coding for AMPA receptor is found mostly in the 
neuronal cell body, it is highly suggested that AMPA receptor is 
synthesised far away from their synaptic targets. The transport of such 
cargo will therefore require highly efficient long distance dendritic 
transport for cargo transportation, which will likely depend on the 
microtubular cytoskeleton along the dendritic shafts. Motor proteins of 
the kinesin and dynein superfamilies drive the active process of  transport 
of organelles on the microtubule tracks (Goldstein and Yang, 2000).  As 
revealed by the yeast two hybrid screening,  the PDZ domain- containing 
Glutamate Receptor Interacting Protein1/ AMPA receptor binding protein 
(GRIP1/ABP) binds directly to the  with heavy chain kinesin (KIF5) (Setou 
et al., 2002). The GRIP1/ABP also binds to  the C-terminal PDZ motif of 
the GluA2 and GluA3, thus it  may serve as a link between the AMPA 
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receptor and the microtubular motor proteins (Dong et al., 1997). 
Immunoprecipitation and yeast two-hybrid screening experiments shows 
that GluA2, GRIP1 and kinesin complexed together and dominant negative 
kinesin decreases the expression of the AMPA receptor on synapses 
(Setou et al., 2002), thus suggesting the importance of kinesin on AMPA 
receptor trafficking. In brain lysates, using coimmunprecipitaion assays, 
Kinesin KIF1 is found to interact with Liprin- α which also interact with 
GluA2/GRIP1 complex (Shin et al., 2003). Liprin mutants which are 
unable to bind to GRIP1 blocks the synaptic targeting of AMPA receptor 
(Wyszynski et al., 2002) indicating that GRIP1/ABP protein act as adaptor 
linking AMPA receptor to kinesins, and thus promoting dendritic 
transport.  
 
Most excitatory synapses in the adult brain occur on small dendritic 
protuberances called spines (Hering and Sheng, 2001). Dendritic spines 
lack microtubular cytoskeletons, but they are rich in highly motile actin 
filaments (Fischer et al., 1998), thus,  AMPA receptor-containing 
organelles wgich are trafficking along microtubular tracks, must be 
transferred to the actin-based cytoskeleton for their final delivery into 
synapses.  
 
Protein 4.1N, another actin adaptor protein, is also associated with AMPA 
receptor and is proposed to play an important role in mediating the actin-
based movement of the AMPA receptor.  Direct binding of the neuronal 
isoform of protein 4.1 N with GluA1 through the juxtamembrane region in 
their cytoplasmic C- tail is important  in stabilization and regulation  of 




1.6.3.2 Exocytosis of the AMPA receptor  
There is much evidence which show that the insertions of the AMPA 
receptor occur following LTP induction.  Up to this date, it is still unclear 
whether AMPA receptor was first inserted into the extra synaptic plasma 
membrane or inserted directly into the synapse. A possible scenario will 
be that the AMPA receptor are firstly inserted into the plasma membrane 
in the soma at extra synaptic sites and travel to the dendrites via the 
lateral diffusion in the plasma membrane until it reach a synapse and gets 
anchored in the PSD.  Using membrane impermeable photoreactive AMPA 
receptor antagonist and measuring the subsequent AMPA receptor 
exocytosis electrophysiologically, most of the receptors are found to be 
inserted in the somatic plasma membrane (Adesnik et al., 2005) 
 
Secondly, another possible exocytosis of the AMPA receptor is the 
trafficking of AMPA receptor intracellularly into the dendrites via the 
cytoskeleton-associated motors before the direct insertion at synaptic 
sites. Exo70, an exocyst complex, mediates AMPA receptor insertion 
directly within the PSD rather than at extra synaptic membranes (Greger 
et al., 2006) 
 
Thirdly, the AMPA receptor may be synthesized in the dendritic 
compartment and then directly inserted into the synapse. AMPA receptor 
are seen to be inserted along the dendrites and is dependent on the 
subunits present (Ju et al., 2004; Sekine-Aizawa and Huganir, 2004) 
 
As AMPA receptor insertion can be blocked using tetanus toxin SNARE-
dependent exocytosis, it shows that that AMPA receptor are inserted via 
SNARE-dependent exocytosis (Lu et al. 2001). These processes differ 
according to the different subunits present. As discussed earlier, various 
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subunits have different cytoplasmic tail and these allow differential 






1.6.3.3 The two distinct pathways of AMPA receptor delivery 
The delivery of AMPA receptor into the postsynaptic terminal is a very 
dynamic process which involves varying AMPA receptor cycling in and 
out of synapse under different synaptic plasticity and development 
situations (Ehlers, 2000).  
 
Depending on the subunit composition, AMPA receptor can reach the 
synapse by two distinct pathways: constitutive or regulated pathway. 
While the GluA2-GluA3 oligomers are delivered continuously into the 
synapse regardless of synaptic activity (Passafaro et al., 2001; Shi et al., 
2001), GluA1-2 and GluA-4 containing receptors in contrast are activity-
dependent and are added into the synapse based on NMDA receptor 
activation.  As GluA1 trafficking signals rules dominate over those of 
GluA2 in term of insertion, heteromers of GluA1-2, will behave like GluA1 
homomers (trafficked slowly and is activity dependent)  while GluA2-3 
will behave like a GluA2 homomeric receptors(trafficked fast and   
constitutively) (Shi et al., 2001).  The constitutive pathway allows the 
maintenance of synaptic strength regardless of protein turnover and the 
regulated pathway act transiently dependent on the presence of synaptic 
plasticity.  
 
 Together with the fact that different subunit compositions regulate AMPA 
receptor trafficking differentially, it is also known that these subunits 
have different sets of protein interacting with their cytoplasmic  terminal. 
The GluA2 and the GluA3 bind to GRIP/ABP and PICK1. The GluA2 C 
terminus also binds to N-ethylmaleimide-sensitive fusion protein (NSF) 
and to the clathrin adaptor AP2 which regulate the rapid exocytosis of 
GluA2 at synaptic sites (Beretta et al., 2005)  by probably controlling 
membrane fusion (Rothman, 1994).  The C-terminus of the GluA1 binds to 
SAP-97 while the C-termini of the GluA1 and the GluA4 bind to 
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cytoskeletal protein 4.1N. Internalization of the GluA2-containing is 
modulated by PICK1 interaction while the GluA2-NSF interaction is 
important for the recycling of AMPA receptor into synapses. It is 
interesting to note that NSF influence the interaction of GluA2 with 
another interacting protein, PICK1, which bind and stabilize the 
intracellular pool of GluA2 and thus providing a ready source of receptors 
for fast membrane insertion. The binding of NSF dissociate the GluA2-
PICK1 complex (Hanley et al., 2002) which allows membrane insertion.   
 
1.6.3.4  Synaptic targeting and membrane diffusion  
Retention of the AMPA receptor at the synapse is important so that they 
can be localized to efficiently response to presynaptically-released 
glutamate. Such retention will also allow the maintance of high density of 
receptors at the synapse.  AMPA receptor interacting proteins such as the 
PSD-95 as well as others in the same family are known to be important for 
the synaptic targeting of the AMPA receptor. The overexpression of PSD-
95 is shown to increase the AMPA receptor currents (Béïque and 
Andrade, 2003; El-Husseini et al., 2002). The knockdown of PSD-95 in 
contrast decreases the AMPA receptor synaptic levels (Béïque et al., 2006; 
Elias et al., 2006). 
 
PSD-95 does not bind to AMPA receptor directly but instead bind to the 
stargazin and other transmembrane AMPA receptor regulatory proteins 
(TARPs) proteins. TARPs bind to all four AMPA receptor and the C-
terminal domain of PSD-95. TARPs and PSD-95 interaction appears to be 
crucial for AMPA receptor targeting to synapses (L. Chen et al., 2000; 
Tomita et al., 2005b) . The interaction between stargazin and PSD-95 has 
been shown to be crucial for AMPA receptor diffusion in and out of 




Insertion of the AMPA receptor is proposed to be a two-step process 
which is mediated by stargazin. The AMPA receptor is firstly recruited 
into the surface membrane from an intracellular pool by stargazin. The 
interaction between the C-terminal tail of stargazin and the first two PDZ 
domains of PSD95 via Protein Kinase A (PKA) subsequently allows the 
AMPA receptor to be recruited to the synaptic site. Stargazin and other 
TARPs protein is also important for the maintenance of the surface 
expression of AMPA receptor and thus reducing the turnover rate. 
Stargazer-mutant mice are shown to express a complete loss of surface 
AMPA receptor in cerebellar granule cells. Disruption of this interaction 
result in an increase in AMPA receptor diffusion and prevented AMPA 
receptor accumulation at synaptic sites (Bats et al., 2007), suggesting that 
the stargazin–PSD95 complex regulate AMPA receptor lateral diffusion at 
synapses and is important for the retention of receptors at synapses. 
 
1.6.3.5 Endocytosis of the AMPA receptor 
Apart from the delivery of AMPA receptor to the surface, there are also 
constitutive and regulated pathways for the removal of AMPA receptor 
from synapses.  The highly conserved endocytosis mechanism for 
membrane protein regulation is clathrin-mediated (Mousavi et al., 2004). 
Dynamin and endophilin is important for endosome formation, while AP-
2 clathrin adaptor molecules link specific cargo with the clathrin lattice. 
The AMPA receptor endocytosis requires dynamin and occurs through the 
clathrin –coated pits. The endocytic zones which is segregated from the 
PSD can be found  in the lateral margins of the excitatory synapses 
(Blanpied et al., 2002).  
 
 
1.6.3.6 Recycling and degradation of the AMPA receptor  
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The activation of the NMDA receptor regulate the rate of recycling and 
also the balance intracellular versus surface of AMPA receptor (Park et al., 
2004) . After LTP,  there is an upregulation of recycling of endocytic cargo 
and also translocation of recycling endosomes into the spines (Park et al., 
2006, 2004). Neuron-enriched endosomal protein of 21 kDa (NEEP21) is 
localized to early and recycling endosomes (Steiner et al., 2002) and 
interacts with general endocytic/recycling proteins such as syntaxin 13 
(Prekeris et al., 1998) Down regulation of NEEP21 leads to a general 
reduction of recycling (Debaigt et al., 2004; Steiner et al., 2002). Following 
NMDA receptor-induced internalization,   the suppression of the NEEP21 
is  found to slows down the GluA1 and GluA2 recycling (Steiner et al., 
2002) through its interaction with its interaction with GRIP and syntaxin 
13 (Steiner et al., 2005).  These results suggest that the AMPA receptor -
interacting proteins GRIP and PICK1 may play some role in the regulation 
of receptor recycling to modulate the level of synaptic receptors.  
Studies have shown the proteins responsible for the 
ubiquitin/proteasome system (UPS), is involved in the degradation of the 
AMPA receptor. Direct ubiquitation of the AMPA receptor interacting 
protein is observed but not AMPA receptor itself, and these may be 
important in the trafficking of AMPA receptor. Direct ubiquitation of the 
PSD-95 by the ubiquitin ligase Mdm2 is found to cause a loss of surface 






1.6.4 Importance of the GluA2 in the AMPA receptor   
The presence of GluA2 within the tetramer dictates the calcium 
permeability of the AMPA receptor. The ability of the GluA2 to regulate 
calcium permeability is in turn dependant on the RNA editing, a post 
transcriptional modification that alters a codon encoding glutamine (Gln; 
Q) to a codon encoding arginine (Arg; R) in the GluA2 mRNA. The 
presence of the edited GluA2(R) subunit will render the AMPA receptor to 
be calcium impermeable. A negative electrostatic potential is formed 
within the N-terminus of the M2 loop when a Gln (Q) is present, and thus 
attracting cations. With the replacement of neutral Gln(Q) to positively 
charged Arg(R) , this potential is neutralized and the diffusion of divalent 
cations through the channel is prevented (Kuner et al., 2001). While 
GluA2 encodes an Arg(R) at position 607, GluA1,3,4 encodes a Gln(Q). 
Using  site directed mutagenesis to alter the Arg(R) mRNA to a Gln(Q) , as 
found in other subunits, investigators showed that GluA2(Q) subunits 
self-assembled into functional Ca2+ permeable AMPA receptor . This 
showed that the calcium permeability of the AMPA receptor depends on 
the presence of a single amino acid at position 607 in the GluA2 
mRNA(Hume et al., 1991; Lee et al., 1998) . 
The AMPA receptor is deemed calcium permeable if they are 1) GluA2- 
lacking or 2) if they contain the unedited GluA2 (Q) subunit. There are 
many evidence up to date that suggest that these GluA2-lacking AMPA 
receptor contribute to normal functioning of the brain and diseases (Isaac 
et al., 2007; Man, 2011; Pellegrini-Giampietro et al., 1997; Wiltgen et al., 
2010). Almost all GluA2 RNA undergoes RNA editing and only less than 
1% of these remain to be unedited across the grey matter of the brain. 
Due to the very minute percentage of unedited GluA2 receptors, it is often 
suggested that these do not play any major role in brain function and 




RNA editing of the GluA2 involves the formation of a double stranded 
RNA (dsRNA) structure  between an editing site in the pre-mRNA and an  
intronic sequence called the editing complementary sequence(ECS), 
located in intron 11 downstream  of editing site(Higuchi et al., 1993). The 
primary RNA editing enzyme, adenosine deaminase acting on 
RNA(ADAR), identifies this dsRNA structure and alters the CAG codon 
encoding Glutamine(Gln) to a CIG codon encoding Arginine (Arg), though 
it is still unclear how this site recognition occurs (Dabiri et al., 1996). Up 
to date, three ADAR family members have been identified namely ADAR1-
3. Although ADAR3 is exclusively expressed in the brain (C. X. Chen et al., 
2000),  its deaminating activity has not been demonstrated and may play 
a regulatory role in RNA editing.  In contrast, the ADAR2 is fully 
responsible for the GluA2Q/R site at amino acid 607 (Bass, 2002; Melcher 
et al., 1996). ADAR2 also edits all AMPA receptor subunits at amino acid 
position 764 which alters the codon for Arginine(R) to Glycine (G) at the 
R/G site. Both ADAR1 and ADAR2 also catalyse the Q/R sites of GluR5 and 
GluR6 subunits of kainite receptors. ADAR2 pre-mRNA and mRNA 
themselves are susceptible to A-to-I editing mediated by ADAR2. 
The edited GluA2 is shown to be retained in the ER before it is being 
trafficked to the synapse(Greger et al., 2002). The edited GluA2 at the Q/R 
site forms a stable pool of the subunits in the ER which is stored for later 
use of AMPA receptor formation. GluA2 RNA editing at the Q/R site also 
plays a role in AMPA receptor tetramerization as edited GluA2 
preferentially form dimers (Greger et al., 2003).  In the absence of GluA2 
Q/R RNA editing, hetero- as well as the homotetramers are formed and 
trafficked form the ER to the plasma membrane.  Tetramerization, 
however, also dependent upon the editing at the R/G site (Greger et al., 
2007). When editing occurs at the Q/R site, but is not present at the R/G 
site, GluA2 subunits are more likely to tetramerize (Greger et al., 2006) . 
Such AMPA receptor trafficking can cause the excessive Ca2+ influx in the 
diseased brain. Using pep2m peptide to block the interaction between the 
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NSF and the heterotetramer leads to reduction of cell toxicity, suggesting 
that interaction of the unedited GluA2 with other proteins may regulate 
the unedited GluA2 mediated excitotoxicity(Mahajan and Ziff, 2007).  
 
1.7 AMPA and NMDA RECEPTOR IN SYNAPTIC PLASTICITY 
1.7.1 Synaptic plasticity  
Synaptic plasticity plays an important role in the cognitive function, 
allowing synapses the ability to strengthen or weaken over time 
depending on whether there is a need to increase or decrease their 
activity.  
Short term plasticity is caused by the activity of synapse either 
increase or decrease the synaptic transmission of that particular 
synapse for a few minutes or seconds.  
Long term plasticity is similar to short term plasticity except that 
it affects the transmission for long time.  
Homeostatic plasticity is how the synapse change the sensitivity 
of an excitatory neuron depending on what is required for synaptic 
gain and firing 
 
Long-Term Potentiation(LTP) was discovered by Terje Lomo in 1973 
when he first discovered that tetanic (high-frequency) stimulation to the 
presynaptic perforant pathway cause a lasting increase in the activity of 
the postsynaptic dentate gyrus (Lømo, 2003).  Over the years of research, 
it was understood while high frequency stimulation caused the induction 
of LTP, low frequency stimulation caused Long-term depression (LTD). 
During LTP, the post-synaptic neuron is more sensitive to the same pre-
synaptic stimuli, increasing the amplitude of the EPSC. The opposite 
happens during LTD. Most types of LTP and LTD require the activation of 
NMDA receptor and the subsequent cascade of signalling events triggered 
by the Ca2+ influx influence the recycling of the AMPA receptor. The fast 
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excitatory and dynamic nature of the AMPA receptor allows the synaptic 
strength of the neurons to be tightly regulated by the recycling of the 
AMPA receptor in and out of the synapse.  LTP is generated by delivering 
more AMPA receptor into the synaptic membrane by lateral diffusion, 
whereas LTD is generated by removing more AMPA receptor from the 
synaptic membrane (Adesnik et al., 2005; Collingridge et al., 2004; Groc et 
al., 2004; Malinow and Malenka, 2002; Song and Huganir, 2002). The 
recycling of the AMPA receptor is dependent on the subunit-specific 
AMPA receptor interacting protein as well as the post-translational 
modification that occur at their c-terminal of AMPA receptor. Thus, AMPA 
receptor is responsible for the expression of dynamic changes in neuronal 
synaptic efficiency while NMDA receptor for its control.   
 
1.7.2 The role of AMPA and NMDA receptor in synaptic 
plasticity  
As discussed, glutamate activates two main kinds of receptors, NMDA and 
AMPA receptor which often co-exist on post-synaptic neurons but each 
with their own distinct physiological properties. Released glutamate from 
the axon terminal by weak electrical stimulation of the presynaptic 
neuron will then bind to both the AMPA and NMDA receptor. Although 
both the receptors are permeable to Na+ and K+ ions, the weak stimulation 
only activates the AMPA receptor, causing a slight depolarization of the 
postsynaptic neuron. Few ions flow through the channel when the 
glutamate binds to the NMDA receptor. The presence of Mg2+ ions causes 
this low conductance by preventing the ions from moving freely through 
the channel. Thus, the EPSC is mediated by AMPA receptor. In the 
presence of sufficient stimulation strength, the AMPA receptor is able to 
depolarized post synaptic membrane sufficiently to expel the Mg2+ from 
the NMDA receptor channel (Esteban, 2003). With this, the NMDA 
receptor can now actively respond to glutamate, allowing entry Ca2+ on 
top of Na+, which triggers synaptic delivery or removal of AMPA receptor 
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and causes LTP or LTD, respectively (Bredt and Nicoll, 2003; Esteban, 
2003; Hayashi, 2000; Shi et al., 1999; Song and Huganir, 2002). Calcium is 
an important second messenger in the activation several intracellular 
signalling cascades. One of them involve the calcium binding to 
calmodulin, which then activates several protein kinase  including 
Ca2+/calmodulin-dependent kinase II (CAMKII) which affects the AMPA 
receptor. Conductance to Na+ is increased when CAMKII phosphorylate 
AMPA receptor that are already present in the dendritic spine membrane. 
In addition, CaMKII also promotes movement of AMPA receptor from 
intracellular stores into the membrane, allowing more receptors to 
stimulate the spine. Ca2+ may also facilitate the release of transmitter 
from the presynaptic axon terminal via retrograde signals such as nitric 
oxide (NO).  
 
1.7.3 Role of NMDA and AMPA receptor in Long-term 
potentiation (LTP)  
The activation of CaMKII during the induction of long-term 
potentiation(LTP)  has been  well studied (Lisman et al., 2002). Calcium 
influx through the NMDA receptor induces LTP which results  in the 
activation of CaMKII (Fukunaga, 1993). LTP is shown to be blocked when 
inhibited post synaptically using  CaMKII inhibitors and through genetic 
deletion of CaMKII subunit (Malenka et al., 1989; Malinow et al., 1989; 
Silva et al., 1992). Constitutive activation of CaMKII in contrast enhances 
the synaptic transmission and also LTP (Lledo et al., 1995). Although 
CaMKII is phosphorylated during LTP, it is not required for synaptic 
delivery (Hayashi et al. 2000). This evidence strongly suggests the 
importance of CaMKII in LTP.  
 
The phosphorylation of GluA1 by CaMKII at Ser831 also increase the 
AMPA receptor levels (Benke et al., 1998). As a result of increased 
number of AMPA receptor at the surface, the response to a stimulus of any 
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given strength will be stronger that it was before the NMDA receptors are 
activated. This enhancement of synapse is thought to be the mechanism 
underlying the expression of LTP. CaMKII also phosphorylates other 
downstream molecules such as stargazin and rasGAP to lead to synaptic 
delivery of AMPA receptor (Nicoll et al., 2006; Zhu et al., 2002) The 
phosphorylation of  RasGAP is inhibitory and results in the accumulation 
of RasGTP(active Ras) which triggers p42 MAPK  and the 
phosphatidylinositol-3 kinase (PI3K) , thus leading to AMPA receptor  
synaptic delivery 
 
Another site which is important for the induction of LTP is 
phosphorylation of GluA1 at Ser845 by Protein Kinase A (PKA).  In GluA1-
transfected HEK 293 cells, intracellular perfusion of PKA resulted in a 
potentiation reduction of peak amplitude of the whole-cell glutamate-
gated current (Roche et al., 1996) and regulate the open channel 
probability of the receptor (Banke et al., 2000). The mutation of Ser845 to 
alanine reversed the effect. In addition, the phosphorylation of the Ser818 
by Protein kinase C (PKC) also leads to the induction of LTP.  Site-directed 
mutagenesis of Ser845 of the GluA1 showed that although 
phosphorylation of this site is necessary during LTP, it is not sufficient for 
the delivery of GluA1 during LTP (Malinow, 2003). Ser845 
phosphorylation may also induce AMPA receptor delivery to the extra 
synaptic membrane and then to the synapse through surface diffusion 
(Man et al., 2007; Oh et al., 2006) 
 
The importance of phosphorylation sites in LTP is confirmed when knock-
in mouse with Ser831 and Ser845 mutation diminishes LTP(Lee et al., 
2000). Mutation at the PDZ ligand on the GluA1 prevents the 
incorporation of GluA1 into spines and synapses, indicating its 
importance for activity-dependent trafficking of AMPA receptor (Piccini 
and Malinow, 2002) and synapses (Hayashi, 2000; Kim et al., 2001) The 
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GluA1 knockout mice lack LTP in the CA1 region of the hippocampus and 
can be rescued by genetically expressing GluA1 (Mack et al., 2001) 
 
Recent studies of endogenous AMPA receptor shows that these receptors 
can be driven into the post synaptic membrane during LTP (Shi et al., 
2001) and by experience (Takahashi et al. 2003) which involves C-
terminal interactions.  The deletion of the GluA1 C-tail prevents LTP and 
the experience-dependent delivery of AMPA receptor. Surface expression 
and inducible exocytosis of GluA1 are impaired when the C-terminus is 
mutated (Passafaro et al., 2001). 
 
1.7.4 Role of NMDA and AMPA receptor in Long-term 
depression (LTD)  
It is not easy to study the exact mechanisms that underlie LTD as AMPA 
receptor endocytosis can occur due to either Long-Term Depression 
(LTD) (Beattie et al., 2000; Lissin et al., 1998)or in response to stimuli 
(Ehlers, 2000; Lin et al., 2000; Man et al., 2000).  
 
Immunocytochemical data  showed that NMDA receptor-dependent LTD 
in hippocampal cultures decrease  AMPA receptor  surface receptors 
(Carroll et al., 1999). A decrease in the number of AMPA receptor in 
synaptoneurosomes is observed when hippocampal LTD is induced in 
vivo(Heynen et al., 2000).  LTD is also blocked when a peptide that 
disrupts dynamin function is applied to CA1 pyramidal neurons or 
cerebellar Purkinje cells (Wang and Linden, 2000).  
 
Activation of NMDA receptor which results in AMPA receptor requires 
calcium influx and activation of the calcium-dependent phosphatase 
calcineurin (Beattie et al., 2000; Ehlers, 2000). LTD is also induced by the 
dephosphorylation of GluA1 at Ser845 and the CaMKII site at Ser831. 
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Mutations at these two sites resulted in significant deficits in LTD and 
NMDA receptor induced AMPA receptor internalization (Lee et al., 2003) 
In GluA2, the clathrin adaptor protein AP-2 interacts with a site that 
overlaps with the NSF-binding site which is critical for NMDA-induced 
internalization of AMPA receptor. The blocking of GluA2-AP2 interaction 
using a peptide also block the induction of LTD (Lee et al., 2002). 
 
The GluA2-interacting proteins GRIP, ABP/GRIP2, and PICK1 which all 
bind the PDZ domain at the C-terminal play a critical role in AMPA 
receptor endocytosis and LTD.  A mutated form of GluA2 does not allow 
binding to GRIP/ABP in hippocampal neurons which  will get targeted  to 
the surface, reducing its accumulation at synapses as compared with wild-
type GluA2 (Osten et al., 2000; Shi et al., 2001) . Thus, the stabilization of 
AMPA receptor at the synapse requires the binding of GluA2-containing 
receptors to GRIP/ABP, which limit their endocytosis or by increase 
recycling of GluA2. 
 
In cerebellar LTD, AMPA receptor internalization requires the activation 
of protein kinase C (PKC) at Ser880 (Chung et al., 2000; Linden and 
Connor, 1991) . The activation of PKC with a phorbol ester is sufficient to 
induce LTD and AMPA receptor internalization. Phosphorylation of GluA2 
PDZ-binding site by PKC, prevents the association of GluA2 with GRIP and 
ABP (Chung et al., 2000; Matsuda et al., 2000, 1999)  but promotes 
binding to PICK1 (Chung et al., 2000; Matsuda et al., 1999; Perez et al., 
2001) 
 
During LTD, Ca2+ entry through NMDA receptor, activates a Rap-GEF, 
which increases the active Rap(Rap-GTP).  Rap activates p38 MAPK 
cascade leading to the removal of AMPA receptor from synapses (Groc 
and Choquet, 2006; Kawasaki et al., 1998) In addition, a decrease of PSD-
95 availability due to proteasome-mediated degradation leads to 
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endocytosis of synaptic AMPA receptor (El-Husseini Ael et al., 2002; 






Figure 1.4 Schematic diagram showing the signalling cascade mediating 
LTP and LTD 
Opening of the NMDA receptor which allows the entry of calcium ions(Ca2+) in 
the post synaptic terminal, lead to both addition and removal of synaptic AMPA 
receptor resulting in LTP and LTD respectively.  LTP: Ca2+ entry through synaptic 
NMDA receptor, activates CaMKII which inturns inhibits RasGAP by 
phosphorylation. Accumulation of active Ras (Ras-GTP) as a result of a decrease 
of RasGAP, triggers the p42MAPK and PI3K which  lead to synaptic delivery of 
AMPA receptor. LTD: Ca2+ entry through extra-synaptic NMDA receptor, 
activates a Rap-GEF, which increases the active Rap(Rap-GTP) by stimulating the 
release of GDP to allow binding to GTP.  Rap activates p38 MAPK cascade leading 
to the removal of AMPA receptor from synapses.  
 






methylisoxazole-4-proprionic acid; CaMKII,Ca2+/calmodulin-dependent kinase II; 
p42MAPK,p42 mitogen-activated protein kinase; PI3K, phosphatidylinositol-3 
kinase; Ras/Rap GAP,inactive small GTPase Ras/Rap; Ras/Rap-GTP,active small 
GTPase Ras/Rap; GDP,Guanosine diphosphate; GTP, Guanosine triphosphate; Rap 
GEF,Guanine nucleotide exchange factor; GDP,Guanosine diphosphate; 
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2.1 DEMENTIA AND COST TO SOCIETY  
The increase of life expectancy worldwide has caused much concern 
about ageing-related impairments. One of the chronic illnesses most 
experienced by the elderly is dementia.  Dementia is an umbrella term for 
progressive neurodegenerative syndromes diagnosed when there is 
persistent cognitive and intellectual impairment in at least three areas 
which includes memory, language, visuospatial skills, emotions and 
personality, and complex cognition. Symptoms may include loss of 
memory, difficulty in finding the right word or understanding what 
people are saying, difficulty in performing previously routine tasks, 
personality, and mood changes.  These symptoms progressively get worse 
with time and are more severe than those experienced in normal aging. 
Dementia can be caused by cerebrovascular disease (such as stroke) or 
neurodegenerative disease (such as Alzheimer’s disease) which affect the 
central nervous system resulting in brain cell loss.  Although dementia is 
commonly associated with memory dysfunction, there are also dementia 
cases where the patient experiences dysfunction of executive function 
and speech but with relatively intact memory. 
Being one of the major causes of disability and dependence among the 
elderly worldwide, affecting not only the patients but also their caregivers 
and families, dementia is increasingly turning into a major social and 
economic burden.  At present, the number of people living with dementia 
worldwide in 2011 is nearly 35.6 million, and is expected to double to 66 
million in 2030, and reach 115.4 million by 2050. The estimated 
worldwide economic burden of these diseases is estimated at US$ 604 
billion. It is estimated that informal care (defined as unpaid care provided 
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to parents or friends who present functional and or/and cognitive 
disability) takes up 36 to 85 % of the total costs of dementia (“2013 
Alzheimer’s disease facts and figures,” 2013).  It is hoped that by investing 
in research and development approaches to early diagnosis and care, the 
future societal cost of dementia can be anticipated and more properly 
managed. 
 The most common causes of dementia whose prevalence increases with 
age includes Alzheimer disease (AD), vascular dementia (VaD), Mixed 
dementia (MIX) and Lewy body dementia (LBD) (Refer to figure 2.1). 
These dementias are caused by multiple factors including accumulation of 
proteins (lewy bodies or amyloid protein) and ischemic damage due to 
cerebrovascular diseases.  
 
Common causes of Dementia 
Alzheimer’s disease:  This is one of the most common causes of 
dementia. The accumulation of amyloid plaques and neurofibrillary 
tangles proteins prevent the efficient transportation of neurotransmitter 
as well nutrients through the neurons resulting in neuronal loss and 
changes in morphology of the neurons and synaptic plasticity such as the 
dendritic spine shrinkage and reduction in spine density. Patients 
deteriorate progressively with time.  
Dementia with Lewy bodies: This dementia is caused by the 
accumulation of very small spherical lewy bodies inside nerve cells such 
as brain cells, leading to disruption of normal brain function. As lewy 
bodies are also found in Parkinson’s disease, their symptoms of 
movement dysfunction are similar. Patients deteriorated progressively, 
like those of Alzheimer’s patients.  
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Cerebrovascular-associated dementia: The brain requires oxygen-rich 
blood to function.  Damage to the blood vessels (such as in stroke) leads 
to irregularities in the brain’s blood supply causing neuronal loss due to 
lack of nutrients. Depending on the location of the vascular lesion, the 
clinic-pathology of dementia caused by stroke varies. The symptoms can 




Figure 2.1 Summary of frequencies of different types of dementia 
Sources:  
Alzheimer’s Disease : (“2013 Alzheimer’s disease facts and figures,” 2013; 
Thies et al., 2013) 
Vascular dementia: (Jellinger, 2007b; Pohjasvaara et al., 2000)  
Lewy body dementia: (Aarsland D et al., 1996; Aarsland et al., 2003; 
McKeith et al., 2005) 






2.2 ALZHEIMER’S DISEASE (AD)  
AD is the most common form of dementia among the elderly and involves 
progressive loss of memory especially recent memories and as well as 
other cognitive functions and will eventually progressively deteriorate 
rendering patients dependent on the caregivers. Alzheimer’s disease is a 
multi-factorial disease with advanced age being one of the major factors.  
The risk of AD increased to 20 % in people over 80 years old compared to 
5% in those above 70 years old, suggesting aging-related biological 
processes may be implicated in the pathogenesis of the disease.  This is  
also suggestive of cumulative effect of  risk factors over a longer life span 
(Kawas et al., 2000; Kukull et al., 2002).    There are different stages of AD 
progression namely early, mid and late stages which display varying 
symptoms.  Symptoms such as hallucination, confusion, aggression and 
depression are common.  Death usually occurs between 3-15 years after 
diagnosis usually from pneumonia.  At present, there are over 36 million 
people worldwide with dementia, costing USD 604 billion (Thies et al., 
2013). With the increasing global ageing population, both the number of 
AD patients as well as cost is expected to increase exponentially, posing a 
huge social and economic burden.   
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2.2.1 Neuropathogical Features of AD 
The main neuropathological features of AD are numerous extracellular 
deposits termed senile plaques (Amyloid β aggregates) and intra-
neuronal neurofibrillary tangles (NFTs) (Bi, 2010; Kawahara and Kuroda, 
2000; Peers et al., 2009; Tanzi et al., 1987a). Other molecular hallmarks of 
the disease include extensive loss of neurons in the patient's brain (Tanzi 
et al., 1987b; Zhang et al., 2011), cholinergic loss and changes  in synapse 
in the hippocampus and other areas of brain essential for cognitive and 
memory functions (Parihar and Hemnani, 2004), gross atrophy (30-40 % 
loss of brain weight) of the brain resulting from massive neuronal loss 
from the cortical and well as the subcortical region which causes  
enlarged ventricles as well as widening of the sulci.  This section will 
discuss current theories which hypothesis the neurodegeneration of AD.  
 
2.2.1.1 The amyloid hypothesis  
In the amyloid hypothesis, the generation and aggregation of extracellular 
Amyloid-β (Aβ) plaques is the principal causative feature of AD 
pathogenesis. APP, a ubiquitious transmembrane required for cell 
signaling and neuronal growth undergoes cleavage by three secretases: α, 
β- and γ-secretases.  The cleavage of APP can either go through the non-
amyloidogenic or amyloidogenic pathway. In the non-amyloidogenic 
pathway, APP is cleaved by firstly by α-secretase, followed by γ-
secretases, generating a soluble 40 amino-acid peptide (Aβ 1-40) and 
large soluble APP fragment (sAPPα), which is released extracellularly. In 
contrast, in the amyloidogenic pathway, APP is cleaved by firstly by β- 
secretases followed γ-secretases, resulting in the generation of the 
neurotoxic and fibrogeneic Aβ fragment, Aβ42. Aβ monomers  combine to 
form soluble dimers and oligomers which build up to become fibrils and 
plaques (Hardy and Selkoe, 2002). These extracellular plaques causes an 
interruption of cell communication amongst neurons which will 
eventually lead to cell death (Masters and Selkoe, 2012). In early AD, the 
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Aβ plaques were firstly observed in the temporal cortex, followed by the 
hippocampus and subsequently spread to the other brain areas (Braak 
and Braak, 1991) (see figure 2.2).  In AD, the protein level expression and 
activity of β-secretases is found to be significantly increased, resulting in  
the increase in the production of toxic Aβ42 (Fukumoto et al., 2002). As 
total APP levels have not been observed to change significantly in AD, this 
leads to a corresponding decrease of the levels of non-amyloidogenic 
sAPPα (Lannfelt et al., 1995) . Research has shown that enhancing α-
secretase activity may actually be a putative therapeutic strategy for the 
treatment of AD (Lannfelt et al., 1995; Lichtenthaler, 2011; Vincent and 
Govitrapong, 2011).  
 
2.2.1.2 The tau hypothesis 
Tau protein which binds to the microtubules via a C-terminal binding 
domain stabilizes microtubules by forming cross bridges between them. 
Stabilized microtubules promote tubulin polymerization which is  
fundamental for axon elongation and maintenance thus providing 
structural support to the neurons  (Kosik, 1993). Tau is a phosphoprotein 
and is phosphorylated by numerous serine/threonine kinases, including 
GSK-3β, PKA, PKC, CDK5, MARK, JNK, p38MAPK and casein kinase II.  
Once phosphorylated by kinase, will be released from the microtubulin 
and loses its ability to bind to microtubules.  The microtubule dynamics is 
maintained by co-ordinated kinase and phosphatase actions on tau. 
(Mandelkow et al., 1995) 
In the normal brain, tau protein is phosphorylated at a number of directed 
sites, which leads to regulation of microtubule dynamics. In AD brains 
however, tau is abnormally hyper phosphorylated to form pair helical 
filaments (PHF) which greatly reduced the ability to bind to microtubules. 
PHF formed the neurofibrillary filament which is found mainly in the 
cytoplasm of pyramidal neurons and is observed as dense aggregate of 
long unbranched filaments (refer to figure 2.2). Hyper-phosphorylated 
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Tau which involves phosphorylation at serine 396 and serine 404 forms 
major part of PHFs; impairing Tau and resulting in the destabilization of 
microtubules in AD brains, ultimately leading to neuronal degeneration. 
The formation of fibrillary tangles and the subsequent disruption of the 
axonal transport is the reason for neuronal cell death(Evans et al., 2000). 
The number of NFT is found correlated with the severity of the dementia 
(Bierer et al., 1995). However, measuring the levels of tau in the CSF is not 
definitive because there is an overlap of normal and AD patient (Kolarova 
et al., 2012). 
Currently, it is not yet established how amyloid plaque and neurofibrillary 
tangles results in the pathology of AD. However, it is known that 
accumulation of such proteins lead to the disruption of calcium ion 
homeostasis which in turn induces apoptosis. Certain enzyme function 
and the utilisation of glucose by neurons may also be affected. The 
accumulation of amyloid plaque and neurofibrillary tangles also disrupt 
cell communication between neurons and cause neurotransmitter 







 Figure 2.2 Neuropathological features of AD 
Photomicrograph of the temporal cortex of a patient with 
Alzheimer's disease. Numerous senile (neuritic) plaques (black 
arrows) and neurofibrillary tangles (red arrow) are shown. 





2.2.2 Clinical Diagnosis of AD 
Before the diagnosis of AD can be made, the following has to be done 
 Assessing of the symptoms 
 Assessing of full medical history and medications that is being 
taken 
 Assessing of mental abilities using cognitive test such as the MMSE 
or CAMCOG 
 Physical examination  
 Blood test to rule out other causes of the symptoms. 
 Computed tomography(CT) scan or Magnetic Resonance 
imaging(MRI) 
 
Diagnosis of definite AD is made using The National Institute of 
Neurological and Communicative Disorders and Stroke (NINCDS) and the 
Alzheimer's Disease and Related Disorders Association (ADRDA) criteria 
(NINCDS-ADRDA Alzheimer's Criteria) (McKhann et al., 1984). Eight 
cognitive domains are most commonly impaired includes memory, 
language, perceptual skills, attention, constructive abilities, orientation, 
problem solving and functional abilities.  The CERAD neuropathology 
protocol which involve Braak staging (Braak and Braak, 1991) to assess 
neurofibrillary tangle involvement and amyloid senile plaque assessment 
is used to diagnosis of AD (Mirra et al., 1991).  
 
2.2.3 Different types of AD 
AD exists in two forms namely a familial early-onset form (FAD) and the 
sporadic form. FAD is linked to amyloid precursor protein (APP) and 
presenilin gene mutations (Zhang et al., 2011) while the sporadic form 
that may be due to environmental factors and genetic susceptibility (Li et 
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al., 2009; Zhang and Le, 2010). While the mutations that cause FAD are 
known, not much is known about what causes the 95 % of AD cases which 
are sporadic.  
 
2.2.3.1 Sporadic Alzheimer's disease   
This form of AD also called late-onset Alzheimer’s disease (LOAD), is the 
most common form of Alzheimer's disease, accounting for about 95% of 
cases, and usually occurs after age 65. Sporadic Alzheimer's disease 
affects almost half of all people over the age of 85. Late-onset disease is 
more likely due to a gradual accumulation of age-related malfunctions. 
Some studies have noted that the pathologic hallmarks (protein deposits 
called plaques and tangles) are more severe in eFAD than LOAD 
 
2.2.3.2 Early-onset familial Alzheimer disease (eFAD) 
This form of extremely rare Alzheimer’s Disease is entirely hereditary and 
has a much earlier onset with symptoms appearing at an usually early age 
(often in the 30s -50s). At least two generations of members suffer from 
AD in affected families.   
The study of eFAD families has led to the discovery of autosomal-
dominant mutation on three genes that cause familial AD: amyloid 
precursor protein (APP) on chromosome 21, presenilin-1 (PS1) on 
chromosome 14, and presenilin-2 (PS2) on chromosome 1. While the PS1 
mutations account for most eFAD, APP and PS2 are rarer. The possession 
of pathogenic mutation in any one of these three genes will lead to the 
development of eFAD.  There are also cases of eFAD that cannot be linked 
to one of these three genes.  
The disease progression of eFAD is similar to those of the more common 
late-onset AD, the patients will gradually lose memory and other mental 
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functions over several years, before becoming completely dependent on 
others. Since eFAD occur in a relatively young person, the AD clinical 
symptom is pure without the complications of old age. The progressive 
loss of brain function prematurely is also tragic for someone who is at his 
prime and physically active. This results in psychiatric complications such 
as depression and agitation.  
ApoE, a gene found on chromosome 19, affect the likelihood that a person 
will develop AD. The different allele of APOE genes are ApoE2, ApoE4 and 
APoE4. It is estimated that almost 60-90% of AD cases are associated with 
ApoE susceptibility to late-onset AD. This susceptibility is due to the 
combination of allele; the risk of developing AD increases and the mean 
age onset decreases with each copy of the APoE4 inherited. A person that 
possesses two APOE4 alleles has an increased risk of developing AD by 
12-15 folds. By contrast, the inheritance of ApoE2 decreases the 
development of AD and increase the mean age of onset. This correlation 
between different ApoE alleles and susceptibility of AD development is 
observed in both familial as well as the sporadic cases. The smaller 
number of E4/E4 and E3/E4 correlates with the lower prevalence of AD 
in Japan with higher mean age of onset. In a given family with an APP or 
presenilin-2 (but not presenilin-1) mutation, carriers who also have 
inherited an ApoE4 gene tend to become symptomatic at a younger age 
than their relatives who have the more neutral ApoE3 or ApoE2 alongside 
the APP or presenilin mutation.  One hypothesis on the increased AD risk 
associated with Apoe4 allele is the reduced efficiency of protein turnover 
which lead to the accumulation of damaged protein such as advanced 
glycosylation end products (Kim et al., 2009)  
 Another gene that is known to be a risk factor for AD is CLU (gene which 
encode clusterin) where a variant of the  gene  can damage the wiring of 
the gene when one is 20 years old. Thus, increasing the risk of getting 




2.2.4 Impairment of the Glutamatergic system in Alzheimer’s 
disease (AD) 
In addition, deficits of cholinergic, glutamatergic, GABAergic as well as 
serotoninergic innervation have been reported in AD (Francis et al., 2010; 
Tsang et al., 2006). The cholinergic and glutamatergic systems are 
thought to play key roles in the progress of cognitive decline in AD 
because of their crucial function in cognition (Schaeffer and Gattaz, 2008). 
Dsyregulation in the cholinergic system such as loss of basal forebrain 
cholinergic nuclei leading to large reduction of  cholinergic neuron as well 
as choline acetyltransferase activity is a well-known observation in AD 
(Francis et al., 1999).  Currently, most drug treatments for cognitive 
dysfunction in AD target slowing down cholinergic neurodenegeration or 
its consequences of the mechanism action (Mufson et al., 2008). 
The perforant pathway is the primary source of cortical input originating 
from the entorhinal cortex to the hippocampal formation including 
dendate gyrus, all CA fields and the subiculum. As entorhinal cortex was 
destroyed in AD and glutamate is the main neurotransmitter involved in 
the excitatory action of the pathway, the glutamatergic system is thus 
well-regarded to be affected in AD (Francis, 2003). Hyman et al observed 
a significant decrease of free glutamate in the terminal zone of the 
perforant pathway in AD compared to non-demented controls, suggesting  
perforant pathway destruction and corticolimbic pathway disruption 
which may underlies memory dysfunction in AD (Hyman et al., 1987). 
Rupsigh et al also found decreased hippocampal glutamate levels in AD 
compared to normal elderly controls using magnetic resonance 
spectroscopy(MRS) (Rupsingh et al., 2011). Procter et al observed 
reduction of glutamate levels in the cerebral cortex of antemortem 
(biopsy) of early AD. Decrease in cerebrospinal fluid glutamine levels and 
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brain glutaminase activity in brain tissue also indicates the presence of an 
early metabolic abnormality (Procter et al., 1988)   
Other glutamatergic  system impairments in AD also includes  loss of 
pyramidal neurons and synapses (Morrison and Hof, 1997; Neary et al., 
1986; Terry et al., 1991) , loss of vascular glutamate transporters VGLUT1 
and VGLUT2 (Kashani et al., 2008) , reduced synaptic glutamate reuptake 
(Procter et al., 1994) , reductions in the expression of NMDA and AMPA 
complex (Armstrong and Ikonomovic, 1996; Greenamyre and Maragos, 
1993; Yasuda et al., 1995)  , and reduced receptor binding (Cowburn et al., 
1988; Cross et al., 1987; Palmer et al., 1986) , etc. Co-localization of 
glutamate pyramidal neuron with NFT and senile plaques has been found 
in post-mortem AD brains  (Braak et al., 1993; Francis et al., 1992) 
Neurochemical changes in AD human brains such as selective alterations 
in NMDA receptor subunit protein and mRNA levels have been detected in 
susceptible regions of post mortem AD brains. Chun-I Sze et al measured 
protein levels of phosphorylated and non-phosphorylated NMDA receptor 
subunits using four brain regions of AD, early AD and control post-
mortem brains by means of immunoblotting. The proteins levels were 
then correlated with cognitive assessment obtained prior to death and 
synaptobrevin levels (a pre-synaptic marker). GluN1 and GluN2B subunit 
receptor density was decreased in hippocampus region of AD.  GluN2A, 
GluN2B and their respective phosphorylated subunits were reduced in 
entorhinal cortices of AD. The levels of non-phosphorylated and 
phosphorylated NMDA receptor subunits correlated positively with the 
cognitive scores and synaptobrevin levels, indicating that abnormalities 
of NMDA receptor correlated with presynaptic alterations and cognitive 
deficits (Sze et al., 2001). By using real-time PCR and western blotting, 
Hynd (1a) et al observed selective loss of GluN1 subunit isoforms in AD. 
Those isoforms which contain the N-terminal peptide was found to be low 
in susceptible region of AD brains  (Hynd et al., 2004a). Decreased 
expression of the  GluN1 mRNA was also observed by Ulas et al  in  
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selected area of the brain such as layers II-IV of the perirhinal cortex (Ulas 
and Cotman, 1997).  Hynd (1b) et al studied further into transcript and 
protein levels of GluN2A-D.  Loss of GluN2A and GluN2B but not GluN2C 
and GluN2D was observed in susceptible regions of AD brains.  Such 
alterations may lead to excessive calcium ion influx and subsequent 
dysregulation of downstream cellular signalling (Hynd et al., 2004b) . 
Loss of GluN2A and GluN2B mRNA was also found to be altered in the 
hippocampus and the entorhinal cortex of AD (Bi and Sze, 2002). Also, 
Selective decreases in GluN2A receptor density was observed in 
hippocampal post-synaptic membrane and was found to be associated 
with AD (Tsang et al., 2008).  No studies has been reported on GluN3A-B 
subunit changes in AD post-mortem brains but  basic research which had 
been done on cell lines and mice suggest that the GluN3A-B receptors is 
worthwhile to look into. Co-expression of GluN3A subunit with 
GluN1/GluN2 in heterologous cells leads to a reduction in NMDA-induced 
currents, decreased magnesium sensitivity and calcium permeability 
(Perez-Otano et al., 2001)  . GluN3A knockout mice also showed increased 
NMDA receptor current (Das et al., 1998) . Synder et al observed the 
internalization of NMDA receptor following in vitro exposure to β-amyloid 
(A) peptide. This observation might underlie reductions of NMDA 
receptor binding in AD (Snyder et al., 2005)  . 
 
Neurochemical changes which affect the AMPA receptor is also described 
in AD human brains. Down regulation of edited GluA2 was observed in 
AD, which might result in calcium influx and downward signaling 
dysregulation.  Akbarian et al found that 99 % of the GluA2 in the 
prefrontal cortex AD postmortem brains were edited as compared to 
99.9% in controls (Akbarian et al., 1995).  Studying the state of AMPA 
receptor of the `vulnerable ‘(regions which is more susceptible to 
developing AD pathology) and `resistant’ regions of the hippocampus AD 
brains using quantitative measurement of western blotting and 
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autoradiography, Carter et al found that in the `vulnerable’ regions,   
GluA2 and GluA2/3 protein levels were decreased 63.8% and 60.6% in 
association with more severe AD neuropathology.  GluA1 levels found to 
be unchanged in `vulnerable‘regions.  They hypothesized that the 
increased of calcium levels due to reduction of GluA2 in ‘vulnerable’ 
regions might play a role in increased susceptibility to glutamate 
stimulation thus leading to more severe neuropathology (Carter et al., 
2004)  Using in-situ hybridization, Pellegrini-Giampietro et al found  
decreased GluR1 mRNA levels in the dentate gyrus in advanced AD 
(Pellegrini-Giampietro et al., 1994) In a study to measure anatomical 
distribution of functional AMPA receptor, Dewar et al used 
autoradiography on post-mortem AD and control brain tissue. AMPA 
receptor binding was found to be reduced in CA1 region of the 
hippocampus and parahippocampal gyrus.  Wakabayashi et al found a 
reduction of GluA1 protein levels by immunoblotting in entorhinal cortex, 
subiculum, dentate gyrus and hippocampus in advanced AD patients 
(Dewar et al., 1991). Disruption of glutamate receptors at Shank-
postsynaptic platform was also observed in  AD (Gong et al., 2009). 
Ikonomovic et al found a loss of GluA2(3) immunoreactivity precedes 
neurofibrillary tangle formation in the entorhinal cortex and the 
hippocampus of AD brain (Ikonomovic et al., 1997) 
Several in vitro and animal-based studies suggest that the exposure to 
Aβ42 peptide, may lead to AMPA receptor dysfunction through 
mechanism which might involve the GluA2 down regulation (Chang et al., 
2006; Hsieh et al., 2006; Liu et al., 2010).  
These AMPA and NMDA receptor abnormalities suggest impairment of 
fast excitatory neurotransmission in specific regions of the AD brain.  It is 
also proposed that in addition to direct consequences of Aβ and 
neurofibrillary tangles, glutamatergic neurons may also be dying due to 
excitotoxicity. Loss of glutamatergic function in AD may be related to the 
increased levels of oxidative stress observed in AD patients (Greenamyre 
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and Young, 1989).  After years of studying AD, it is still not established 
though whether AMPA and NMDA receptor dysregulation cause the 





Summary of NMDA receptor Changes in Alzheimer's Disease 
NMDA receptor Subunit Localization Function Changes in Alzheimer's Disease 
1) Localised to post synaptic 
membrane of the excitatory 
synapses 2) Located on all 
neurons and enriched on 
pyramidal neurons 3) 
Heteromultimeric, 
consisting of one obligatory 
GluN1 and at least one type 
GluN2 subunits 
4)Differential assembly of 
subunits confer distinct 
functional and 
pharmacological properties 
5) GluN2 subunits 
determines agonist affinity, 
Mg and Zinc ions sensitivity, 
modulation by polyamines, 




ubiquitously expressed in brain 
and spinal cord during 
development and adulthood Glycine binding 
1) Decreased in hippocampus, (HP) no reduction in occipital 
cortex (OC) or caudate (Chun-I Sze, 2001). 2) Selective loss of 
NMDA receptor GluN1 subunit isoforms in AD(Hynd, 2004 ) 
3)Conflicting Mk-801 binding results(Hynd, 2004)  
GluN2A 
Partially replaced GluN2B as 
brain matures. Expressed 
mostly in CNS in adult brain 
Glutamate Binding, GluN2A containing 
NMDA receptor have rapid kinetics 
compared to those of GluN2B-
containing NMDA receptor. LTP and 
depotentiation requires GluN2A 
containing NMDA receptor (Massey, 
2004) 
1) Decrease in GluN2A and phosphorylated GluN2A in entorhinal 
cortex (EC) (Chun-I Sze, 2001)2) Decrease in GluN2A mRNA and 
protein in susceptible regions of AD i.e. cingulate gyros, temporal 
cortex and HP (Hynd (1a), 2004). 
GluN2B 
Expressed throughout CNS 
embryonic brain. Expressed 
mostly in the forebrain in adult. 
Glutamate Binding. De novo LTD 
requires the activation of GluN2B 
containing NMDA receptor (Massey, 
2004) 
1)GluN2B decreased in HP, phosphorylated 2B decreased in 
EC(Chun-I Sze, 2001) 2) GluN2B  mRNA  and protein  decrease in  
susceptible regions of AD brain (Hynd (1b),2004) 
GluN2C 
Expressed mostly exclusively in 
the cerebellum Glutamate Binding 
No change in mRNA in cingulate. HP , temporal, motor and OC( 
Hynd, 2004) 
GluN2D 
Expressed in the thalamus, 
brainstem and olfactory bulb in 
adult Glutamate Binding 
No change in mRNA in cingulate. HP , temporal, motor and OC( 
Hynd, 2004) 
GluN3A 
1)cerebral cortex, subcortical 
forebrain, midbrain and 
hindbrain, cortical region, 
thalamus and pon (highest 
amount) 2)Low during 
gestation, surge soon after birth, 
decline progressively through 
adolescence and adulthood              
1)Glycine binding( A Nilsson, 2007) 2) 
Attenuate NMDA receptor-mediated 
current, limit calcium influx, suppress 
dendritic spine formation 
No studies on AD 
GluN3B 
1) constant during postnatal 
development and into 
adulthood 
2) Increased in motor neurons, 
expressed highly in pons, 
midbrain, medulla and spinal 
cord but low levels in the 
forebrain and cerebellum 
1)Dominant subunit that decrease 
calcium permeability 2)Co-expressed 
GluN1 and GluN2A 
Table 2.1  Summary of NMDA receptor changes in Alzheimer’s Disease 
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Summary of AMPA Receptor Changes in Alzheimer's Disease 
AMPA Receptor Subunit  Localization  Function  Changes in Alzheimer's Disease 
1) Localised to post 
synaptic membrane of 
the excitatory synapses 
2) Located on all 
neurons and enriched 
on pyramidal neurons 
3) Heterotetramer 
consisted of one pair of 
dimers of AMPA 
receptor subunits 
4)Differential assembly 
of subunits confer 
distinct functional and 
pharmacological 
properties 5) GluA2 
subunits determines 
calcium permeability of 
the AMPA receptor 
GluA1 
1)Expressed 
gradually over the 
course of post natal 
development 2) 
Found mostly in 




with other AMPA 
receptor subunits 
1) GluA1 protein unchanged within vulnerable sectors 
throughout all stages of disease(Carter, 2004) 2) GluA1 
mRNA not changed in AD HP(Wakabayashi, 1999)  AMPA 




gradually over the 
course of post natal 
development 2) 
Found mostly in 




dependent on the 
presence of edited 
forms of GluA2 at 
Q/R region of 
second 
transmembrane 
1)99% of edited  editing of GluA2  in AD as compared to 
99.9% in controls (Akbarian, 1995)  2)Differential 
preservation of AMPA receptor subunits in the hippocampi 
of Alzheimer's Disease patients according to their Braak 
staging 3) Disruption of glutamate receptors at Shank-
postsynaptic platform in AD (Gong 2009) 4) Loss of Glu2(3) 
immunoreactivity precedes neurofibrillary tangle formation 




gradually over the 
course of post natal 
development 2) 
Found mostly in 




with other AMPA 
receptor subunits 
No study found 
GluA4 
Lowly expressed in 
CNS except in 
brainstem, thalamus 
and cerebellum  
Found mostly in 
early postnatal 
development with 
yet to unidentified 
function 
No study found 




2.2.5 Current treatments for AD 
2.2.5.1 Cholinergic based treatment therapy 
The severity of AD is correlated with loss of the cholinergic neurons of the 
basal forebrain. Thus cholinergic-based treatment therapy has been 
developed by increasing cholinergic transmission through preventing the 
breakdown of acetylcholine from the remaining cholinergic neuron 
(Mufson et al., 2008).  
Treatments for AD currently are limited to those that provide 
symptomatic relief, and are not a cure for the devastating disease.  The 
current cholinergic based AD treatment involves alleviating the 
symptoms caused by loss of cholinergic neurons. Drugs which has been 
found useful include acetylcholinesterase inhibitors (AChEIs) (Auchus et 
al., 2007; Dichgans et al., 2008; Meyer et al., 2002; Moretti et al., 2001) 
such as donezepil, rivastigmine, and  galantamine.  
 
2.2.5.2 Glutamatergic-based treatment for AD 
Targeting the glutamatergic dysfunction in AD can be tricky because 
although an excess of NMDA receptor activation causes neurotoxicity, 
physiological NMDA receptor activity is however important for normal 
neuronal function. Potential neuroprotective agents such as NMDAR 
antagonist which blocks all NMDA receptor will likely lead to have 
unacceptable clinical side effect.  
NMDA receptor are generally more permeable to calcium, excessive 
activation lead to production of damaging free radicals and other 
enzymatic process leading to cell death. The disruption of energy 
metabolism leads to glutamate not being cleared properly or 
inappropriately released.  Without energy, these neurons become 
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depolarised. They become more positively charged because the ionic 
homeostasis cannot be maintained without energy. Depolarization 
relieves normal Mg2+ block of NMDA receptor because positive charge of 
cells repels positively-charged Mg2+ from channel pore. Thus in many 
neurodegenerative diseases and by long period of ischemia, extra 
stimulation of glutamate receptor is thought to occur. Thus NMDA 
receptor antagonist is thought to have potential therapeutic benefit. As 
the subunits differ regionally in the brain and temporally during 
development, most of the NMDA antagonist is developed in selective for 
GluN2B (which is predominantly in forebrain). 
Current glutamatergic therapy is through the usage of Memantine 
(adamantane derivative) which is a low-affinity voltage-dependent 
uncompetitive antagonist at glutamatergic NMDA receptor. Memantine is 
marketed under brand name Namenda (Forest), Axura and Akatinol 
(Merz), and Ebixa and Abixa (Lundbeck). Memantine has been used in 
various animal models and has been shown to have neuroprotective 
against neurodegeneration as well as vascular processes. 
Memantine is an open channel blocker, enters receptor-associated ion 
channel preferentially when it is excessively open. By binding to the 
eNMDA receptor with a higher affinity than Mg
2+
 ions, memantine is able 
to inhibit the prolonged influx of Ca
2+
 ions, which forms the basis of 
neuronal excitotoxicity, while sparing normal synaptic activity. The low 
affinity and rapid off-rate kinetics of memantine at the level of the NMDA 
receptor-channel, however, preserves the physiological function of the 
receptor, as it can still be activated by the relatively high concentrations 
of glutamate released following depolarization of the presynaptic neuron. 
The off-rate is relatively fast so that it does not substantially accumulate 
in the channel to interfere with normal synaptic transmission (Anand et 
al., 2013). Clinical trials have shown that memantine treatment leads to 
functional improvements in AD patients with severe dementia (Miguel-
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Hidalgo et al., 2002; Parsons et al., 2007, 1999; Winblad and Poritis, 
1999). 
A second generation of memantine derivatives, Nitromemantine, was 
developed in 2006 by Lipton et al and has been shown to have enhanced 
neuroprotection as well as safety efficacy compared to memantine.  
Nitromemantine is a combination of 2 FDA approved drugs, nitro glycine 
and memantine. Nitro glycine is a common treatment for chest pain and 
angina in people with coronary heart disease which has a cardiovascular 
vasodilator effect leading to sharp drop of blood pressure in stroke and 
traumatic injury. Nitro glycerine generate NO-related species that can act 
at the s-nitrosylation site of the NMDA receptor, limiting excessive NMDA 
receptor activity which induces conformation change in receptor protein 
making the glutamate and zinc ions more tightly to the receptor, thus 
causing the receptor to desensitize and the ion channel to close  (Lipton, 
2006; Nakamura and Lipton, 2010).  
The principle behind the nitromemantine is similar to memantine and the 
combination with nitro glycerin is shown to reduced excitotoxicity from 
over-activation of the glutamatergic system by shutting down hyperactive 
eNMDARs more effectively.  
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2.3 LEWY BODY DEMENTIA (LBD) 
INTRODUCTION  
2.3.1 Parkinson Disease (PD) 
Parkinson’s disease is a well-studied neurodegenerative disease, known 
to affect 7-10 million people worldwide which is characterised by motor 
impairment and dysregulation (Pringsheim et al., 2014). The average age 
of onset is 60 years old and the risk progressively increase with age, 
although there are cases that begin before 50 years old (Abdullah et al., 
2014). 
One of primary neuropathological characteristic of PD is the degeneration 
of dopaminergic neurons in substantia nigra of the mid brain, which plays 
an important role in the basal ganglia circuitry. Loss of dopamine in the 
basal ganglia affects motor function. In addition, accumulation of lewy 
bodies in the neurons of the substantia nigra is also observed in post-
mortem PD brains (Caballol et al., 2007). Lewy bodies (LB), which are 
made of aggregates of α-synuclein protein, accumulate inside nerve cells,  
disrupt normal brain functioning and may trigger cell death possibly 
through apoptotic or non-apoptotic pathways  (Cappai et al., 2005; 
Cookson and van der Brug, 2008; Saha et al., 2000). The mechanism 
behind the aggregation of the α-synuclein and the formation of 
pathological LB is still unknown. The impairment of ubiquitin-proteasome 
system which degrades α-synuclein has been suggested as one of the 
mechanism (Bedford et al., 2008; McNaught et al., 2001, 2002; Olanow 
and McNaught, 2006).  
The clinical features of PD include akinesia (loss of control of voluntary 
muscle movements), bradykinesia (abnormal slowing movement), 
tremor, rigidity, postural deformities, postural instability, freezing, 
micrographia (decreased in the size of handwriting) (Jankovic, 2008). 
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Although most cases of PD are sporadic, 10-15% of the cases are familial 
due to the mutation in specific genes. One such mutation is found in the 
PARK2 gene which affect parkin protein’s role in the ubiquitin-
proteasome system. Another is found in the PARK1 gene which leads to a 
mutation in the alpha-synuclein protein (Klein and Westenberger, 2012) .  
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2.3.2 Involvement of glutamatergic neurons in the basal ganglia 
circuitry  
The basal ganglia circuitry which involves basal ganglia and substantia 
nigra, processes the signals that flow from the cortex, regulating the 
correct execution of voluntary movements through the balance of direct 
and indirect circuit pathway. Within the basal ganglia circuitry, 
glutamatergic neurons play an important part in providing excitatory 
input. Figure 2.3 depicts the basal ganglia circuitry under physiological 
condition; the blue, red and green represents excitatory glutamatergic, 
inhibitory GABAnergic and dopaminergic neurons respectively. 
Glutamatergic neurons play an important part in providing excitatory 
inputs in the basal ganglia circuitry. In the direct pathway, the cortical 
cells project excitatory glutamatergic input to the striatum(S) which in 
turn project inhibitory GABAnergic input onto the Globus pallidus interna 
(GPi). Inhibition of the inhibitory GPi projection onto the thalamus leads 
to reduction of inhibition of thalamus via straitum. This leads to reduced 
inhibition (stimulation) of excitatory glutamatergic neurons  projected 
from the thalamus to motor cortex; resulting in movement through the 
excitation of the motor cortex by the thalamus.  In the indirect pathway, 
the cortex project excitatory input into the straitum which in turn project 
inhibitory input onto the cells of the globus pallidus externa (GPe), which 
inhibits the subthalamic nucleus (STN). This leads to reduced inhibition of 
the inhibitory input which projects from GPe to STN. The STN then 
projects excitatory input into the GPi. Stimulation of the inhibitory GPi 
projection onto the thalamus leads to increased inhibition of thalamus via 
straitum. This leads to increased inhibition of excitatory glutamatergic 
neurons  projected from the thalamus to motor cortex; resulting in lack of 
movement through the inhibition of the motor cortex by the thalamus. 
The direct and indirect pathway has opposite functions and it modulated 
by the substantia nigra pars compacta (SNc) which produces dopamine. 
Excitatory output from STN into the SNc subsequently enhances 
dopaminergic efferent.  Dopamine from SNc acts on D1 receptors in the 
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striatum to stimulate the direct pathway and dopamine that binds the D2 
receptors inhibit the indirect pathway. Dopamine therefore increases the 
excitatory effect of the direct pathway (causing movement) and reduces 
the inhibitory effect of the indirect pathway (preventing full inhibition of 
movement) (Schmidt, 1998). Striatal cholinergic neurons provide 
acetylcholine which works with dopamine in  equilibrium to maintain 
motor function (Bonsi et al., 2011).  
In Parkinson’s disease, the denegeration of dopaminergic neurons of the 
substantia nigra pars compacta triggers a cascade of disruption in the 
basal ganglia-thalamocortical motor circuit, which plays a critical role in 
controlling motor activity. Loss of dopamine cause the direct pathway to 
malfunction resulting in no movement is initiated and the indirect 
pathway is in overdrive resulting in too much inhibition of movement. 
This will lead to tremor, slowness of movement, stiffness, and balance 








Figure 2.3 Schematic diagram of the basal circuitry under physiological condition. The 
basal ganglia circuitry which involves basal ganglia and substantia nigra, processes the signals 
that flow from the cortex, regulating the correct execution of voluntary movements through the 
balance of direct and indirect circuit pathway. Fig3.1 depicts the basal ganglia circuitry under 
physiological condition; the blue,red and green represents excitatory glutamatergic, inhibitory 
GABAnergic and dopaminergic neurons respectively. In the direct pathway, the cortical cells 
project excitatory glutamatergic input to the striatum(S) which in turn project inhibitory 
GABAnergic input onto the Globus pallidus interna( GPi). Inhibition of the inhibitory GPi 
projection onto the thalamus leads to reduction of inhibition of thalamus via straitum. This 
leads to reduced inhibition(stimulation) of excitatory glutamatergic neurons  projected from 
the thalamus to motor cortex; resulting in movement through the excitation of the motor 
cortex by the thalamus. In the indirect pathway, the cortex project excitatory input into the 
straitum which in turn project inhibitory input onto the cells of the globus pallidus externa 
(GPe), which inhibits the subthalamic nucleus (STN). This leads to reduced inhibition of the 
inhibitory input which projects from GPe to STN. The STN then projects excitatory input into 
the GPi. Stimulation of the inhibitory GPi projection onto the thalamus leads to increased 
inhibition of thalamus via straitum. This leads to increased inhibition of excitatory 
glutamatergic neurons  projected from the thalamus to motor cortex; resulting in lack of 
movement through the inhibition of the motor cortex by the thalamus. The direct and indirect 
pathway has opposite functions and it modulated by the substantia nigra pars compacta (SNc) 
which produces dopamine. Excitatory output from STN into the SNc subsequently enhances 
dopaminergic efferent. Dopamine from SNc acts on D1 receptors in the striatum to stimulate 
the direct pathway and dopamine that binds the D2 receptors inhibit the indirect pathway. 
Dopamine therefore increases the excitatory effect of the direct pathway (causing movement) 





2.3.3 Current treatment of Parkinson’s disease 
Current treatments of PD aim to restore the lost dopaminergic function in 
SNc. These include a) dopamine agonist drugs such as Pramipexole and 
Opinirole which activate the dopamine receptor by mimicking the 
function of dopamine in the brain. b) Levodopa (L-DOPA), a precursor 
drug which enters the brain nerve cell and gets converted to dopamine, 
thus restoring the decreased concentration of dopamine concentration 
caused by the degeneration of the dopaminergic neurons. Levodopa is 
most commonly given in combination with carbidopa, a peripheral 
system decarboxylase inhibitor which prevents dopamine to be active in 
the peripheral system thus reducing side effects such as nausea, diarrhoea 
and abdominal pains. However, there are still long-term side effect such 
dyskinesia and confusion (Jankovic and Aguilar, 2008). Catechol-O-methyl 
transferase (COMT) inhibitor, which blocks the degradation of dopamine, 
is usually given with Levodapa thus improving its effectiveness; c) 
Monoamine oxidase-B inhibitor which reduces breakdown of dopamine in 
the brain(Vijverman and Fox, 2014). One of the main side effects that 
comes with these treatments is the development of dyskinesia especially 
in patients that were treated with levodopa, known as  Levodopa-induced 
dyskinesia(LID) which is characterised by hyperkinetic (Thanvi et al., 
2007).  
Other types of treatments include using anti-cholinergic drugs such as 
Trihexyphenldy, which is most useful in young PD patients. The loss of 
dopamine causes an imbalance of acetylcholine and dopamine 
equilibrium which is required for motor function.  Drugs that target the 
effect of acetylcholine have the potential to restore the equilibirium.  Thus 
reducing the symptoms of PD (Katzenschlager et al., 2003). 
Overactivation of the glutamatergic system has been observed in the 
development of LID (Cenci, 2014; Duty, 2012; Sgambato-Faure and Cenci, 
2012). Amantadine, a non-selective NMDA receptor antagonist, has been 
79 
 
used in several trials and has been found to result in  general 
improvement of dyskinesia(Cenci, 2014).  
 
2.3.4 Glutamate excitotoxicity in PD 
Overstimulation of the glutamate receptor due to increased release and 
decreased reuptake of glutamate has been thought to be one of the 
causative factors in neurodegenerative disorders and in stroke as well as 
head injury. The accumulation and increase of glutamate in the synaptic 
cleft in these conditions are so massive in the brain that it overwrites the 
brain efficient capability of removing excess glutamate. However, it is 
thought that such excessive accumulation glutamate of  does not happen 
in PD and glutamate-mediated excitoxicity plays a secondary role and 
does not directly cause neurodegeneration in PD. Loss of dopaminergic 
neurons in SNc trigger a cascade of functional modifications in basal 
ganglia circuitry (Blandini et al., 2000). One of such functional 
modification is overactivation of STN which result in an increased 
excitatory (glutamatergic) output into its target nuclei; GPe and SNc.  
Initially the increased of the excitatory input onto SNc compensate the 
dopaminergic cell loss by enhancing the acivity of dopaminergic neurons 
thus enhancing the activity of surviving dopaminergic. However, 
prolonged glutamatergic overstimulation  of the surviving SNc neurons 
may be responsible for the sustain progression of neurodegeneration 
found in PD (Rodriguez et al., 1998).  
Parkin gene is known to regulation the functionality and stability of the 
glutamatergic synapses. Mutated parkin in PD has been found to enhance 
the synaptic efficacy of glutamate synapses resulting in neuronal 






2.3.5 Types of Lewy Body Dementia  
2.3.5.1 Parkinson’s Disease Dementia (PDD) and Dementia with Lewy 
Bodies (DLB)  
 Although PD is well-known for being a movement disorder, there is more 
and more evidence which suggest that PD is also characterised by the 
non-motor dysfunction such as cognitive and behavioural symptoms, 
increasing the complexity of this disease. Parkinson’s Disease  
Dementia(PDD) and Dementia with Lewy bodies(DLB) are two types of 
dementia that are associated with underlying lewy body disease 
pathology and made up 10-15 % of the 35 million worldwide dementia 
sufferers, forming the second most common cause of dementia  (Aarsland 
D et al., 1996; Aarsland et al., 2003; McKeith et al., 2005). In general, these 
two forms of Lewy bodies dementia(LBD)  are clinically characterised 
with both parkinsonism and dementia syndrome with predominant 
impairment of attentional, visuospatial and executive dysfunction, with 
largely preserved memory (Ballard C et al., 2001; McKeith et al., 2005).  
 
2.3.5.2 Clinical features of PDD and DLB 
Studies have shown that 80% of the PD patients eventually developed 
dementia (Francis, 2009) which is PDD. The clinical impaired cognitive 
domains in PDD include visuospatial function, attention, executive 
function, free-recall memory and language. The most impaired domain is 
the executive function which involve  inhibition, initiation, planning and 
monitoring (Dodel et al., 2008). PDD patients suffer a high prevalence of 
behavioural disorders, with at least 89% of them developing at least one 
symptom (Aarsland et al., 2007). Some of the behavioural symptom 
commonly experienced include depression, apathy, anxiety , visual 
hallucinations, delusions, personality change, daytime sleepiness, etc. 
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(Aarsland et al., 2007; Dodel et al., 2008).  Currently, knowledge on the 
neuropathology and neurochemistry of PDD is still limited.  
 
2.3.5.3 Clinical diagnosis of PDD and DLB 
 It is still widely debatable whether PDD and DLB are different 
representations on a single spectrum of LB disease, or they are actually 
two distinct disease entities led to by different underlying molecular 
mechanisms. Currently, the distinction between DLB and PDD depends on 
the duration of Parkinsonism prior to dementia. Within the original 
operationalized clinical criteria for DLB (where cut off of one year is 
chosen), PDD was diagnosed if the dementia occurred one year after the 
onset of Parkinsonism, whereas dementia prior to, or within one year 
after the onset of Parkinsonism was classified as PDD. (McKeith et al., 
1996). The third report of the DLB consortium (McKeith et al., 2005) 
increased the emphasis  of the overall clinical (Aarsland et al., 2009; 
McKeith et al., 2005) and pathological (Ballard et al., 2006) similarities of 
DLB and PDD, yet maintain the arbitrary one year rule for distinguishing 
the two syndrome for research purposes.  
There is much controversy in the biological significance of using such 
means of differentiating of PDD and DLB. Is the arbitrary one year rule 
able to provide meaningful distinction between clinical entities with 
different clinical presentations? Does the one year rule reflect the 
measurable difference in the brain changes? More research should be 
done to address these key conceptual questions. This will better improve 
our understanding of these LBD and thus lead to establishment of 
biological markers which can hopefully lead to improved prognostic 
indicators. Further studies should also correlate the relationship between 




2.3.5.4  Neuropatholgical features of PDD and DLB 
Neuropathologically, it has been found that  the Alzheimer’s disease-type 
pathology (AD-neurites and neurofibrillary tangles), as well as cortical 
and subcortical Lewy bodies correlate significantly with the cognitive 
decline in PDD (Caballol et al., 2007). In addition, aggregated α-synuclein 
proteins in the synapse may be implicated in the cognitive decline 
(Kramer and Schulz-Schaeffer, 2007).  With evidence implicating that Aβ 
peptide has the ability to enhance α-synuclein accumulation (Masliah et 
al., 2001), it has been suggested that  Lewy body and AD-type pathologies 
may be interactive.  
As dopaminergic therapy has limited efficacy in the restoration of 
cognitive functions, it is thought that other neurotransmitter systems are 
also affected in PD.  Subsequently, cholinergic, serotonergic and 
noradrenergic deficits were reported, with the impairment of cholinergic 
system thought to be the major mechanism leading to cognitive decline 
(Zgaljardic et al., 2004). Neurochemically,  cholinergic impairment in PDD 
includes cholinergic neuron loss (Perry et al., 1985; Whitehouse et al., 
1983), reduced activity of choline acetyltransferase (ChAT) (Perry et al., 
1983) and reduced activity of acetylcholinesterase (AChE )  (Bohnen et al., 
2003).  It has been suggested that, the cholinergic deficits gradually 
overweigh dopaminergic deficits as the disease progresses along the 
progression of cognitive decline (Whitehouse et al., 1983). Currently, 
cholinesterase inhibitors are used as an effective treatment to offset the 
cholinergic deficitsin PDD.  
DLB patients experience fairly similar clinical, neuropathological and 
neurochemical features with PDD. Both display parkinsonism and 
dementia syndrome. Both display similar extent neuronal and synaptic 
loss (less severe than AD), cortical lewy body pathology as well as 
neurotransmitter system deficit (Aarsland et al., 2004). Although both 
LBD are quite similar, slight differences can be found which include more 
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extensive executive functions impairment in DLB than the PDD patients; 
more pronounced visual hallucinations and delusions in DLB; more 
severe postural instability and walking difficulties in DLB; more extensive 
cortical Aβ protein deposition in DLB than PDD, etc. (Aarsland et al., 
2004).  
 
2.3.5.5 Limited evidence of glutamatergic system impairment in PD, 
PDD and DLB 
As mentioned earlier, the glutamatergic neurons play an important part in 
providing excitatory input in the basal ganglia, resulting in optimum 
motor function. Thus it is essential to study the glutamatic transmission in 
PD, PDD and DLB. Unlike AD, the status of glutamatergic system in PD, 
PDD and DLB is not well studied. Limited evidence of glutamatergic 
deficits in PD include reduction of the VGLUT1 in the prefrontal as well as 
temporal cortex (Kashani et al., 2008) and deficit in glutamate and 
glutamine in basal ganglia that is associated with motor symptoms using 
neuroimaging (Modrego et al., 2011) as well as glutamate deficits in non-
demented PD patients (Griffith et al., 2008). 
In DLB,  GluA2/3 protein were found to be reduced in the hippocampus 
and entorhinal cortex in lewy body variant of Alzheimer’s disease (Thorns 
et al., 1997). In addition, group I metabotropic glutamate receptors were 
also found to be impaired in frontal cortex of DLB (Albasanz et al., 2005). 
In addition, glutamate levels deficit was also observed in PDD patients 
(Griffith et al., 2008).  
 
2.3.5.6 Glutamatergic-based treatments used in PDD and DLB  
PDD patients have showed significant improvements in cognition, sleep, 
daily life ability and global functioning in two out of five clinical studies 
84 
 
exploring the efficacy of memantine over placebo. In addition, meta-
analysis of three studies comparing memantine and placebo also showed 
significant improvement in global functioning (Aarsland et al., 2012). In a 
separate study, PDD patients were found to suffer from cognitive 
impairment following  withdrawal of memantine (Leroi et al., 2009). In 
addition, a prospective double-blinded randomised trial, DLB and PDD 
patient treated with memantine are observed to have longer survival 
after 36 months. However due to the small study sample, more studies 




2.4 CEREBROVASCULAR-ASSOCIATED DEMENTIA 
2.4.1 Vascular Dementia (VaD) 
Vascular dementia is the third most common form of dementia after 
Alzheimer’s disease (AD), making up 8-10% of the dementia cases, but the 
number varies depending on the criteria used (Jellinger, 2007; 
Pohjasvaara et al., 2000).  
 In contrast to AD where women make up most of the cases below the age 
of 75, VaD is more common in men. The prevalence of VaD is also 
increased in ethnicities more affected with cerebral  small vessel such as 
the Blacks, Hispanics and Asian (Dubois and Hébert, 2001).  VaD is a 
result of ischaemic, hypoperfusive or haemorrhagic brain lesions, causing 
the death of brain cells by the deprivation of oxygen and nutrients.  
Depending on where these lesions happen (cortically or subcortically), 
some parts of the brain are affected while some are relatively unaffected. 
Cortical lesions, which affects the cerebral cortex (associated with 
cognitive processes such as language and memory), leads to aphasia 
(disturbance of the comprehension and formulation of language), apraxia 
(loss in ability to execute learned purposely movement) and epileptic 
lesion. In contrast, subcortical lesion affects brain areas that are deeper 
than the cortex and is associated with bradyphrenia(slowness of 
thought), executive dysfunction(loss of a set of mental skills which are co-
ordinated by the frontal lobe of the brain , for example, management of 
time and attention) and gait abnormalities(inability to walk normally). 
The severity of this disease is dependent on the brain area affected. VaD 
has a heterogeneous range of clinical phenotype and pathological 
mechanisms as it is a group of syndromes relating to different vascular 
mechanisms and not a single disease. Depending on the location and the 
size of the stroke lesion, clinical symptoms/signs and rate of disease 
progression vary and no single neuropsychological profile characteristic 
of VaD has been defined, although executive dysfunction is common. A 
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slightly higher mortality rate (which is partly due to concomitant vascular 
diseases such as recurrent stroke) and slower progression in cognitive 
deterioration are reported in VaD compared with AD. But unlike AD, VaD 
can be prevented by rigorous identification and treatment of 
cardiovascular disease risk factors. Therefore, early detection and an 
accurate diagnosis is important (Román, 2003).  To acknowledge the wide 
spectrum cognitive dysfunction as a result of vascular lesions of the brain, 
the term vascular cognitive impairment (VCI) (Hachinski et al., 2006; 
Román et al., 2004) was introduced and included minor deficit such as the 
vascular MCI which is a transition stage between normal cognition aging 
and VaD. It has been shown vascular MCI is  more likely to progress to  
dementia (Wentzel et al., 2001) It is hoped that an introduction of the 
term VCI will be able to prevent progression to VaD by providing control 
for risk factors  and treatment for cerebrovascular disease (CVD). 
However, the diagnosis of VCI is not easy as there is a lack of strict 
definition of VCI and operational diagnostic criteria.  
 
2.4.2 Risk factor for VaD 
The risk factors for VaD include advanced age, cigarette smoking, diabetes 
mellitus, heart, chronic hypertension, complicated stroke and recurrent 
stroke. The risk for developing dementia is significantly increased by the 
occurrence of ischemic stroke (Aharon-Peretz et al., 2002; Savva and 
Stephan, 2010). Cognitive impairment which occur pre-stroke also 
increases the risk of a more severe cognitive impairment after the stroke 
(Savva and Stephan, 2010). Recurrent strokes determine the severity of 
cognitive impairment (Aharon-Peretz et al., 2002; Savva and Stephan, 
2010). Epileptic  seizures after stroke is also associated with increased 
cognitive impairment (Cordonnier et al., 2006). Oxygen deprivation 




2.4.3 Clinical diagnosis of VaD 
The diagnosis of VaD is complicated, with clinical severity ranging from 
mild cognitive impairment (MCI) through severe dysfunction. It is quite 
difficult to differentiate AD and VaD patients and some patients have a 
mixture of both. In contrast to AD, VaD may progress in an unpredictable 
manner depending on how the strokes occur, leading to a ‘stepped’ or 
slow deterioration.  The symptoms firstly worsen due to stroke and 
stabilised for some time.  When another stroke happens again months and 
years later, the symptoms will worsen again. However, the progression of 
VaD may be more gradual with the occurrence of several smaller strokes. 
Patients with VaD patients tend to maintain their personality and 
emotional response, making them more aware of their conditions and are 
thus more prone to depression compared to patients with AD. VaD 
progression varies from one person to another but on average a person 
with VaD can live around 5 years from onset of first symptoms. The cause 
of death for VaD patients is normally either a stroke or heart attack 
(Román, 2003) 
 
Before the diagnosis of VaD can be made, the following has to be done 
 Assessing of the symptoms 
 Assessing of full medical history and medications that is being 
taken 
 Assessing of mental abilities using cognitive test such as the MMSE 
or CAMCOG 
 Physical examination  
 Blood test to rule out all other causes of the symptoms. 





There are several clinical criteria which can be used to diagnose VaD  
 Diagnostic and Statistical Manual of Mental Disorders, Fourth 
Edition (DSM-IV)   
 The International Classification of Diseases 10th version (ICD-10) 
(“WHO | International Classification of Diseases (ICD),” n.d.) 
 the State of California Alzheimer's Disease Diagnostic and 
Treatment Center (ADDTC) criteria (Chui et al., 1992) 
 The National Institute of Neurological Disorders and Stroke and 
Association Internationale pour la Recherché et l'Enseignementen 
Neurosciences (NINDS-AIREN) criteria (Román et al., 1993) 
 
All the currently used clinical criteria are ‘consensus criteria’ derived 
from expert opinion based on prevailing knowledge and pathogenic 
hypotheses of dementia. These criterions are focused on dementia and 
thus do not include the mild cognitive impairment cases.  The different 
clinical criteria of VaD have their own pros and cons. The DSM-IV criteria 
have good sensitivity, but low specificity and do not specify subtypes. ICD-
10 specifies six subtypes with superficial clinical description. ADDTC do 
not specify subtype in detail but highlight the importance of classification 
of VaD in research such as the location of the lesion (cortical, white 
matter, periventricular, basal ganglia, thalamus) size, distribution (large, 
small, micro vessel), severity (chronic ischemia versus infraction), the  
etiology (embolism, atherosclerosis, arteriosclerosis, cerebral amyloid 
angiopathy,  hypoperfusion. In contrast, the NINDS-AIREN criterion is the 
most specific of all available criteria and is used most commonly in 
research. In my thesis, the VaD subjects used are clinically diagnosed 




In general, diagnosis of the VaD is made when the following is observed 
 Evidence of dementia( memory and at least 2 additional cognitive 
domains) 
 Focal neurological signs and symptoms  
 Imaging evidence of cerebrovascular disease (CVD) 
 Evidence of casual relationship between cognitive impairment and 
CVD. The consensus is the onset of dementia happening 3 months 
following stroke. The physician will categorized the relationship 











2.4.4 Clinical features of VaD 
Some of the clinical manifestation of the VaD include forgetfulness, 
changes in speech and delayed psychomotor response due to executive 
cognitive dysfunction (Roman GC, 1999). Such symptoms are the result of 
the disruption of prefrontal-subcortical circuits by the ischemic lesions 
(Ishii et al., 1986; Wolfe et al., 1990) .  These circuits are executive control 
of working memory, organisation, language, mood, regulation of 
attention, constructional skills, motivation, and socially responsive 
behaviours (Cummings, 1993; Mega and Cummings, 1994). 
 
The method of detecting clinical features and symptom of VaD can vary 
depending on the medical setting. While the focal neurological signs that 
resulted in the cerebrovascular events are recognised by the stroke and 
neurology services, psychiatrists put more emphasis on the broader range 
of cognitive, mood and psychiatric symptoms, it is also important to use 
tests which measures the prefrontal-subcortical symptoms as dementia 
screening tests  
 
2.4.5 Neuropathology of VaD 
Unlike AD, there are no commonly accepted neuropathogical criteria for 
the diagnosis of VaD. Currently, the classification of VaD is based on the 
type of brain vessel affected. There are several subtypes of VaD which are 
defined by blood vessel size and the pathological processes namely large 
and medium-sized vascular dementia, small vessel dementia, strategic 
infract dementia, hypoperfusive dementia, dementia elated to 






2.4.5.1 Large and medium-sized vessel vascular dementia 
The vessels of the Circle of Willis are affected in large and medium-sized 
vessel disorders and such disorders increases in prevalence with 
increasing age and vascular risk factor such as hypertension. 
Atherosclerosis is an example of such a disorder, where the 
atherosclerotic plaques are prone to rupture which can lead to vessel 
occlusion and can cause the obstruction of smaller arteries.  
 
2.4.5.2 Small-vessel vascular dementia  
This disorder affects all the small vessels of the brain and produces two 
major syndromes, Binswanger disease and lacunar state. Small vessel 
disease results in arterial wall changes, expansion of the Virchow-Robin 
spaces, and perivascular parenchymal rarefaction and gliosis. In clinical 
studies, it is found that 36-67% of the vascular dementia cases are small-
vessel vascular dementia (Chui, 2001) 
  
2.4.5.2.1 Subcortical Ischemia Vascular Dementia (SIVD) 
SIVD defined clinically by cognitive impairment and evidence of 
subcortical vascular brain injury, including lacunar infarcts and deep 
white matter changes. The lesions in SIVD, caused by damage to the tiny 
blood vessel that lie deep within the brain, manifest in subcortical areas 
mainly involving areas such as the basal ganglia, cerebral white matter. 
SIVD dementia is caused by ischemic injury which include both complete 
(lacunar infracts and micro infracts) and incomplete infarction (deep 
cerebral white matter) leading to lacunar dementia/state and Binswanger 
respectively. These two clinical pathways can overlap though and it is not 
uncommon to observe the occurrence of both the lacunes and white-
matter lesions together. Symptoms may include difficulties walking, 
clumsiness, and lack of facial expression and speech difficulties. Loss of 
bladder control early on in the disease is also common. These symptoms, 
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however, are not always present and may come and go. Some people may 
experience sub-cortical vascular dementia as well as stroke. A genetic 
cause of SIVD is CADASIL (Chui, 2007; Kalaria and Erkinjuntti, 2006; 
Román et al., 2002; Tomimoto, 2011). 
 
2.4.5.2.2 Binswanger’s disease 
Binswanger disease (also known as subcortical leukoencephalopathy) is 
caused by diffuse incomplete infarction of deep white matter disease 
caused by the critical stenosis and hypoperfusion of multiple medullary 
arterioles. In Binswanger disease, vascular changes observed are fibro 
hyalinosis of the small arteries and fibroid necrosis of the larger vessels 
inside the brain (Román, 1985). 
 
2.4.5.2.3 Lacunar dementia or lacunar state (état lacunaire) 
Formation of lacunes caused by the occlusion of the arteriolar lumen due 
to arteriolosclerosis and also occlusion of small vessel causing small 
cavity lesions (Wardlaw, 2008) are the main causes of lacunar disease. 
These lacunae are found more typically in the internal capsule, deep grey 
nuclei, and white matter. Lacunar state is a condition in which numerous 
lacunae, which indicate widespread severe small vessel disease, are 
present. (Román, 1985) 
 
 
2.4.5.3 Ischemic Infarct dementia 
Larger infracts, which are mostly greater 10mm in diameter, are often 
caused by artery occlusion. Approximately 10 % of these brain infracts 
are localized at the two major arteries. The single large strokes that occur 
at strategic locations are the ones that are easiest to diagnose. The 
occurrence of ischemic and haemorrhagic stroke are found to cause 
cognitive decline, with more than a third of them developing it after soon 
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after the first stroke (Pendlebury and Rothwell, 2009). Cognitive decline 
may also appear gradually several months to years after the stroke 
(Pendlebury and Rothwell, 2009; Sachdev et al., 2004; Tatemichi et al., 
1994). 
 
2.4.5.3.1 Multi-infarct dementia (MID) 
MID is an umbrella term used to describe the cognitive decline caused by 
the cumulative effect of multiple stroke, involving both small and large 
lesion which are both cortical and subcortical in location. Lacunar infracts 
(around 10mm in diameter lesions which are largely found in the cerebral 
white matter and subcortical structures) and as well as micro infracts 
(visible only by imaging examination) are known to cause cognitive 
decline. The combined effects of different infarcts in MID usually affect 
the neural net resulting in  cognitive decline (Wolfe et al., 1990).  
 
2.4.5.3.2 Strategic infarct dementia (SID) 
SID is caused by a single infarct in functionally critical areas of the brain 
(angular gyrus, thalamus, basal forebrain, posterior cerebral artery or 
anterior cerebral artery). Different areas in the brain can be affected, 
which may result in significant impairment in cognition. This may be 
observed in cases of anterior cerebral artery infarct, parietal lobe infarcts, 
thalamic infarction, and singular gyrus infarction (Knopman, 2007). 
 
2.4.5.4 Dementia related to angiopathies 
Cerebral amyloid angiopathies (CAA) involves the deposition of amyloid 
in the walls of arteries, arterioles, and, less often, capillaries and veins of 
the central nervous system, causing damage to the subcortical white 
matter which may lead to cerebral haemorrhage, ischemic lesions, and 
dementia. CAA occurence which can be sporadically and hereditary, may 
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be classified according to the amyloid protein deposited.  The heritable 
forms of CAA are caused by amino acid substitutions at four sites in the 
APP, causing cerebral haemorrhages, white matter lesions, and cognitive 
impairment. Those with hereditary CAA have recurrent cerebral 
haemorrhages before age 40 years that can lead to dementia. Prevalence 
of cerebral amyloid angiopathy is consistently higher in patients with 
dementia than in patients without dementia, which indicates its 
significant role in the pathogenesis of dementia. Both the sporadic and 
hereditary CAA has similar clinical and pathological similarities, differing 
only in when they appear. Sporadic CAA appears 20 or more years later 
than hereditary CAA (Fujishiro et al., 2010; Zhang-Nunes et al., 2006). 
 
2.4.5.5 Hereditary VaD 
Cerebral autosomal dominant arteriopathy with subcortical infarcts and 
leucoencephalopathy (CADASIL) is a rare autosomal dominant condition 
localized to chromosome arm 19q12 that affects small vessels supplying 
the deep white matter. Pathologically, multiple small infarcts are 
observed in the white matter, thalamus, basal ganglia, and pons (Hervé 






2.4.6 Therapy and treatment for VaD 
Different types of treatment are given to VaD patients. If the disease is 
caught when it is still at the vascular cognitive impairment (VCI) stage 
before it progresses to dementia, lifestyle changes (excising to lose excess 
weight, stopping smoking, and eating healthy) as well as control of the 
blood pressure are rendered in order to prevent future damage to the 
brain, thus preventing the formation of VaD such as the usage of the 
antihypertensive drugs. If the Vascular cognitive impairment has already 
progressed to Vascular Dementia, the treatment that can be rendered will 
only slow down but not stop the disease progression. Rehabilitation 
treatment such as physiotherapy and speech therapy is useful to help 
patients to recover some of their lost functions. Activities that involve 
memory can also help the patients. The symptoms of VaD usually get 
worse after many years. As the brain damage experienced by the patients 
is permanent, the life span of the patients is shortened. Most of the VaD 
patients will either die from either the complications of the dementia 
which includes pneumonia or by subsequent stroke.  
 
Drugs which has been found useful to alleviate the symptoms of VaD 
includes cholinesterase inhibitors (ChEIs) (Auchus et al., 2007; Dichgans 
et al., 2008; Meyer et al., 2002; Moretti et al., 2001), and memantine 
(Orgogozo et al., 2002). Some are more  effective than others, but studies 
are not conclusive as the effect size is small and  there is significant 
heterogeneity ( Kavirajan and Schneider, 2007) among all the studies. The 
benefit of these drugs on the VaD may be due to its effect on existing AD.  
Donepezil has limited effect on CADASIL (Deschaintre et al., 2009).  
 
There are some reported beneficial effects of cerebrolysin (Muresanu et 
al., 2008), citicoline (Secades, 2011) and ginkgo biloba (Napryeyenko et 
al., 2009), but these studies are still inconclusive. Other drugs such as 
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anxiolytics, antidepressant drugs, sleeping pills, anticonvulsants help to 
alleviate the non-cognitive manifestations. Neuroleptic drugs should be 
used with care as they have unfavourable effect on cardiovascular disease 
(Ray et al., 2009; Trifirò et al., 2009). Other unconventional therapies 
include acupuncture and social interaction to improve VaD symptoms and 
recurrence of vascular lesions.  
 
2.4.7 Mixed Dementia (MIX) 
2.4.7.1 Symptoms of MIX 
Similar to other types of dementia, the symptoms of MIX dementia varies 
depending on the type of brain changes involved and the brain region 
affected. Depending on the individual cases of MIX dementia, some cases 
can appear indistinguishable from Alzheimer ’s disease and some cases 
display symptoms which suggest the presence of more than one type of 
dementia (Jellinger, 2007a). 
2.4.7.2 Diagnosis of MIX 
To diagnose MIX, clinicians use both the clinical/neuroimaging criteria of 
AD and CVD. In MIX cases, hallmarks of AD (plaques and tangles) are 
found to co-exist with cerebrovascular disease.  It is thought that the 
mixed dementia patients have a worse prognosis due to the combination 
of dementia symptoms  (Jellinger and Attems, 2007) 
2.4.7.3 Risk factors 
Similar to VaD, it is suggested that controlling risk factors for 
cardiovascular disease such as blood pressure, cholesterol and diabetes 
may reduce the prevent the vascular changes that occur in MIX(Jellinger, 





2.4.7.4 Treatment for MIX 
The patients of MIX are often treated depending on the type of dementia 
they are diagnosed with. There are currently no specific drugs specifically 
just for MIX. Those are diagnosed with AD or VaD will be treated with 
approved FDA medication to address those dementias (Jellinger, 2007a). 
 
2.4.8 Mechanism of glutamate excitotoxity following stroke 
Blood is responsible for the transportation of oxygen and sugar (glucose) 
to the organs and tissues of the body. Once there is a block in blood flow, 
the level of blood flow and oxygen level is decreased. The lack of blood 
and sugar cause the neuron to stop the production of adenosine 
triphosphate (ATP) which is a source of energy for ion pumps.  The ATP-
driven ion transport pump fails, causing cells to become depolarize 
resulting in calcium to flow into cell. The presence of calcium triggers the 
release of glutamate into synaptic cleft. Glutamate stimulates calcium- 
permeable NMDAR on the post synaptic neuron which allow calcium into 
cell. Overexpress calcium entry overexcites cells and causes the 
generation of harmful free radicals, reactive oxygen species, calcium-
dependent enzyme calpain, endonuclease, ATPase and phospholipases. 
As the cell membrane is broken down by phospholipase, it becomes more 
permeable allowing ions and harmful chemicals to flow into cell. The 
breakdown of mitochondria releases apoptosis factors into cells. Caspase- 
dependent apoptosis cascade is then initiated resulting in apoptosis. Also, 
cell death through necrosis will release glutamate and toxic chemicals to 
environment around the injured cells. Thus initial influx of calcium can 
also lead to the release of more glutamate (Hazell, 2007).  
As VaD is developed three months after the onset of stroke, similar 
glutamatergic excitotoxicity observed in stroke may underlie 




2.4.9 Limited evidence of glutamatergic system impairment in 
VaD and MIX 
Although not well studied, there is some evidence to suggest 
glutamatergic impairment in VaD. Using western blotting to detect 
VGLUT1 proteins, it was observed that the frontal but not the temporal 
glutamatergic synapses appeared to be preserved in VaD(Kirvell et al., 
2010). Using magnetic resonance spectroscopy (MRS), glutamate levels 
was found to be reduced in the hippocampus and cingulate/precuneal 
cortices (PCC) in SIVD patients (Shiino et al., 2012).  
 
2.4.10 Glutamatergic-based treatments in VaD and MIX 
Hypothesis of glutamate excitotoxicity in cerebral ischaemia has lead to 
clinical trials examining the usage of  memantine in VaD and MIX patients. 
In one study, memantine of 20 mg/d was found to be well tolerated and 
was found to have improved cognition consistently across different 
cognitive scales in patients with mild to moderate vascular dementia. No 
deterioration in global functioning and behaviour was 
observed(Orgogozo et al., 2002). In the second study, based on the ADAS-
COG scores, memantine was shown to improve cognition relative to 













Purpose of thesis 
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SECTION 2  
Purpose of thesis 
Dementia a clinical syndrome caused by neurodegeneration and is 
characterised by the progressive cognitive decline and reduced capacity 
of independent living. As the demographic aging increases, dementia is 
increasing becoming a health and economic burden to the society 
especially in developing countries. Alzheimer’s Disease (AD) has been 
well studied neurochemically, but less is known about other types of 
dementias which include Vascular Dementia (VaD), Mixed dementia 
(MIX), Parkinson’s Disease with Dementia (PDD) and Dementia with 
Lewy Body (DLB).  As discussed later in the AD chapter, significant 
neurotransmitter dysfunctions such as in the cholinergic and 
glutamatergic system have been observed in AD. The changes in the 
glutamatergic system are especially important as it is the major excitatory 
system with important roles in synaptic plasticity.  However, not much is 
known about the status of glutamatergic system in neurological diseases 
other than AD.   
Thus, the purpose of my thesis is to study the glutamatergic system 
(NMDA and AMPA receptor) of VaD, MIX, PDD and DLB in post-mortem 
human samples and correlate any changes with neuropathological 
presentations, with hope that these findings can be used further to 
develop potential therapeutic targets.     Questions that will be answered 
in this thesis include the following 
1) Are the glutamatergic changes observed similar to AD?  
2) What is the correlation of these changes with the clinical data? 
3) How does this change suggest new treatment for the disease? 
4) Do these changes give rise to new neuropathogical insights? 
5) How do these findings improve scientific knowledge? 
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Aims and Hypotheses  
Aim 1: To study the ionotrophic receptors in Lewy body 
dementias, PDD and DLB  
Hypothesis 1a: Down-regulation of NMDA and AMPA receptor levels in 
lewy body dementias. Rationale: It is hypothesised that losses of 
glutamatergic subunits are associated with the severity of cognitive 
impairment observed in Lewy body dementias. 
Hypothesis 1b: The glutamatergic alteration can be used to distinguish 
clinically defined DLB from PDD. Rationale: The glutamatergic losses are 
hypothesised to be more severe in PDD patients compared to the DLB as 
PDD patients suffer from a more severe motor disability and longer 
duration of Parkinsonism.  
 
Aim 2: To study the ionotrophic receptors in 
cerebrovascular-related dementia, VaD and MIX  
Hypothesis 2a: Down-regulation of NMDA and AMPA receptor levels in 
VaD compared to controls. Rationale: As neuronal loss is a well-known 
observation in stroke patients, loss of glutamatergic receptors are 
hypothesized 
Hypothesis 2b: Down-regulation of NMDA and AMPA receptor levels in 
MIX compared to controls. Rationale: MIX patients are known to have 
concurrent pathology of VaD and AD, and cognitively worse compared to 
VaD patients. It is hypothesised that a reduction in glutamatergic subunits 
may be responsible for the cognitive dysfunction in MIX.  
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CHAPTER 3  
Role of NMDA and AMPA receptors in PDD and DLB 
 
Aim 1: To study the glutamatergic system in Lewy body 
dementias, PDD and DLB 
Hypothesis 1a: Down-regulation of NMDA and AMPA receptor levels in 
lewy body dementias. Rationale: It is hypothesised that losses of 
glutamatergic subunits are associated with the severity of cognitive 
impairment observed in Lewy body dementias. 
Hypothesis 1b: The glutamatergic alteration can be used to distinguish 
clinically defined DLB from PDD. Rationale: The glutamatergic losses are 
hypothesised to be more severe in PDD patients compared to the DLB as 
PDD patients suffer from a more severe motor disability and longer 
duration of Parkinsonism.  
 
3.1 Introduction  
3.2 Materials and Methods  
3.3 Status of the AMPA receptor subunits in the parahippocampal gyrus 
cortex (BA36) of PDD and DLB  
3.4 Status of the NMDA receptor subunits in the parahippocampal gyrus 
cortex (BA36) of PDD and DLB 
3.5 Status of the AMPA and NMDA receptors receptor subunits in the 
inferior temporal cortex (BA20) of PDD and DLB 




3.1 Introduction  
As mentioned earlier in Chapter 2.3, glutamatergic neurons provide 
excitatory inputs in the basal ganglia circuitry. Degeneration of 
dopaminergic neurons in SNc affects the excitatory glutamatergic inputs 
in the circuitry which affect motor and cognitive functions. Although there 
are increased dysregulated glutamatergic transmission and proposals for 
the use of AMPA and other glutamatergic receptor ligands in PD 
pharmacotherapy (Johnson 2009), not much is known about the 
involvement of cognitive and non-cognitive features of LBD. 
The neurochemistry of LBD is one area that is in need of further research. 
While much is known about the neurochemistry dysfunction in AD, not 
much can be said of LBD, especially those of the glutamatergic system 
which is highly known for its role in cognition. In this study, the 
immunoreactives of the NMDA receptor (GluN1, GluN2A and 
GluN2Bsubunits) and AMPA receptor (GluA2, A3 and A4 subunits) are 
compared in the post-mortem neocortex of a cohort of prospectively 
assessed DLB and PDD patient to test the following hypothesis  
1) The GluA subunits are altered in LBD  
2) The GluA subunit alterations can be neurochemically distinguished 
clinically defined DLB from PDD.  
Brodmann areas of the cerebral cortex are originally defined and 
numbered by the Korbinian Brodmann based on the cytoarchitectural 
organization of neurons observed using Nissl cell staining. These areas 
have been shown to be related to their cortical functions. For this study, 
post-mortem tissues from parahippocampal gyrus (Brodmann Area 36, 
BA36) and inferior temporal cortex (Brodmann Area 20, BA20) of the 
temporal cortex are chosen to study how AMPA and NMDA receptors are 
affected in different areas of the temporal cortex.   
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Parahippocampal gyrus (BA36), is the medial limbic structure of temporal 
lobe providing an essential connecting pathway of the limbic system. 
Together with fornix, hippocampus, cingulate gyrus and amygdala, BA36 
forms the limbic system which mediates emotions, learning and memory. 
Associated functions of   BA36 includes memory( working memory and 
memory encoding) (Van Hoesen, 1982). The limbic system is known to be 
affected in the Parkinson’s disease; loss of dopamine and noradrenaline 
innervation  in the limbic system (Remy et al., 2005) and alteration in the 
brain stem raphe (Becker et al., 1997).  
Inferior temporal area (BA20) is one of gyri in the cytoarchitecturally 
defined temporal region of cerebral cortex. Associated functions of BA20 
includes language(language comprehension and production, selective 
attention to speech), visual (integration of visual elements into 
perception), memory (dual working memory task processing) (Miyashita, 
1993).  
This study will help to not only shed some light on how the ionotrophic 
AMPA and NMDA receptors are affected in PDD and DLB in temporal 
region but also if these receptors are affected differentially in different 
areas of the temporal region. 
 
3.2 Materials and methods 
3.2.1 Patients, clinical and neuropathological assessments 
The study has been approved by the respective Institutional Review 
Boards in Stavanger, Newcastle and Singapore, and consent for post-
mortem studies was obtained from patients or their next of kin. The study 
consisted of 27 patients with LBD (11 DLB, 16 PDD) who participated in 
the Stavanger community PD cohort (Aarsland et al., 2003)or the UK 
Dementia Case Register series, Newcastle upon Tyne(Ballard C et al., 
2001), together with seven age-matched controls who had no history of 
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psychiatric or neurological illness (Table  3.1). Duration of dementia and 
parkinsonism was recorded and used to distinguish between DLB and 
PDD using operationalized criteria(McKeith, 2006), whilst diagnosis of PD 
was performed according to the established neuropathological and 
clinical criteria (Aarsland D et al., 1996; Gelb et al., 1999)Progression of 
parkinsonism was rated on the Hoehn and Yahr scale (Goetz et al., 2004). 
Annual assessments of cognitive impairment were performed using the 
Mini-Mental State Examination (Folstein et al., 1975). Fifteen PDD 
patients were administered L-Dopa but none was taking L-Dopa by the 
last assessment before death. In contrast, only three DLB patients 
received L-Dopa, with none on the medication by the pre-death 
assessment. In addition, one PDD patient was administered neuroleptics, 
two DLB patients were given benzodiazepines, and one DLB patient was 
on neuroleptics and benzodiazepines. 
Frozen brain tissues from parahippocampal gyrus (Brodmann area BA36) 
and inferior temporal area (Brodmann area BA20) cortex were sourced 
from the Newcastle Brain Tissue Resource and the Brains for Dementia 
Research (BDR) network. All neuropathological evaluations were 
performed blind to clinical assignment by two neuropathologists at 
Newcastle. Lewy bodies were assessed by a-synuclein immunostaining 
and semi-quantitatively rated on a 0–20 scale which incorporated 
additional rating points within the ‘‘neocortical’’ range of the DLB 
consensus criteria (Ballard et al., 2006; McKeith et al., 1996). Coexisting 
cerebrovascular pathology was assessed based on findings of micro 
infarcts, lacunae, white matter and small vessel disease in subcortical 
structures, and none in the present cohort had concurrent SIVD based on 
operationalized diagnostic criteria (Kalaria et al., 2004). To assess AD 
pathology, Braak staging was performed to assess neurofibrillary tangle 
involvement (Braak and Braak, 1991) while amyloid senile plaque burden 
was determined in areas of maximum plaque density and semi-
quantitatively rated as ‘‘none’’, ‘‘sparse’’, ‘‘moderate’’ and ‘‘frequent’’ 
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based on CERAD guidelines (Mirra et al., 1991). In the present cohort, 
only three subjects (all DLB) had sufficient pathology to meet CERAD 
diagnostic criteria for co-existing AD(Mirra et al., 1991). 
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Table 3.1 Demographics and disease variables in a cohort of control 
and Lewy Body Dementias (LBD)  
  Control  DLB PDD 
Demographic variables    
Maximum Na 7 11 16 
Age at Death, years 80  ±  6 80.3 ± 3 80.4 ± 1 
Sex, Male/Female 3 M/4 F 5 M/6 F 9 M/7 F 
Post-mortem Interval, 42.4 ±  11 37.6 ± 6 36.8 ± 5 
hours    
Tissue pH 6.25 ±  0.1 6.56 ± 0.08 6.36 ± 0.07 
Disease variablesa    
 MMSE score at NA 11.7 ± 3 9.9 ± 2 
pre-death    
Neocortical Lewy body NA 11.5 ± 1 11.8 ± 2 
(LB) scoreb    
PD duration before NA -1.5 ± 0.7c 9.0 ± 1.1* 
dementia, years    
Hoehn and Yahr score at NA 1.6 ± 0.7 4.7 ± 0.2* 
pre-death    
Senile plaque burdend,e    
None NA 1 (11%) 2 (15%) 
Scarce  1 (11%) 4 (31%) 
Moderate  4 (44%) 4 (31%) 
Abundant  3 (33%) 3 (23%) 
Braak stagee    
0 NA 0 (0%) 0 (0%) 
I/II  4 (44%) 8 (62%) 
III/IV  3 (33%) 4 (31%) 
V/VI  2 (22%) 1 (7%) 
        
    
Data are mean ± S.E.M 
DLB dementia with Lewy body, MMSE mini-mental state examina-tion, NA not applicable, 
PDD Parkinson’s disease dementia 
Demographic data were available for the maximum N of controls and cases. For disease 
variables, cognitive assessments were available for 24 patients (9 DLB, 15 PDD); LB 
scores were available for 24 patients (11 DLB, 13 PDD); pre-death Hoehn and Yahr scores 
were available for 15 patients (5 DLB, 10 PDD); Senile plaque scores and Braak staging 
were available for 22 patients (9 DLB, 13 PDD)  
Measured using a-synuclein immunostaining on a semi-quantitative 0–20 scale (see  
Materials and methods section)  
In DLB, parkinsonism occurred on average 1.5 years after dementia onset (range -5.5 to 
0.0 years)  
Semi-quantitative measurements based on CERAD guidelines (see  Materials and 
methods section)  
Percentage values are based on available cases  
* Significantly different from DLB (Student’s t test, p < 0.01) 
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3.2.2 Tissue processing for immunoblotting 
All chemicals used in this study were of analytical grade and from Sigma-
Aldrich Co. (USA) unless otherwise stated. Blocks of brain tissues 
previously stored at -80 °C were thawed on ice, dissected free of white 
matter and meninges, then homogenized in lysis buffer (Cell Signalling 
Technology Inc., USA) at a tissue concentration of 50 mg/ mL with the 
addition of 2 mM 4-(2-aminoethyl) benzene sulfonyl fluoride 
hydrochloride (AEBSF) and Complete MiniTM protease inhibitor tablet 
(Roche Diagnostics, USA). Measurements of protein were performed 
using Coomassie Plus reagent (Pierce Biotechnology Inc., USA). 
Homogenates were then added to Laemmli sample buffer (Bio-Rad 
Laboratories, USA) at 1:1 vol./vol. and boiled at 95–100 LC for 5 min for 
immunoblotting. Not all assays were performed for all cases due to 
limited tissue availability. 
 
3.2.3 Immunohistochemistry 
Immunohistochemical detection of polyclonal anti-GluA2 and anti-GluA3 
(both from Santa Cruz, USA), anti-AMPA receptor which recognizes 
GluA2/3/4 (Cell Signaling Technology Inc., USA), and anti-cathepsin D 
(Santa Cruz Biotechnology, USA) was undertaken employing standard 
procedures. Frontal cortical wax sections (seven microns) of aged 
controls (one male, 85 years, 46 h post-mortem delay; one female, 84 
years, 9 h post-mortem delay) were de-waxed in xylene followed by 
washes through descending concentrations of alcohols into water. 
Thereafter, antigen retrieval was carried out by heating the slides in a 
microwave oven (1 x 10 min at 900 w followed by 1 x 10 min at 300 w) in 
10 mM citrate buffer, pH 6.0. GluA2 and A3 antibodies were applied at a 
dilution of 1:100, GluA2/3/4 antibody was used at 1:50 dilution, while 
cathepsin D antibody was used at 1:1,000 dilution. The AMPA subunit 
antibodies were incubated with sections adjacent to those incubated with 
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cathepsin D antibody. Further development of antibody binding employed 
appropriate biotinylated secondary antibodies, avidin–biotin complex and 
DAB (3,3’-diaminobenzidine) kits (Vector Laboratories, UK). Images were 
captured on a Leica DMRB microscope equipped with DFC420 camera. 
 
3.2.4 Immunoblotting 
Prepared brain homogenates in Laemmli buffer were electrophoretically 
separated on 10 % polyacrylamide gels, transferred onto nitrocellulose 
membranes, and blocked in 10 mM phosphate buffered saline, pH 7.4 
with 0.1 % Tween 20 and 5 % skim milk (PBSTM) before blotting with 
primary antibody (GluA2, A3, A2/3/4, GluN1, GluN2a, GluN2B, all 1:1,000 
dilution, all GluN antibodies from Cell Signalling Technology Inc.,USA) in 
PBSTM overnight at 4 °C, followed by washings in PBST and incubation 
with appropriate horseradish peroxidase conjugated secondary 
antibodies (1:5,000, Jackson Immuno Research Inc., USA). One lane in 
each membrane consisted of fixed amounts of brain homogenate from a 
specific case to act as external control for normalization of 
immunoreactivities across separate membranes. Immunoreactive bands 
on the membranes were detected by enhanced chemiluminescence and 
quantified by an image analyzer (UVI tec, UK). Membranes were stripped 
and re-blotted with anti-b-actin (A1978, mouse monoclonal from Sigma 
to Aldrich Ltd., 1:5,000 dilution) as loading control. Normalized 
immunoreactivities were expressed in arbitrary units. 
 
3.2.5 Statistical analyses 
Data were analysed using SPSS statistics software version 13 (SPSS Inc., 
USA). Normality of data was first checked using the Kolmogorov–Smirnov 
tests. Comparisons of group means were performed by one-way analyses 
of variance (ANOVA) followed by Bonferroni post hoc tests, or by 
Kruskal–Wallis ANOVA as appropriate. Student’s t tests or Mann–Whitney 
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U tests were used to compare variables applicable to the dementia 
groups, or to compare controls with combined LBD group. Inter 
correlations were analyzed by Pearson’s product moment or Spearman’s 
rank correlation. Results were considered statistically significant if p < 
0.05. 
 
3.3 Status of the AMPA receptor subunits in the 
parahippocampal gyrus cortex(BA36) of PDD and DLB  
3.3.1 Demographic and disease variables of controls and LBD 
Demographic and disease variables in the three study groups are listed in 
Table 3.1. Age, post-mortem interval and cortical pH (as an indicator of 
tissue quality, (Monoranu et al., 2009) were not significantly different 
among the groups (ANOVA with post hoc Bonferroni, p >0.05). 
Table 3.1 also shows that the severity of dementia (indicated by pre-death 
MMSE scores), as well as neocortical Lewy body burden was closely 
matched between DLB and PDD, in agreement with previous findings 
(Jellinger, 2009). PD progression and motor disability (indicated by pre-
death Hoehn and Yahr scores) and duration of PD before dementia were 
expectedly higher in PDD than in DLB. Furthermore, senile plaques and 
neurofibrillary tangles were common features in the patients, of which 
DLB seemed to have a higher burden than PDD as indicated by higher 
percentages of available DLB cases with ‘‘moderate’’ to ‘‘abundant’’ 
plaques, or with Braak V/VI tangle scores (Table  3.1). 
 
3.3.2 GluA subunit immunohistochemistry 
To determine whether the antibodies used in this study label neurons, we 
performed immunohistochemistry with the GluA antibodies and 
compared the staining patterns with those labelled with cortical neuronal 
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marker cathepsin D (Reid et al., 1986) in adjacent sections. Our data 
showed that a subset of cathepsin D-positive cells was also labelled by 
GluA2, A3 or A2/3/4 (Fig.  3.1). Under higher magnification, at least a 
proportion of GluA subunit immunoreactivities seemed to be localized to 







































Figure 3.1 Immunohistochemical identification of AMPA receptor 
sub-units in postmortem human neocortex. The left column shows 
representative pictures of AMPA receptor subunits labeled by the same 
antibodies as those used in the immunoblotting studies, while the middle 
column shows corresponding adjacent sections labeled by cathepsin D as 
a neuronal marker. The right column shows GluA immunoreactivities at 
higher magnification, with numerical values above scale bars indicating 




3.3.3 GluA subunit immunoblotting in controls and LBD: 
correlations with disease and clinical variables 
Initial analyses between controls and the combined LBD (DLB and PDD) 
group show that immunoreactivities for all three antibodies were reduced 
in the dementia group (Fig  3.2a). When comparing controls with DLB and 
PDD separately, GluA3 reductions reached post hoc statistical significance 
in both DLB and PDD, while GluA2/3/4 decrease was significant in PDD 
only, and GluA2 showed non-significant trends toward decreases (ANOVA 
F2, 31 = 2.56, p = 0.09, see Fig. 3.2b). We next investigated associations 
between GluA immunoreactivities and the clinical features of LBD, and 
found GluA2/3/4 immunoreactivities to be negatively correlated with 
pre-death Hoehn and Yahr scores (Fig.  3.3) as well as with duration of PD 
before dementia (Table  3.2). In contrast, Table 3.2 shows that GluA2, 
GluA3 and GluA2/3/4 immunoreactivities did not correlate with pre-
death MMSE (as an indicator of dementia severity) or neocortical Lewy 
body scores (Table  3.2). Age, post-mortem delay or pH also did not 
correlate with GluA immunoreactivities in control and disease groups 
(Spearman p > 0.05). In addition, immunoreactivities were not 
significantly affected by L-Dopa medication, CERAD plaque load or Braak 




Figure 3.2 AMPA receptor subunit immunoreactivities in neocortex(BA36) of controls and Lewy body dementias. 
Bar charts of GluA2, GluA3 and GluA2/3/4 immunoreactivities in parahippocampal gyrus (BA36) (all single bands *100 
kDa) normalized to b-actin (42 kDa), in arbitrary units, in controls and (a), combined LBD as well as (b), DLB and PDD 
subgroups. Data are mean ± S.E.M. Available N values are controls = 7, DLB = 11, PDD = 16. (c), representative immunoblots 
of GluA2, GluA3 and GluA2/3/4 and b-actin in controls (Ct), DLB (D) and PDD (P). *Significantly different from respective 




























Figure 3.3 Correlations of 
AMPA receptor subunit 
immunoreactivities with 
motor disability in 
neocortex(BA36) of Lewy 
body dementias. Scatter 
plots and linearly regressed 
best-fit trend lines of GluA2, 
GluA3 and GluA2/3/4 
immunoreactivites with pre-
death Hoehn and Yahr scores 
as a measure of motor 
disabilities (N=15). Analyses 
of dementia patients were 














Variable (available N) GluA subunits  
    
 GluA2 GluA3     GluA2/3/4a 
    
MMSE score at pre-death (24) -0.043 0.192  0.102 
Neocortical Lewy body score (24) 0.117 0.202       -0.06 
PD duration before dementia, -0.203 -0.351       -0.462* 
years (24)    
 
a Measured using an antibody which recognizes GluA2, GluA3 and GluA4  
* p < 0.05 (Spearman correlation) 
Table 3.2  Summary of correlation coefficients of GluA immunoreac-









Figure 3.4:  Effect of  (A) L-DOPA and (B) neurectic plaques on GluA 
immunoreactive level Data are mean immunoreactivities ± SEM in arbitrary 
units normalised to a common external standard (see methods). Available N are 
listed on the respective key insert. Non significant (NS) changes is observed 















Figure 3.5: Effect of neurofibrillary tangles on GluA 
immunoreactive level Data are mean immunoreactivities ± SEM 
in arbitrary units normalised to a common external standard (see 
methods). Available N are listed on the respective key insert. Non 
significant(NS) changes is observed between control and 





AMPA receptors are well-known to mediate and regulate synaptic 
processes involved in learning, memory and behaviour, and have been 
shown to be affected in neuro-degenerative dementias. For example, 
GluA2 and A3 are reported to be reduced in AD, where GluA2 loss has 
been speculated to contribute to Ca2+ mediated excitotoxicity due to its 
physiological role in limiting Ca2+ influx (Carter et al., 2004; Gong et al., 
2009). On the other hand, GluA2 is found to be upregulated in subcortical 
ischemic vascular dementia and correlated with milder dementia, which 
was interpreted as a neuroprotective synaptic plasticity process related 
to decreased Ca2+ mediated excitotoxicity (Mohamed et al., 2011). In this 
study, investigations of AMPA receptor was extended to a cohort of LBD 
(DLB or PDD) patients, and moderate losses of GluA subunits was found 
to be correlated with pre-death Hoehn and Yahr scores as well as 
duration of PD before dementia. 
 
3.3.4.1 Interpretation and limitations of data 
 
Immunoreactivities of all three anti-bodies (GluA2-specific, A3-specific, 
and one which recognized GluA2/3/4 subunits) are reduced in LBD 
neocortex compared to controls. Because the GluA2/3/4 antibody 
recognizes GluA2 and A3 in addition to A4, the extent of contribution by 
GluA4 to changes in GluA2/3/4 immunoreactivities is at present unclear. 
At the point of this study, the commercially available GluA4 antibody is 
unspecific thus analysis of this subunit is not possible. However, it is 
important to note that future work will include studying GluA4 as it is 
thought to be involved in synaptic plasticity and the functional neural 
circuitry development through the recruitment of other AMPA receptor 
subunits (Luchkina et al., 2014). For example, the deletion of GluA4 
resulted in slower evoked and miniature AMPA receptor-EPSCs, and 
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spatial acquisition reference memory was observed to be affected in 
GluA4 knockout mice (Sagata et al., 2010).  
Although further subgroup analyses indicated that GluA3 was decreased 
in DLB and PDD, and GluA2/3/4 was decreased only in PDD, the 
comparable direction of change in immunoreactivities suggests a general 
loss of GluA2/3/4 in LBD rather than subunit-specific changes (Fig.  3.2b). 
Taken as a whole, losses of GluA subunits may be more severe in PDD 
than in LBD (Fig.  3.2b), with PDD also manifesting more severe motor 
disabilities (Table  3.1). This suggests that GluA alterations may 
potentially distinguish clinically defined PDD from LBD neurochemically. 
However, follow-up studies of larger cohorts are needed to confirm this. 
Furthermore, although it is shown here that a subset of cathepsin D-
positive cells is stained for GluA2, A3 and 2/3/4, supporting a neuronal 
labelling for these antibodies (Fig.  3.1), it is possible that GluA expression 
in other cell types (e.g., astrocytes and microglia) may also contribute to 
the observed neurochemical changes, and further studies are needed. 
Because coexisting brain pathologies may contribute to the observed 
changes, we also assessed the presence of vascular and AD pathology in 
this cohort. While none of the subjects had sufficient vascular changes to 
be diagnosed as with SIVD (Kalaria et al., 2004), three DLB subjects met 
diagnostic criteria for concurrent AD (Mirra et al., 1991). Therefore, 
further studies on the effects of AD pathology (senile plaque load and 
Braak staging) on GluA immunoreactivities was done , and it is found that 
plaque and tangle burden did not have further effects on GluA2, A3 and 
A2/ 3/4 levels in the LBD cohort. This suggests that whilst both AD and 
LBD showed decreased AMPA receptor subunits, the effects may not be 
additive in comorbid diseases. Taken together, our data suggest that 
GluA2/3/4 loss is a neurochemical marker for motor disability and 
duration of PD in LBD. 
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The putative mechanisms by which neocortical GluA2/3/4 alterations 
may underlie motor disability in LBD are currently unclear. Figure 2.3  
shows that multiple areas of the cerebral cortex project to the basal 
ganglia via glutamatergic corticostriatal pathways which interact with the 
nigrostriatal dopaminergic system to regulate motor and cognitive 
functions(Strafella et al., 2005)  and abnormalities of this glutamate–
dopamine interaction are thought be involved in PD 
pathophysiology(Calabresi et al., 2000; Carlsson and Carlsson, 1990).  
Studies on various animal models of PD have shown both increased 
corticostriatal glutamatergic activation as well as increased striatal 
neuron excitability (Calabresi et al., 2000; Campbell and Björklund, 1994; 
Gainetdinov et al., 2001; Lindefors and Ungerstedt, 1990). Interestingly,   
in an acute mouse model of PD (Gainetdinov et al., 2001), treatment with 
blockers of glutamate N-methyl-D-aspartate (NMDA) receptor-mediated 
transmission has shown to both exacerbated hyperactive behaviours as 
well as prevented the inhibitory effects of psychostimulant and 
serotonergic drugs on hyperactivity. Given that AMPA receptor function 
to potentiate NMDA receptor activation by increased excitatory 
postsynaptic potentials and removal of Mg2+ block (Malinow and Malenka, 
2002) we postulate that motor disability in LBD is likewise related to 
hampered NMDA receptor function due to GluA2/3/4 losses and 
associated AMPA receptor hypofunction. Alternatively, the observed GluA 
subunit changes may simply reflect an adaptive synaptic plasticity arising 
from long-term corticostriatal dopamine–glutamate imbalance. Another 
possibility would be the involvement of a common factor e.g., cortical 
Lewy bodies (LB) which may both affect GluA levels as well as be 
associated with PD progression, although this was not supported by our 
data which showed that LB scores did not significantly correlate with 
either GluA immunoreactivities or pre-death Hoehn and Yahr scores. 
However, this lack of correlation may also be attributable to (a) a 
relatively small cohort with a narrow range of cortical LB scores; and (b) 
the involvement of brain regions and receptors other than those under 
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study. Therefore, to further delineate the potential role of AMPA receptor 
changes in the clinical features of Lewy body dementias, follow-up studies 
on larger cohorts and multiple brain regions are needed, including those 
involved in motor circuits. More comprehensive measurements of motor 
disability (e.g., motor sub-score of revised Unified Parkinson’s Disease 
Rating Scale (UPDRS) (Goetz et al., 2007).   UPDRS is commonly used 
study the longitudinal course of Parkinson Disease and is made up 
different sections as stated below: 
 Part I: evaluation of Mentation, behavior, and mood; 
 Part II: self-evaluation of the activities of daily life (ADLs) including 
speech, swallowing, handwriting, dressing, hygiene, falling, salivating, 
turning in bed, walking, cutting food; 
 Part III: clinician-scored monitored motor evaluation; 
 Part IV: Hoehn and Yahr staging of severity of Parkinson disease. 
 Part V: Schwab and England ADL scale. 
As Hoehn and Yahr only forms part of UPDRS, using this comprehensive 
scale may improve the accuracy and sensitivity of clinical-neuro-chemical 
correlations. 
It is also important to study the changes in other subunits (e.g., GluA1) 
and receptors (e.g., NMDA) at both mRNA and protein levels in order to 
Lastly, it may be worthwhile to compare the current findings with further 






Using a clinically well-characterized cohort of patients with Lewy body 
dementias (DLB and PDD), we report moderate losses of AMPA receptor 
GluA2/3/4 subunits in parahippocampal gyrus region(BA36) which 
correlated with pre-death Hoehn and Yahr scores and PD to dementia 
interval. In this cohort, GluA2/3/4 immunoreactivities did not correlate 
with pre-death MMSE scores or cortical LB scores; and also did not seem 
to be affected by senile plaque or neurofibrillary tangle burden. This 
suggests that GluA subunit changes in LBD may be a neurochemical 
marker of severity or chronicity of parkinsonism and related to 
alterations arising from corticostriatal dopamine–glutamate imbalances. 
This clinical-neurochemical association appears to be corroborated by the 
finding that although clinically defined PDD and DLB are two aspects of 
the same entity (LBD) and share similar brain changes (e.g., GluA deficits), 
PDD appears to be characterized by higher GluA2/ 3/4 losses, and also 
manifests more severe motor disability and longer duration of 
parkinsonism. Given recent proposals to use AMPA receptor antagonists 
in PD, especially for levodopa-induced dyskinesia(Johnson et al., 2009) 
our data suggest both potential and caution in extending such therapeutic 
rationales to LBD in view of altered levels of receptor drug targets; as well 
as indicate further studies to elucidate the relationships between 
parkinsonism, dementia and GluA neurochemical alterations. Therefore, 
we reiterate the importance of focusing on interactions between the 
neurochemical, genetic and demographical basis of clinical phenotypes in 





3.4 Status of NMDA receptor subunits in parahippocampal 
gyrus (BA36) of PDD and DLB 
Together with AMPA receptor, NMDA forms an intergral part of the 
glutamatergic system. NMDA receptors mediate critical synaptic 
processes in learning and memory (Hunt and Castillo, 2012), but 
excessive activation of NMDA receptors may disrupt receptor-mediated 
signaling and lead to intracellular Ca2+ overloading resulting in 
excitotoxicity (Cacabelos et al., 1999; Francis et al., 2012; Hynd et al., 
2004a).  
3.4.1 Materials and methods  
To study the status of NMDA receptor, immunoblotting of GluN1,2A and 
GluN2B was performed on BA36 of PDD and MIX (refer to Chapter3.2) 
3.4.2 Results  
This results shows that there are no change in the NMDA receptor subunit 
controls when compared to age-match controls in the parahippocampal 
gyrus (BA36), suggesting that NMDA receptor is not affected in that 








Figure 3.6: NMDA receptor immunoreactivies in the parahippocampal 
gyrus(BA36) of  controls, PDD and DLB. (A) Bar charts of NMDA receptor 
(GluN1, GluN2A,GluN2B and GluN3A)  immunoreactivites normalised to β-
actin, in arbitrary units, in controls , PDD and DLB subgroups. (B) 
representative immunoblots of GluN1, GluN2A and GluN2B and b-actin in 
controls (C), DLB (D) and PDD (P)  Data are mean ± S.E.M. Non 




3.4.3 Discussion and conclusion  
The unaltered NMDA receptor subunits in the parahippocampal gyrus 
(BA36) was unexpected as it was postulated that the GluA2/3/4 and 
associated AMPA receptor hypofunction found in same region might 
hamper NMDA receptor function. This study suggests differential 
ionotrophic glutamatergic receptor changes in PDD and DLB of BA36. It is 
essential to look at RNA editing efficiency of the GluA2 to study whether 





3.5 Status of AMPA and NMDA receptor subunits in inferior 
temporal cortex (BA20) of PDD and DLB 
To observe whether similar glutamatergic changes observed in 
parahippocampal gyrus is found in other parts of the temporal region, 
NMDA and AMPA receptor immunoblotting was performed in the inferior 
temporal cortex of the PDD and DLB patients of the same cohort. 
 
3.5.1 Materials and Methods 
To study the status of NMDA receptor, immunoblotting of GluN1,2A and 
GluN2B was performed on BA36 of PDD and MIX (refer to Chapter3.2) 
 
3.5.2 Results  
This results shows that there are no significant changes in the NMDA and 
AMPA receptor subunits controls when compared to age-match controls 
in the inferior temporal cortex(BA20) suggesting that differential 









Figure 3.7 AMPA receptor immunoreactivies in inferior temporal 
cortex(BA20) of controls,  PDD and DLB. (A) Bar charts of AMPA (GluA2, 
GluA2,3,4) immunoreactivites normalised to β-actin, in arbitrary units, in 
controls , PDD and DLB subgroups.(B) representative immunoblots of 
GluA2, GluA2/3/4) and b-actin in controls (C), DLB (D) and PDD (P) Data 
are mean ± S.E.M. Non-significant(NS) changes is observed between 
control and dementia groups.   
 
Figure 3.8 NMDA receptor immunoreactivies in inferior temporal 
cortex of controls(BA20),  PDD and DLB. (A) Bar charts of NMDA 
receptor (GluN1, GluN2A, GluN2B)  immunoreactivites normalised to β-
actin, in arbitrary units, in controls , PDD and DLB subgroups. (B) 
representative immunoblots of GluN1, GluN2A and GluN2B and b-actin in 
controls (C), DLB (D) and PDD (P). Data are mean ± S.E.M. Non-





3.5.3 Discussions and conclusions 
No significant glutamatergic changes were observed in PDD and DLB in 
the inferior temporal cortex (BA20) unlike those observed in the 
parahippocampal gyrus (BA 36) suggesting differential glutamatergic 
changes in the same temporal region of the brain. More studies are 
needed to provide an explanation for these findings. 
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3.6 Overall results and conclusions for Chapter 3  
Status of AMPA and NMDA receptor in PDD and DLB  
Parahippocampal gyrus(BA36): The parahippocampal gyrus forms the 
medial limbic structure of the temporal lobe. BA36 forms the limbic 
system which mediates emotions, learning and memory. Associated 
functions of   BA36 includes memory( working memory and memory 
encoding) (Van Hoesen, 1982). The limbic system is affected in the 
Parkinson’s disease; loss of dopamine and noradrenaline innervation in 
the limbic system (Remy et al., 2005) and alteration in the brain stem 
raphe (Becker et al., 1997). The usage of BA36 in this study has the 
potential to give insight on how parkinsonism affects PDD and DLB.  In 
this study, using a clinically well-characterized cohort of patients with 
Lewy body dementias (DLB and PDD), it was reported that moderate 
losses of AMPA receptor GluA2/3/4 subunits in parahippocampal gyrus 
region (BA36) correlated with pre-death Hoehn and Yahr scores and PD 
to dementia interval.  In this cohort, GluA2/3/4 immunoreactivities did 
not correlate with pre-death MMSE scores or cortical LB scores; and also 
did not seem to be affected by senile plaque or neurofibrillary tangle 
burden (though it maybe because of a small cohort). This suggests that 
GluA subunit changes in LBD which may lead to corticostriatal dopamine–
glutamate imbalances may be a neurochemical marker of severity or 
chronicity of parkinsonism. This findings also suggest that although 
clinically defined PDD and DLB are two aspects of the same entity (LBD) 
and share similar brain changes (e.g., GluA deficits), PDD appears to be 
characterized by higher GluA2/ 3/4 losses, and also manifests more 
severe motor disability and longer duration of parkinsonism.  This data 
suggest both caution in extending such PD therapeutic rationales such as 
AMPA receptor antagonist (levodopa-induced dyskinesia) to LBD in view 
of altered levels of receptor drug targets. Further studies to elucidate the 
relationships between Parkinsonism, dementia and GluA neurochemical 
alterations are needed.  
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Inferior temporal cortex(BA20): No significant glutamatergic changes 
were observed in PDD and DLB in the inferior temporal cortex (BA20) 
unlike those observed in the parahippocampal gyrus (BA 36) suggesting 
differential glutamatergic changes in the same temporal region of the 
brain. More studies is needed to provide an explanation for these findings. 
To further delineate the potential role of AMPA receptor changes in the 
clinical feature of PDD and DLB, other multiple brains especially those 
involved in the motor circuit should be look at. This includes the straitum 




Role of NMDA and AMPA receptors in VaD(SIVD) and 
MIX 
 
Aim 2: To study the glutamatergic system status in 
cerebrovascular-related dementia, VaD and MIX  
Hypothesis 2a: Down-regulation of NMDA and AMPA receptor levels in 
VaD compared to controls. Rationale: As neuronal loss is well-known 
observation in stroke patients, loss of glutamatergic receptors are 
hypothesized. 
Hypothesis 2b: Down-regulation of NMDA and AMPA receptor levels in 
MIX compared to controls. Rationale: MIX patients are known to have 
concurrent pathology of VaD and AD, and cognitively worse compared to 
VaD patients. It is hypothesised that a reduction in glutamatergic subunits 
may be responsible for the cognitive dysfunction in MIX.  
 
4.1 Introduction  
4.2 Status of the AMPA receptor subunits in the superior temporal 
cortex (BA22) of SIVD and MIX 
4.3 Status of the NMDA receptor subunits in the superior temporal cortex 
(BA22) of SIVD and MIX 
4.4 Status of the AMPA and NMDA receptor subunits in the prefrontal 
cortex (BA9) of SIVD and MIX 





In this study, we aimed to analyse  the state of AMPA and NMDA receptors 
in subcortical ischemic vascular dementia (SIVD), which is characterized 
by low plaque and tangle burden, as well as in mixed SIVD / AD (MIX) 
using a longitudinally assessed cohort of dementia patients.  Subcortical 
ischemic vascular dementia (SIVD) is clinically homogenous and 
characterized by executive dysfunction, mild dementia and relatively 
preserved language, calculation and other higher cortical functions 
(Roman et al., 2002). MIX dementia, a condition where VaD and AD co-
exist, and is increasingly found among the elderly,   was also studied.  
(Jellinger, 2007) 
In AD cortex, down regulation of GluA2 and other subunits are well-
established findings and may underlie certain glutamatergic dysfunctions 
(Carter et al., 2004; Gong et al., 2009; Ikonomovic et al., 1997). 
Interestingly, data from in-vitro and animal model-based studies suggest 
that exposure to the 42 amino acids-long β-amyloid peptide (Aβ42), 
which is derived from proteolytic processing of the larger amyloid 
precursor protein (APP) and which forms the major component of 
neuritic plaques, may lead to AMPA receptor dysfunction via mechanisms 
possibly involving GluA2 down regulation (Chang et al., 2006; Hsieh et al., 
2006; Liu et al., 2010).  
 
In considering the neurochemical correlates of the clinical and 
neuropathological features of these diseases, it is important to investigate 
the glutamatergic system given its status as the major excitatory 
neurotransmitter system in the CNS and its critical roles both in cognitive 
functions as well as in excitotoxicity (Baudry and Lynch, 2001; Fonnum, 
1984; Francis et al., 1993; Olney et al., 1997). However, while 
glutamatergic dysfunctions have been fairly well characterized in AD 
(Francis, 2003, 1996; Francis et al., 1993), their status in vascular and 
mixed dementias is unclear. It is of particular interest whether differences 
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in glutamatergic alterations may underlie clinical differences in between 
SIVD and AD (e.g., milder dementia in SIVD). For this study, post-mortem 
tissues from Brodmann 9 (BA9) and from Brodmann 20 (BA20) are 
chosen to study the NMDA and AMPA receptor changes in the frontal and 
temporal area respectively.    
 
BA9 is the dorsolateral prefrontal cortex of the brain and serves as the 
highest cortical area responsible for regulation, motor planning and 
planning. The associated  functions of BA9 includes memory (working 
memory , memory encoding, memory retrieval, processing short-term 
memories and retaining longer term memories) and executive functions( 
planning,  inferential reasoning  and decision-making ), motor (executive 
control of behavioral control) and language( verbal fluency). Damage to 
dorsal frontal prefrontal cortex can lead to problems affecting executive 
memory and judgement (Gerhand, 1999). The prefrontal cortex has been 
observed to be affected  in AD;loss of functional connectivity (Grady et al., 
2001) ; degeneration within the prefrontal cortex with AD is observed in 
the inferior PFC region (Salat DH et al., 2001); loss of VGLUT1 and 
VGLUT2 in the prefrontal cortex was found to be correlated with 
cognitive decline in AD (Kashani et al., 2008). In addition, most of the 
GluA2 was found to be edited resulting in majority of the AMPA receptor 
channel calcium impermeable (Akbarian et al., 1995). 
BA22 area(also known as superior temporal area 22)  forms part of the 
Wernicke’s area and is one of gyri in the cytoarchitecturally defined 
temporal region of cerebral cortex. The associated functions of BA22 
includes memory (formation of long-tern memory), language (sematic 
processing, auditory language processing and sentence generation) 
auditory (processing complex sounds), visual (processing of complex 
stimuli like faces and scenes). Damage in brain area 22 often leads to 
language disorder called Wernicke’s aphasia which includes defect in 
language reception and processing(Karnath, 2001). The temporal cortex 
134 
 
has been observed to be affected  in AD; loss of synapses observed in 
early AD(Davies et al., 1987); evidence of DNA fragmentation observed in 
AD suggesting apoptosis (Dragunow et al., 1995); loss of temporal lobe 
atrophy(Chan et al., 2001)  
It is worthwhile to study how the glutamatergic system affected in SIVD 









4.2 Status of the AMPA receptor subunits in the 
parahippocampal gyrus cortex(BA36) of PDD and DLB  
4.2.1 Materials and methods 
4.2.1.1 Patients, clinical and neuropathological assessments  
This study comprised of a total of 42 subjects, consisting of 17 SIVD and 
10 MIX patients, together with 15 non-demented elderly controls from 
the Oxford Project to Investigate Memory and Ageing (OPTIMA, see 
http://www.medsci.ox.ac.uk/optima), whose postmortem tissues are 
now part of the Thomas Willis Oxford Brain Collection(Table 4.1). The 
majority of subjects from the OPTIMA cohort had been assessed annually 
using a cognitive assessment battery, including the Mini-Mental State 
Examination (MMSE,(Folstein et al., 1975) , maximum score = 30), with 
the majority of cases (13 controls, 16 SIVD, 9 MIX) followed till death, and 
pre-death MMSE scores were used as an indicator of severity of cognitive 
impairment. Aautopsies were performed with informed consent from 
next-of-kin, and Institutional Review Board (IRB) approval had been 
obtained for the study. For all subjects, tissue blocks from one 
hemisphere were dissected and fresh frozen, while the contralateral 
hemisphere was formalin fixed and processed for pathological 
assessment, which included the Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD) criteria (Mirra et al., 1991)for the diagnosis 
of AD and Braak staging of neurofibrillary tangle involvement (Braak and 
Braak, 1991). Vascular dementia was clinically diagnosed using NINDS-
AIREN operationalized criteria (Román et al., 1993) while 
neuropathological determination of SIVD was based on findings of 
microinfarcts, lacunae, white matter and small vessel disease in 
subcortical structures (Kalaria et al., 2004). None of the SIVD patients had 
higher than Braak stage III / IV tangle burden or more than “sparse” 
plaque counts by CERAD criteria. Cases were considered to be mixed SIVD 
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/ AD (MIX) only if criteria for SIVD were met in addition to a CERAD 
“probable” or “definite” AD diagnosis. All control subjects died from non-
neurological causes, had no history of dementia or psychiatric conditions, 
and did not meet neuropathological diagnostic criteria for 




  Control SIVD  MIX         
Demographics         
    Maximum number of cases  15 17 10 
    Age at Death (years)  80.5 ± 2 82.7 ± 2  78.4 ± 3  
    Sex (Male/Female) 11M / 4F 10M / 7F 5M / 5F 
    Follow-up (years) 3.9 ± 0.6 4.5 ± 0.7 4.6 ± 0.8 
    Postmortem Interval (hours) 52.0 ± 9 54.2 ± 8 33.0 ± 5 
Disease variables        
    MMSE score at study entry 27.9  ± 0.5 27.0 ±  0.7 14.9 ± 2.5** 
    Predeath MMSE score    27.9  ± 0.4 22.7 ± 1.4*  3.7 ± 1.8**  
    Braak staging (N)                
   0 - II 
   III/IV 















Data are mean ± S.E.M. MIX, mixed dementia (SIVD / Alzheimer’s disease); 
MMSE, Mini-Mental State Examination; N, number of cases; NFT, neurofibrillary 
tangle; NP, neuritic plague; SIVD, subcortical ischemic vascular dementia.  
*Significantly different from Control (ANOVA with post-hoc Tamhane, p < 
0.05)**Significantly different from Control and SIVD (ANOVA with post-hoc 
Tamhane, p < 0.01) 
 




4.2.1.2 Tissue processing   
All reagents used in this study were of analytical grade and from Sigma-
Aldrich Co. (USA) unless otherwise stated. For RNA extraction, 25 mg 
aliquots of grey matter were cut from frozen superior temporal gyrus 
(Brodmann Area 22) and prefrontal cortex (Brodmann 9) and stored at -
75°C in TRIzol® reagent (Invitrogen, USA). Remaining tissues were 
thawed on ice, dissected free of meninges, then homogenized at 50 mg 
tissue / mL in either ice-cold 5M guanidine HCl / 50 mM Tris-HCl, pH 8.0 
or lysis buffer (Cell Signalling Technology Inc., USA, product no. #9803) 
with the addition of 2 mM 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) and Complete Mini™ protease inhibitor tablet 
(Roche Diagnostics, USA). Protein concentrations were measured using 
Coomasie Plus reagent (Pierce Biotechnology Inc., Rockford, IL). 
Guanidine / Tris-HCl treated brain homogenates were stored frozen for 
enzyme-linked immunosorbent assay (ELISA) while lysis buffer treated 
homogenates were then added to Laemmli sample buffer (Bio-Rad 
Laboratories, USA, 1:1 vol. /vol.) and boiled at 95-100 °C for 5 min for 
immunoblotting. Due to tissue availability, not all assays were performed 
for all cases. The available N values for each assay are listed in Results or 
Figure legends. 
 
4.2.1.3 Aβ42 and tau ELISA 
Guanidine / Tris-HCl treated brain homogenates were thawed, diluted 
and processed for ELISAs of Aβ42, tau phosphorylated at serine-396 
(pS396 tau) as well as total tau using commercially available kits 
(Invitrogen, USA; product nos. KHB3441, KHB7031 and KHB0041 
respectively) according to manufacturer’s instructions, and measured in 
ng / mL.  
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4.2.1.4 Subcellular Fractionation 
To understand better where the AMPA receptor subunit are localized, 
subcellular fractionation were performed. Separation of post-mortem 
brain homogenates into membrane and cytosolic fractions were 
performed as previously described (Poore et al., 2010) with minor 
modifications. Briefly, brain homogenates in cell lysis buffer (Cell 
Signalling, cat no: # 9803) were placed on ice for 10 min before 
centrifugation at 1000 × g for 5 min at 4°C.  After discarding the nuclear 
fraction pellet, the supernatant was subsequently centrifuged at 150,000 
× g for 30 min at 4°C to yield the membrane (pellet) and cytosolic 
(supernatant) fractions. Fractions were added to SDS sample buffer (Bio-
Rad #161-0737) containing β-mercaptoethanol with or without boiling 
for subsequent immunoblotting.   
 
4.2.1.5 Immunoblotting 
Primary antibodies used in this study as well as respective dilutions are 
listed in Table 4.2. First, brain homogenates in sample buffer were 
electrophoretically separated on 10% polyacrylamide gels, transferred 
onto nitrocellulose membranes, and blocked in 10 mM phosphate 
buffered saline, pH 7.4 with 0.1% Tween 20 and 5% skim milk (PBSTM) 
before immunoblotting with primary antibody at the stated dilutions in 
PBSTM for 3 h at room temperature (RT) or overnight at 4°C, followed by 
washings in PBST and incubating with appropriate horseradish 
peroxidase conjugated secondary antibodies (1:5000, Jackson 
ImmunoResearch Inc., USA). Immunoreactive bands on the membranes 
were detected by enhanced chemiluminescence and quantified by an 
image analyzer (UVItec, UK). Some membranes were stripped and 
reblotted with anti-β-actin for normalization of sample loading. 










C3T GluA1 Rabbit 1:1000 Millipore 
GluA2 GluA2 Goat  1:1000 SantaCruz 
AMPA 
RECEPTOR 
GluA2/3/4 Rabbit 1:1000 Cell Signaling 
EGFR EGFR Rabbit 1:1000 Cell Signaling 













Table 4.2 Primary Antibodies used to study the AMPA and NMDA 
receptor in SIVD and MIX.   
 
Abrreviation: EGFR, epidermal growth factor receptor; GAPDH, 





4.2.1.6 RNA isolation and cDNA synthesis 
 Total RNA was isolated from brain samples  using the TRIzol® reagent 
(Invitrogen, USA) method according to the manufacturer’s protocol. RNA 
quality and concentration were evaluated using a NanoDrop machine 
(ThermoScientific, USA) and results confirmed by a Bioanalyzer (Agilent 
Technologies, USA). cDNA was synthesized with random hexamers and 
oligo(dT)12–17  primers using SuperScript® II reverse transcriptase, all 
from Invitrogen, USA.  
 
4.2.1.7 Quantification of GluA2 mRNA using quantitative real-time PCR 
(qRT-PCR) 
Quantitation of GluA2 (encoded by GRIA2 gene) and -actin (endogenous 
reference) mRNA expression was performed on a 7500 Fast Real-Time 
PCR system from Applied Biosystems, USA using its Assay-on-Demand 
primers and probes sets for GluA2 (Hs00181331_m1) and -actin ( 
Hs99999903_m1) along with Universal Taqman™ Master Mix PCR kit 
(Qiagen, Germany). Initial qRT-PCR reactions were comprised of 7.5μL of 
Universal TaqMan Master Mix, 0.75μL of probe Master Mix and 1.5 μL of 
sample containing target template in a final reaction volume of 15 μL. The 
initial TaqMan® assay amplification program (according to 
manufacturer’s directions) consisted of an activation step (95 °C, 10 min) 
followed by 45 cycles of denaturation (95 °C, 15 s), annealing and 
elongation (60 °C, 1 min). Comparative CT method was used to measure 
relative quantitation. The amount of GluA2 mRNA, normalized to -actin 
and relative to a calibrator is given the formula 2−ΔΔCT.  Mean ± S.E.M. of 
relative mRNA expression was determined for each group and expressed 
in arbitrary units. 
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4.2.1.8 Statistical analyses  
All statistical analyses were performed using SPSS 13.0 for Windows 
software (SPSS Inc.). Normality of data was first checked using the 
Kolmogorov-Smirnov tests. Because the N of the groups were not 
matched and equal variances could not be assumed, comparisons of 
normally distributed variables between controls, SIVD and MIX groups 
were performed by one-way analyses of variance (ANOVA) followed by 
post-hoc Tamhane’s T2 tests, while non-normally distributed variables 
were compared with Kruskal-Wallis tests. Correlations between cognitive 
scores and neurochemical measures were analyzed by Pearson’s product 
moment or Spearman’s rank correlation. Results were considered 














4.2.2 Results and Discussion 
Status of AMPA receptor subunits in superior temporal cortex 
(BA22) of SIVD and MIX 
4.2.2.1 Demographic and disease variables of controls, SIVD and MIX 
Table 4.1 lists the various demographic and disease variables in the three 
groups. Age, post-mortem interval and follow-up duration were not 
significantly different among the groups (ANOVA with post-hoc Tamhane, 
p > 0.05), while there was a higher proportion of males in the control and 
SIVD groups. However, none of the neurochemical measures were 
significantly different between males and females in either controls or 
SIVD, or with other demographic factors such as age and postmortem 
delay (data not shown). Table 4.1 also shows that the majority of control 
(87%) and SIVD (76%) patients had Braak stages 0 – II, with none above 
stage IV, while all MIX patients were Braak stages V / VI. Lastly, the MIX 
group was found to have the most severe cognitive impairment, with 
significantly lower MMSE scores than the other groups both at study 
entry and at pre-death. In agreement with previous findings (Román et al., 
2002), cognitive impairment in SIVD was milder, with the reduction in 
MMSE reaching significance only at pre-death when compared with 
controls (Table 4.1). 
 
4.2.2.2 Aβ42, phosphorylated tau and total tau concentrations in 
controls, SIVD and MIX 
Biochemical markers of AD neuropathological features were obtained 
with measurements of Aβ42, the major component of neuritic plaques, as 
well as pS396 tau which, together with other hyperphosphorylated tau, 
form neurofibrillary tangles (Augustinack et al., 2002). Figure 4.1 shows 
that Aβ42 and pS396 tau concentrations were low in SIVD and not 
significantly different from controls, while MIX patients had significantly 
higher concentrations of both markers. Given that total tau levels were 
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similar in all groups (Figure 4.1), the observed changes in pS396 tau likely 
reflect increased tau phosphorylation in MIX. In agreement with previous 
studies (K.A. Jellinger, 2002), this  data suggest that plaque and tangle 
burden in SIVD is comparable to non-demented controls but becomes 











Figure 4.1 Concentrations of Aβ, phosphorylated and total tau in control 
and dementia neocortex Bar chart of Aβ42, pS396 tau and total tau 
concentrations (in ng / mL). Data are mean ± S.E.M. Available N values are as 
follows (controls, SIVD, and MIX): Aβ42 (14, 13, 7), pS396 tau (15, 14, 7), total 
tau (15, 14, 7). 
*Significantly different from control and SIVD (ANOVA with post hoc Tamhane, 





4.2.2.3 AMPA receptor subunit immunoreactivities and GluA2 mRNA 
levels in controls, SIVD and MIX(BA22) 
Immunoblotting of processed brain homogenates with both the anti-
GluA2/3/4 and the anti-GluA2 antibodies resulted in a reactive band of 
around 100 kDa. Figure 4.2 shows that immunoreactivities for both 
antibodies were increased in SIVD compared to controls, while MIX did 
not show significant alterations. In contrast, GluA1 levels were unchanged 
in SIVD and MIX (Figure 4.2). The immunoblot data was corroborated by 
GluA2 mRNA levels, which was significantly increased in SIVD but not in 
MIX (Figure 4.3). In order to study subcellular distribution of GluA 
subunits, immunoreactivities of membrane and cytoplasmic fractions of 
brain homogenates from control, SIVD and MIX (N = 3 per group) were 
compared. As shown in Figure 4.4, GluA2 and GluA2/3/4 
immunoreactivities are predominantly found in the membrane fraction, 






Figure 4.2 AMPA receptor subunit immunoreactivities in superior temporal cortex (BA22) of controls, VaD(SIVD) and MIX 
A, bar chart of GluA2/3/4 (AMPA receptor) and GluA2 immunoreactivities normalized to β-actin (in arbitrary units). Data are 
mean ± S.E.M. Available N values are controls = 15, SIVD = 16, MIX = 10; B, representative immunoblots of GluA1, GluA2, 
GluA2/3/4 and β-actin in controls (Ct), SIVD (V) and MIX (M). 










Figure 4.3 Levels of GluA2 mRNA in control and dementia 
neocortex(BA22) Bar chart of GluA2 mRNA levels normalized 
to β-actin (in arbitrary units). Data are mean ± S.E.M. Available 
N values are controls = 13, SIVD = 13, MIX = 6. 














Figure 4.4 Subcellular distribution of GluA subunits Representative 
blots of total (unfractionated homogenate), cytosolic and membrane-
enriched fractions of postmortem temporal cortex of Control, SIVD 
and MIX, which had available N = 3 per group with similar results. 
Confirmation of membrane and cytosolic enrichment was by 
immunoblotting with EGFR and GAPDH antibodies, respectively (see 




4.2.2.4 Correlations of AMPA receptor subunit immunoreactivities 
with cognitive impairment, Aβ42 and pS396 tau in dementia 
In order to investigate the correlations between GluA immunoreactivities, 
cognitive and biochemical variables in dementia, analyses were 
performed with SIVD / MIX as a combined group. Figure 4.5 shows that 
GluA2 immunoreactivity negatively correlated with Aβ42 and pS396 tau 
concentrations, while GluA2/3/4 positively correlated with pre-death 
MMSE. In contrast, GluA immunoreactivities did not correlate with any of 
the variables in controls (data not shown). 
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Figure 4.5: Correlations of AMPA receptor subunit immunoreactivities with cognitive impairment, Aβ42 and phosphorylated tau in dementia 
temporal cortex (BA22) 
Scatter plots and linearly regressed best-fit trend lines of GluA2 (top row), GluA2/3/4 (bottom row) immunoreactivities in all dementia (SIVD + MIX) subjects 
with pre-death Mini-Mental State Examination scores (N = 24), Aβ42 (N = 20) and pS396 tau (N = 21) concentrations. 





4.2.3 Discussion and conclusion  
Using postmortem tissues from a well-characterized cohort of dementia 
patients as well as non-demented controls, we report here that in contrast 
to the well-recognized decreases in GluA2 in AD (Carter et al., 2004; Gong 
et al., 2009; Ikonomovic et al., 1997) GluA2 immunoreactivities (as 
indicated by two primary antibodies) and mRNA levels are up-regulated 
in the neocortex of vascular dementia. These changes seem to be limited 
to GluA2, as immunoreactivities of GluA1, the other major AMPA receptor 
subunit, were unchanged (Figure 4.2). Furthermore, by limiting our study 
to a subtype of vascular dementia without extensive neocortical infarcts 
(SIVD) as well as focusing on the temporal cortex, a region of selective 
vulnerability to AD neurodegeneration (Arnold et al., 1991), we were able 
to show that the GluA2 upregulation appears to be absent in the presence 
of concomitant AD (i.e., mixed SIVD / AD). Several potentially significant 
implications may be gleaned from the study. 
 
4.2.3.1 Interpretation of data 
Although the precise mechanisms are unclear, our data indicate that 
increased GluA2 immunoreactivity in SIVD may be mediated by increased 
production or decreased breakdown of mRNA leading to increased gene 
expression (Figure 4.3). Recently, a proteomic study also observed a 
similar increase in AMPA receptor in the VaD compared to control (Datta 
et al., 2014). 
 
Previous studies has shown a decrease in the GluA2 mRNA in vulnerable 
region of  CA1 pyramidal neurons in animal models before delayed cell 
death  (Pellegrini-Giampietro et al., 1992; Pollard et al., 1993). This 
reduction  in GluA2 mRNA  leads to a change in the RNA editing 
mechanism (Peng et al., 2006), thus forming of new calcium-permeable 
GluA2 and allowing more AMPA receptor-mediated Ca2+ entry (Pellegrini-
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Giampietro et al., 1997). However, animal models showed reduced, rather 
than increased GluA2 expression two days after ischemia (Montori et al., 
2010) suggesting differences in gene regulation under ischemia in the 
acute stage versus longer term measures, or the involvement of vascular 
or other SIVD-specific factors. In our cohort, the SIVD group had higher 
pre-death cognitive scores than MIX, even though age and follow-up 
duration were matched between the groups (Table 4.1). The relatively 
mild cognitive impairments exhibited in SIVD has previously been 
observed (Román et al., 2002). Our current data suggest that this clinical 
feature of SIVD may be associated with GluA changes (see Figure 4.5) and 
may be an adaptive process, perhaps by reducing Ca2+ permeability, and 
thereby limiting its excitotoxic effects. In AD, GluA2 is well recognized to 
be reduced (Carter et al., 2004; Gong et al., 2009; Ikonomovic et al., 1997) 
although one recent study showed increased GluA2 in incipient stages of 
disease (Williams et al., 2009). This indicates that a similar adaptive 
process leading to increased GluA2 may occur in early AD, but becomes 
compromised as the disease progresses. Therefore, the relative 
preservation of GluA2 in MIX may be a manifestation of opposing disease 
processes on the brain (i.e., decreases due to AD process ameliorated by 
up-regulation due to the SIVD process). Taken together, the data from 
various studies including this one suggest that GluA2 alteration in 
dementia may be a complex, dynamic process which requires further 
investigation. 
 
In order to study potential relationships between GluA2 
immunoreactivities, cognitive impairment (as indicated by pre-death 
MMSE scores), Aβ42 and pS396 tau, we performed correlations between 
these variables in the combined group of patients consisting of both SIVD 
(which has relatively high MMSE and low Aβ42 / pS396) and MIX (with 
low MMSE and high Aβ42 / pS396). We found that GluA2 and GluA2/3/4 
immunoreactivities correlated positively with pre-death MMSE but 
negatively with Aβ42 / pS396, with trends reaching significance for 
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GluA2/3/4 with MMSE (Figure 4.5 top row) and for GluA2 with  Aβ42 / 
pS396 (Figure 4.5 bottom row). This suggests that upregulation of GluA2 
(and possibly GluA3/4, but not GluA1) receptors may be an adaptive 
plasticity process which leads to a relative attenuation of cognitive 
impairment in SIVD. On the other hand, GluA2-4 (in particular GluA2) 
may be vulnerable to putative toxic effects of Aβ42. Animal studies have 
shown that exposure to amyloidogenic Aβ42 leads to the loss of surface 
GluA2 expression as well as depression of AMPA receptor-mediated 
synaptic transmission (Hsieh et al., 2006; Liu et al., 2010), while loss of 
cyclin-dependent kinase 5 (cdk5)-mediated phosphorylation of δ-catenin 
results in an increase in GluA2 surface expression (Poore et al., 2010). 
Interestingly, cdk5 activity may be suppressed by secreted, non-
amyloidogenically processed APP (Han et al., 2005). Importantly, because 
the subcellular distribution of GluA immunoreactivities did not appear to 
be altered between groups and were enriched predominantly in 
membrane fractions (Figure 4.4), we hypothesize that GluA2 differences 
between SIVD and AD, which may be mediated via APP / Aβ42-related 
mechanisms, manifest as changes in levels of surface GluA2 expression. 
However, as only a small number of samples were available for 
subcellular fractionation studies, follow-up studies are needed to 
delineate GluA subunit-specific changes in surface versus intracellular 
pools in dementia, as well as to ascertain the physiological significance of 
the GluA alterations presently observed. 
 
4.2.3.2 Limitations of data 
As previously discussed, this study deliberately limited  to SIVD and to 
one neocortical area to avoid the substantial heterogeneity of infarct area 
and volume arising from multi-infarct dementia or other vascular 
dementia subtype, thus, the conclusions of this study are necessarily 
limited to SIVD and mixed SIVD / AD.  It would be of interest to follow up 
the current work with studies of carefully demarcated tissues from other 
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vascular dementias, so that neurochemical differences between infarct, 
penumbra and non-ischemic areas could be compared. Another limitation 
which is inherent in all postmortem studies is the correlational nature of 
the analyses. For example, because MIX individuals with severe disease 
invariably have high Aβ42 as well as pS396 tau levels corresponding with 
the high burden of neuritic plaques and neurofibrillary tangles, we were 
not able to dissect the relative effects of β-amyloid formation versus tau 
phosphorylation on GluA changes, and further cell- or animal-based 
studies are needed to delineate the relevant mechanisms. 
 
4.2.3.3 Conclusion 
In this study, it is found that GluA2, and possibly GluA3/4 AMPA receptor 
subunits, are differentially altered in postmortem temporal cortex of SIVD 
and mixed SIVD / AD (MIX). Specifically, GluA2 immunoreactivity and 
mRNA appears to be up-regulated in SIVD but not in MIX. Taken with the 
well-established findings of GluA2 reductions in AD, our data suggest that 
unchanged GluA2 levels in MIX may represent opposing disease 
processes. In support of this, we also showed that disease markers of AD 
(Aβ42 and pS396 tau) negatively correlated with GluA2 
immunoreactivities in SIVD / MIX. Furthermore, the milder cognitive 
impairments in our SIVD cohort may be mediated in part by up-regulated 
GluA2. In terms of rational pharmaco-therapeutic application, our study 
suggests that MIX, but not SIVD, may benefit from AMPA receptor agonist-





4.2.4 Status of ADAR2 levels in SIVD and MIX in superior 
temporal cortex (BA22) 
 
Previous results showing that GluA2 immunoreactivity negatively 
correlated with Aβ42 and pS396 tau concentrations, while GluA2/3/4 
positively correlated with pre-death MMSE shows that AMPA receptors in 
SIVD. To study further the upregulation of GluA2 in SIVD and not MIX, the 
levels of ADAR2, the enzyme responsible for the RNA editing of GluA2 was 
studied.  
 
4.2.4.1 Materials and methods 
In this study, the immunoreactivity of ADAR2(cat no: sc-33180, 
SantaCruz, dilution 1:500) was measured in the same cohort of 
postmortem temporal cortex(BA22) of longitudinally assessed cohort of 
SIVD and MIX as previously used, together with age-matched controls and 




The ADAR2 level was found to be increased significantly in SIVD but not 
in MIX (Figure 4.6A and B). When correlated with levels of GluA2, a 
positive correlation was observed. Higher ADAR2 correlated with higher 





Figure 4.6 ADAR2 immunoreactivities in the neocortex of controls, 
VaD (SIVD) and MIX(BA22). (A) Bar charts of ADAR2 normalised to β-
actin  , in arbitrary units, in controls, SIVD and MIX  (B) Representative 















 Figure 4.7:  Correlation of GluA2 receptor subunit 
immunoreactivities with ADAR2 in temporal cortex (BA22) of 
controls, VaD (SIVD) and MIX 
 Scatter plots and linearly regressed best-fit trend lines of GluA2 
with ADAR2. *Significant Spearman correlation 
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4.2.4.2 Discussion and conclusion 
In this study, we observed that the ADAR2 level was found to be increased 
significantly in SIVD but not in MIX (Figure 4.6A and B). When correlated 
with levels of GluA2, a positive correlation was observed. Higher ADAR2 
correlated with higher levels of GluA2(Figure 4.7). Most of the 
neurodegenerative disease resulted in a decrease in GluA2 levels such in 
ischemia and AD causing dysregulation of calcium homeostasis, thus this 
significant increase of GluA2 need to be studied.  It is tempting to suggest 
that the higher levels of GluA2 in SIVD leads to higher levels of ADAR2, 
which will increase the levels of RNA editing of GluA2 resulting in higher 
levels of calcium impermeable receptor. The reduction of calcium 
excitotoxicity may explain the mild cognitive dementia in SIVD.   However, 
since ADAR2 is responsible for the adenosine to inosine editing of other 
receptors other than GluA2, such as kainate receptors and other 
microRNAs.   Thus, the increase of ADAR2 may not solely act on GluA2 
and further work need to be done. Further work such as RNA editing 
assay, is required to study the increase in GluA2 and ADAR2 in SIVD.  
AMPA receptor can be calcium permeable because 1) GluA2-lacking or 2) 
they contained the unedited GluA2 (Q) subunit. Currently, the detection of 
the Ca2+ permeable AMPA receptor can be detected using the 1) calcium 
imaging or 2) electrophysiology. However calcium detected methods 
currently is not able to differentiate whether the receptors are GluA2-
lacking or unedited GluA2 containing as both are calcium permeable and 
exhibit inward rectification. At present, the unedited GluA2 can be 
identified by analysing RNA from specific cell or brain regions using one 
of these 3 methods.  
1. A “primer extension” assay (Schiffer and Heinemann, 1999; Bryce 
Vissel et al., 2001) 
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2. DNA sequencing (which measures the ratio of edited G nucleotide 
peak to unedited A nucleotide peak in total cDNA;  (Maas et al., 
2001) 
3. Restriction enzyme based assays, usually using the enzyme BbvI 
(Kawahara et al., 2004; Peng et al., 2006) 
The only way which is currently possible to infer the presence of a 
functional unedited GluA2 containing AMPA receptor is by using RNA 
editing assay together with electrophysiology.  Firstly, patch clamp 
electrophysiology is used on neurons to determine the presence of Ca2+ 
permeable AMPA receptor by studying calcium influx changes. Single cell 
PCR as well as various RNA editing assay is performed on RNA extracted 
from these neurons, which can then determine the percentage of the 
unedited and the edited GluA2 (Peng et al., 2006). If the RNA does not 
contain unedited GluA2, it is inferred that these calcium permeable 
receptors are GluA2-lacking. However, RNA editing assay is rarely carried 
out on calcium-permeable AMPA receptor but instead widely assumed 
that they are GluA2-lacking and not due to the presence of unedited 
GluA2. This is because GluA2 is almost 100% edited in the normal brain 
and unedited GluA2 is generally assumed to not play any significant role 
in normal brain function. However, it should be noted that there is much 
difficulty in detecting a single base change in human samples.  
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4.3 Status of the NMDA receptor subunits in the superior 
temporal cortex(BA22) of SIVD and MIX 
The postsynaptic, ionotropic N-methyl-D-aspartate (NMDA) receptors 
mediate critical synaptic processes in learning and memory (Hunt and 
Castillo, 2012), but excessive activation of NMDA receptors may disrupt 
receptor-mediated signaling and lead to intracellular Ca2+ overloading 
resulting in excitotoxicity (Cacabelos et al., 1999; Francis et al., 2012; 
Hynd et al., 2004a). Functional NMDA receptors in the adult brain are Na+, 
K+ and Ca2+ channels formed from heterotetrameric complexes of one 
obligatory GluN1 subunit and at least one of four GluN2 subunits (GluN2A 
– 2D) (Dingledine et al., 1999). In AD, GluN1 levels have consistently been 
reported to be reduced (Hynd et al., 2004b; Mishizen-Eberz et al., 2004; 
Sze et al., 2001; Tsang et al., 2007), while GluN2A and GluN2B deficits 
appear to be more variable with reports of GluN2A-only reduction (Tsang 
et al., 2008), GluN2B-only reduction (Mishizen-Eberz et al., 2004) or 
reduction in both subunits (Hynd et al., 2004c). Sze et al. (Sze et al., 2001) 
also reported regional differences in GluN2A and GluN2B deficits. In 
contrast, GluN2C and GluN2D appeared to be unchanged (Hynd et al., 
2004c). Taken together, these data suggest that perturbations of GluN1, 
GluN2A and GluN2B subunits may be involved in AD (Hynd et al., 2004a) 
In contrast, although frontal, but not temporal glutamatergic synapses (as 
labeled by vesicular glutamate transporter, VGLUT-1) appeared to be 
preserved in VaD (Kirvell et al., 2010), the state of the postsynaptic GluN 
receptors in SIVD and MixD is unclear. In this study, we measured the 
immunoreactivities of GluN1, GluN2A and GluN2B in the postmortem 
neocortex of a cohort of clinically assessed and neuropathologically 




4.3.1 MATERIALS AND METHODS 
4.3.1.1 Patients, clinical and neuropathological assessments  
This study comprised of a total of 42 subjects, consisting of 16 SIVD and 
10 MixD patients, together with 16 non-demented elderly controls from 
the Oxford Project to Investigate Memory and Ageing (OPTIMA, see 
http://www.medsci.ox.ac.uk/optima). The majority of subjects from the 
community-based OPTIMA cohort had been assessed annually using a 
cognitive assessment battery, including the Mini-Mental State 
Examination (MMSE, (Folstein et al., 1975), maximum score = 30), with 
the majority of cases followed till death (see Table 1), and pre-death 
MMSE scores were used as an indicator of severity of dementia. Autopsies 
were performed with informed consent from next-of-kin, and 
Institutional Review Board (IRB) approval from the UK and Singapore had 
been obtained for the study. For all subjects, tissue blocks from one 
hemisphere were dissected and fresh frozen, while the contralateral 
hemisphere was formalin fixed and processed for pathological 
assessment, which included the Consortium to Establish a Registry for 
Alzheimer’s disease (CERAD) criteria (Mirra et al., 1991)for the diagnosis 
of AD and Braak staging for assessing the extent of neurofibrillary tangle 
involvement (Braak and Braak, 1991). Vascular dementia was clinically 
diagnosed using NINDS-AIREN operationalized criteria 27, while 
neuropathological determination of SIVD was based on findings of 
microinfarcts, lacunes, white matter and small vessel disease in 
subcortical structures in the absence of large vessel involvement (Kalaria 
et al., 2004) and insufficient plaque pathology to meet CERAD diagnosis 
for AD. Cases were considered to be mixed SIVD / AD (MixD) only if 
criteria for SIVD were met in addition to a CERAD pathological diagnosis 
for AD. All control subjects died from non-neurological causes, had no 
history of dementia or psychiatric conditions, and did not meet 
neuropathological diagnostic criteria for neurodegenerative diseases. In 
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addition to the diagnostic assessments, semi-quantitative ratings of AD- 
(neuritic plaques and neurofibrillary tangles, rated 0 = “None”, 1 = 
“Sparse”, 2 = “Moderate”, 3 = “Frequent”) as well as SIVD- (lacunes, rated 
0 = “None”, 1 = “One”, 2 = “Multiple” and microinfarcts, rated 0 = “None”, 1 
= “Rare”, 2 = “Frequent”) related pathologies were performed by a senior 
neuropathologist (M.M.E.) blinded to diagnosis in appropriately stained 





Table 4.3 Demographic and disease variables in a cohort of control and 
dementia patients 
  
  Control SIVD MIX 
Demographics         
    Maximum number of cases  16 16 10 
    Age at Death (years)  80.5 ± 2 82.5 ± 2 78.4 ± 3 
    Sex (Male/Female) 11M / 4F 10M / 7F 5M / 5F 
    Follow-up (years) 3.9 ± 0.6 4.5 ± 0.7 4.6 ± 0.8 
    Postmortem Interval (hours) 52 ± 9 55 ± 8 33 ± 5 
Disease variables        
    Predeath MMSE score
1
    27.4  ± 0.8 20.6 ± 2.4* 2.6 ± 1.6** 
    Braak staging (N)                       0 
I-II 
III-IV 

















Data are mean ± S.E.M. MIX, mixed dementia (SIVD / Alzheimer’s disease); 
MMSE, Mini-Mental State Examination; N, number of cases; NFT, 
neurofibrillary tangle; NP, neuritic plague; SIVD, subcortical ischemic 
vascular dementia.  
1Predeath MMSE scores were available for 14 controls, 15 SIVD and 9 
MixD patients. 
*Significantly different from Control (ANOVA, F = 39.6 with post-hoc 
Bonferroni, p = 0.028) 
**Significantly different from Control and SIVD (ANOVA, F = 39.6 with 




4.3.1.2 Tissue processing   
All reagents used in this study were of analytical grade and from Sigma-
Aldrich Co. (USA) unless otherwise stated. Cubes of frozen superior 
temporal gyrus (BA22) around 1 cm3  were thawed on ice, dissected free 
of meninges, then homogenized at 50 mg tissue weight / mL in either ice-
cold 5M guanidine HCl / 50 mM Tris-HCl, pH 8.0 or lysis buffer (Cell 
Signalling Technology Inc., USA) with the addition of 2 mM 4-(2-
Aminoethyl) benzenesulfonyl fluoride hydrochloride (AEBSF) and 
Complete Mini™ protease inhibitor tablet (Roche Diagnostics, USA). 
Protein concentrations were measured using Coomassie Plus reagent 
(Pierce Biotechnology Inc., USA). Guanidine / Tris-HCl treated brain 
homogenates were stored frozen for enzyme-linked immunosorbent 
assay (ELISA) while lysis buffer-treated homogenates were then added to 
Laemmli sample buffer (Bio-Rad Laboratories, USA, 1:1 vol. /vol.) and 
boiled at 95-100 °C for 5 min for immunoblotting. Due to limited tissue 
availability, not all subjects were available for all assays, and respective N 
values will be listed for each assay. 
 
4.3.1.3 Immunoblotting 
Primary antibodies used in this study are rabbit polyclonals against 
GluN1 (expected molecular weight around 110 kDa), GluN2A (around 180 
kDa) and GluN2B (around 180 kDa), all from Merck Millipore (cat no: 
AB1516, AB1555, AB1557P respectively, Chemicon), USA. Prepared brain 
homogenates in sample buffer were electrophoretically separated on 10% 
polyacrylamide gels, transferred onto nitrocellulose membranes, and 
blocked in 10 mM phosphate buffered saline, pH 7.4 with 0.1% Tween 20 
and 5% skim milk (PBSTM) before immunoblotting in PBSTM overnight 
at 4°C with primary antibodies (all at 1:1000 dilution), followed by 
washings in PBST and incubating with appropriate horseradish 
peroxidase conjugated secondary antibodies (1:5000, Jackson 
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ImmunoResearch Inc., USA). Immunoreactive bands on the membranes 
were detected by enhanced chemiluminescence and quantified by an 
image analyzer (UVItec, UK). Membranes were stripped and reblotted 
with anti-β-actin for normalization of sample loading, and normalized 
immunoreactivities were expressed in arbitrary units. 
 
4.3.1.4 Statistical analyses  
All statistical analyses were performed using SPSS 21 for Windows 
software (IBM Inc., USA). Comparisons of variables between controls, 
SIVD and MixD groups were performed by one-way analyses of variance 
(ANOVA) followed by post-hoc Bonferroni tests. ANOVA was also used to 
investigate trends in changes of GluN immunoreactivities over 
neuropathologic scores. Results were considered statistically significant if 
p < 0.05.  
 
4.3.2 Results 
Status of NMDA receptor subunits in the superior temporal 
cortex(BA22) of SIVD and MIX 
4.3.2.1 Demographic and disease variables of controls, SIVD and MIX 
Table 4.2 lists the demographic and disease variables in the three groups. 
Age, post-mortem interval and follow-up duration were not significantly 
different among the groups (ANOVA with post-hoc Bonferroni, p > 0.05), 
while there was a higher proportion of males in the control and SIVD 
groups. However, none of the neurochemical measures were significantly 
different between males and females in either controls or SIVD, or 
correlated with other demographic factors such as age and postmortem 
delay (Pearson’s correlation p > 0.05, data not shown). Table 1 also shows 
the distribution of cognitive scores and Braak staging among the 
diagnostic groups. First, while the SIVD group had significantly lower pre-
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death MMSE scores than controls, the MixD group was found to have the 
most severe cognitive impairment, with MMSE scores lower than both 
control and SIVD groups (Table 1). This observation is in agreement with 
previous reports of milder cognitive impairment in SIVD compared to AD 
[2]. As expected, the majority of control and SIVD patients were Braak 
stages 0 – II, with none above stage III-IV, while all MixD patients were 
Braak stages V / VI due to the presence of AD (Table 1).   
 
4.3.2.2 Alterations of GluN immunoreactivities in SIVD and MIX 
Immunoblotting of brain homogenates with GluN1, GluN2A and GluN2B 
antibodies resulted in immunoreactive bands close to the respective 
expected molecular weights (Figure 4.8A). When normalized 
immunoreactivites were compared among the diagnostic groups, GluN1 
was selectively reduced only in MixD, while both GluN2A and GluN2B 
















Figure 4.8 NMDA receptor subunit immunoreactivities in temporal 
cortex (BA22) of controls, VaD(SIVD) and MIX 
 GluN subunit immunoreactivities in a cohort of aged controls and dementia 
patients. A, representative immunoblots of GluN1, GluN2A, GluN2B and β-
actin in controls, subcortical ischemic vascular dementia (SIVD) and mixed 
SIVD / AD (MixD) patients. B, bar charts of GluN subunit immunoreactivites 
(normalized to β-actin, in arbitrary units) of aged controls (N = 16), SIVD (N = 
16) and MixD (N = 10). Data are mean ± SEM.  
*Significantly different from controls (ANOVA, F = 3.68 with post-hoc 
Bonferroni, p = 0.03). 
**Significantly different from controls (ANOVA, F = 3.41 with post-hoc 
Bonferroni, p = 0.043). 
§Significantly different from controls (ANOVA, F = 3.67 with post-hoc 





4.3.2.3 Association of GluN subunit alterations with Braak staging and 
neuropathologic scores 
In order to study associations of GluN immunoreactivities with ordinal 
neuropathologic ratings, ANOVA analyses were performed to determine if 
trends of GluN changes are statistically significant across the range of 
scores. For AD-related pathology, higher Braak staging is associated with 
losses of GluN1 only (Figure 4.9A), while neurofibrillary tangle and 
neuritic plaque scores showed similar but non-significant trends (Figures 
4.9B and 4.9C). 
Neurovascular pathology such as microinfarct as well as lacunes are 
common features of SIVD. Lacunes are described 3 to 15 mm cavities 
filled with cerebrospinal fluid found in the basal ganglia or white matter 
(Wardlaw, 2008), while  microinfarct is defined as very small region (less 
than 1mm in size) of cell death and tissue necrosis (Smith et al., 2012). 
Both lacune and microinfarct has been found to affect cognitive function 
(Corrada et al., 2014; Tripathi et al., 2011). Thus, correlations of 
glutamatergic changes observed in SIVD and MIX with neurovascular 
pathology was done.  
 This study found that lacunar infarct scores associated with increased 
GluN2A and GluN2B, but not GluN1, immunoreactivities (Figure 4.10A); 
while microinfarct scores showed a similar but non-significant trend 
(Figure 4.10B). Taken together, these data suggest that GluN1 and 
GluN2A/2B changes are related respectively to AD and SIVD pathology, 
although certain scores (e.g., Braak staging and lacunar infarcts) seemed 







 Figure 4.9  Association of GluN subunit alterations with Alzheimer pathology Association of GluN subunit alterations with 
Alzheimer pathology. Bar charts of normalized GluN subunit immunoreactivities (in arbitrary units) over Braak stages (A) and 
semi-quantitative scores of neurofibrillary tangles (B) and neuritic plaques (C). Data are mean ± SEM. Available N are: 
neurofibrillary tangles “None” = 25, “Sparse / Moderate” = 8, “Severe” = 9; neuritic plaques “None” = 18, “Sparse / Moderate” = 14, 
“Severe” = 10. 





 Figure 4.10 Association of GluN subunit alterations with neurovascular pathologyAssociation of GluN subunit alterations 
with neurovascular pathology. Bar charts of normalized GluN subunit immunoreactivities (in arbitrary units) over semi-
quantitative scores of lacunes (A) and neuritic plaques (B). Data are mean ± SEM. Available N are: lacunes “None” = 29, 
“One” = 10, “Multiple” = 3; microinfarcts “None” = 18, “Rare” = 12, “Frequent” = 12. 
*Significant difference among groups by lacune rating (ANOVA, F = 3.34, p = 0.046). 






Status of NMDA receptor subunits in the superior temporal 
cortex(BA22) of SIVD and MIX 
In this first study of GluN subunits in subcortical ischemic vascular 
dementia (SIVD) and mixed SIVD and AD (MIX), we found a selective 
decrease of GluN1 immunoreactivity in MIX but increases of GluN2A and 
GluN2B in SIVD. These disease-specific changes in GluN receptor subunits 
suggest independent but interacting mechanisms underlying their 
alterations. In support of this, we also found that the GluN1 loss was 
associated with higher Braak staging, a measure of severity of Alzheimer 
pathology, while GluN2A and GluN2B increases were associated with 
higher counts of SIVD-related lacunar infarcts. Since a loss of GluN1 has 
been widely reported in AD (Hynd et al., 2004b; Mishizen-Eberz et al., 
2004; Sze et al., 2001; Tsang et al., 2007), the current finding of decreased 
GluN1 in MixD may likely be driven by an underlying Alzheimer’s disease 
process. As GluN1 is the obligate subunit in the assembly of NMDA 
receptors which are in turn critically involved in synaptic plasticity 
processes such as long term potentiation (LTP) (Hunt and Castillo, 2012), 
a loss of GluN1 may lead to impaired NMDA receptor function and 
contribute to the clinical features of MIX. Indeed, in SIVD where no 
significant losses of GluN1 was found (Figure 1B), the cognitive decline 
(as measured by predeath MMSE scores) was also relatively milder than 
MIX (Table 4.3). This suggests that GluN1 loss is a neurochemical marker 
of glutamatergic dysfunction in MixD, as is the case for AD. Importantly, 
our results also suggest the potential utility of memantine for MIX 
pharmacotherapy (Thomas and Grossberg, 2009), although further 
studies are needed to characterize GluN1 in the context of other 
neurochemical changes in MIX.  
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Interestingly, GluN2A and GluN2B were found to be increased in SIVD but 
unchanged in MIX (Figure 4.8), analogous to our previous findings of 
increased GluA2 (AMPA subtype of ionotropic glutamatergic receptors) 
subunits in SIVD and unchanged levels in MIX (Mohamed et al., 2011). 
Influx of Na+ via AMPA receptor channels is known to remove the Mg2+ 
block which initiates NMDA receptor depolarization and subsequent 
increases in excitatory postsynaptic potentials mediating LTP  (Calabresi 
et al., 1992). Therefore, when considered in toto, these data point to up-
regulation of both NMDA and AMPA components, perhaps reflecting an 
adaptive plasticity which was attempting to ameliorate GluN1-related 
deficits, although the precise underlying mechanisms are unclear. In 
MixD, the preserved levels of GluN2A / 2B may reflect an equilibrium 
state from two opposing processes (upregulation in SIVD vs. decreases in 
AD), although it is worth noting that GluN2A and GluN2B deficits may be 
brain region-dependent (see Introduction). Furthermore, to avoid 
substantial heterogeneity in both infarct area and volume arising from 
multi-infarct or other VaD subtypes, this study was purposely limited to 
SIVD. However, the status of GluN receptors in VaD remains largely 
unclear. Therefore, follow-up studies looking at more diverse regions in a 
range of VaD subtypes, as well as validation with quantitative 
immunohistochemical approaches, are warranted. Regions of particular 
interest include the entorhinal cortex, since the absence of tangle 
involvement in this region (Braak 0) is associated with the highest GluN1 
immunoreactivity in the temporal cortex (Figure 4.9).  
It is at present unclear how SIVD pathology, particularly lacunar infarcts, 
may be associated with neocortical GluN2A / GluN2B alterations. 
Subcortical lacunar infarcts have been known to adversely affect 
metabolism in the neocortex and correlate with cognitive impairment 
(Gold et al., 2005; Reed et al., 2004). It is conceivable that subcortical 
lacunes may significantly disrupt intracellular transport, leading to 
perturbations of neurotransmission which in turn alters receptor protein 
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expression. Disruption of neuronal function can also arise in a retrograde 
manner from white matter disease-related axonal interruptions. 
However, more work is needed to elucidate the molecular mechanisms 
underlying these changes.   
In conclusion, this study has found GluN receptor subunit-specific 
changes in MIX (decreased GluN1) and SIVD (increased GluN2A and 2B), 
likely reflecting the interaction of ischemic neurovascular and AD 
processes. This data points to the potential utility of therapeutics which 





4.4 Status of NMDA and AMPA receptor in prefrontal cortex 
(BA9) of SIVD and MIX 
 
To study whether the glutamatergic status is also affected in other parts 
of the brain other than the temporal region, similar immunoblotting of 
various NMDA and AMPA receptors were also performed in SIVD and MIX 
with age-matched controls post-mortem samples in prefrontal cortex 
(BA9). The prefrontal cortex is responsible in for executive function and is 
found to be affected in AD.  
 
4.4.1 Materials and Methods 
In this study, the immunoreactivity of GluN1,2A,2B and GluA2/3/4 was 
measured in the same cohort of postmortem pre-frontal cortex(BA9) of 
longitudinally assessed cohort of SIVD and MIX as previously used (Refer 
to Table 4.1 and 4.2).  
 
4.4.2 Results 
Status of NMDA and AMPA receptor in prefrontal cortex (BA9) 
of SIVD and MIX 
There is no significant NMDA and AMPA receptor change observed in the 
prefrontal cortex (BA9) (Figure 4.11) . This may suggest brain region 












Figure 4.11 NMDA and AMPA receptor subunit immunoreactivities in 
the prefrontal cortex (BA9) of controls, VaD (SIVD) and MIX. (A) Bar 
charts of GluN1, GluN2A, GluN2B and GluN3A normalised to β-actin , in 
arbitrary units, in controls, SIVD and MIX  (B)Representative blots of GluN1, 
GluN2A, GluN2B and GluN3A and also β-actin in controls, SIVD and MIX. (C)  
Representative immunoblots of AMPA and NMDA receptor in control, SIVD 
and MIX. Non- significant(NS) changes is observed between control and 




4.4.3 Discussion and Conclusion 
BA9 is the dorsolateral prefrontal cortex of the brain and serves as the 
highest cortical area responsible for regulation, motor planning and 
planning. Damage to dorsal frontal prefrontal cortex can lead to problems 
affecting executive memory and judgement (Gerhand, 1999). The 
prefrontal cortex has been observed to be affected  in AD;loss of 
functional connectivity (Grady et al., 2001) ; degeneration within the PFC 
with AD is observed in the inferior prefrontal cortex (Salat DH et al., 
2001); loss of VGLUT1 and VGLUT2 in the prefrontal cortex was found to 
be correlated with cognitive decline in AD (Kashani et al., 2008). In 
contrast , most of the GluA2 was found to be edited resulting in majority 
of the AMPA receptor channel calcium impermeable (Akbarian et al., 
1995). In vascular dementia, it was found that the prefrontal cortex, but 
not temporal glutamatergic synapses (as labelled by VGLUT1) was 
preserved in VaD(Kirvell et al., 2010).  
The preservation of NMDA and AMPA receptor subunits found in SIVD in 
this study is similar to that found by Kirvell et al, suggesting that it plays a 
role in sustaining cognition and protecting against dementia following a 
stroke. The preservation of ionotrophic glutamatergic receptors in MIX 
was unexpected as the prefrontal cortex was found to be affected in AD, 
suggesting that the neuropathological of concomitant VaD in MIX might 
underlie preservation of glutamatergic synapses in MIX.   The differential 
changes observed in different region of the brain suggest that SIVD and 
MIX affect different parts of the brain in differentially.   
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 4.5 Overall results and conclusions for Chapter 4 
Cerebrovascular-associated dementia  
Superior temporal cortex (BA22): Using a clinically well-characterized 
cohort of patients with SIVD and MIX, it was found that GluA2 
immunoreactivity and mRNA were up-regulated in SIVD, but remained 
unchanged in MIX. Furthermore, higher GluA2 immunoreactivity was 
associated with milder cognitive impairment and lower concentrations of 
Aβ42 peptide and phosphorylated tau. This suggests that GluA2 up-
regulation may be an adaptive process in SIVD, and that this process is 
repressed in the presence of concomitant AD in mixed dementia. There 
was a significant reduction of GluN1 only in MIX, while significant 
increases of GluN2A and GluN2B were found only in SIVD. Furthermore, 
GluN1 loss and GluN2A/2B upregulation was associated respectively with 
higher Braak stages and lacunar infarct scores. This suggest that the 
differential alterations of GluN subunits in SIVD and MIX may result from 
separate, interacting disease processes, and point to the potential utility 
of glutamatergic approaches for pharmacotherapy. 
Since the absence of tangle involvement is associated with highest GluN1 
immunoreactivity in the temporal cortex, it is worthwhile to study the 
entorhinal cortex to explore how neurofibrillary tangles affect GluN1.  
Dorsalateral prefrontal cortex(BA9): Using a clinically well-
characterized cohort of patients with SIVD and MIX, no significant 
changes is observed between controls and dementia groups.  BA9 is the 
dorsolateral prefrontal cortex of the brain and serves as the highest 
cortical area responsible for regulation, motor planning and planning. 
Damage to dorsal frontal prefrontal cortex can lead to problems affecting 
executive memory and judgement (Gerhand, 1999). The prefrontal cortex 
has been observed to be affected  in AD;loss of functional connectivity 
(Grady et al., 2001) ; degeneration within the PFC with AD is observed in 
the inferior PFC region (Salat DH et al., 2001); loss of VGLUT1 and 
180 
 
VGLUT2 in the prefrontal cortex was found to be correlated with 
cognitive decline in AD (Kashani et al., 2008). In contrast , most of the 
GluA2 was found to be edited resulting in majority of the AMPA receptor 
channel calcium impermeable (Akbarian et al., 1995). In vascular 
dementia, it was found that the prefrontal cortex, but not temporal 
glutamatergic synapses (as labelled by VGLUT1) was preserved in 
VaD(Kirvell et al., 2010).  
The preservation of NMDA and AMPA receptor subunits found in SIVD in 
this study is similar to that found by Kirvell et al, suggesting that it plays a 
role in sustaining cognition and protecting against dementia following a 
stroke. The preservation of ionotrophic glutamatergic receptors in MIX 
was unexpected as the prefrontal cortex was found to be affected in AD, 
suggesting that the neuropathological of concomitant VaD in MIX might 
underlie preservation of glutamatergic synapses in MIX.    The differential 
changes observed in different regions of the brain suggest that VaD affect 






General conclusion  
5.1 Summary of major findings  
In this thesis, the status of glutamatergic system, one of the most 
important neurotransmitter systems in the CNS, was studied in dementias 
other than the Alzheimer’s disease. Correlations of neuropathogical 
parameters with glutamatergic changes observed in VaD, MIX, PDD and 
DLB, provide useful information in these neurodegenerative diseases 
The status of the lewy body mediated dementia was discussed in Chapter 
3. In this study, we measured the various AMPA and NMDA receptor 
subunits levels in the post-mortem neocortex of a prospectively studied 
cohort of PDD and DLB, as well as age-matched controls by 
immunoblotting.  These measurements were carried out on 
parahippocampal gyrus region (BA36) and temporal (BA20) brain 
regions, it was found that in BA36, losses of GluA2/3/4 
immunoreactivities in Lewy Body dementias correlated with higher pre-
death Hoehn and Yahr scores and with longer Parkinson’s Disease 
duration before dementia onset, but not with dementia severity, cortical 
lewy body burden or amyloid plaque and neurofibrillary tangle burden. 
This suggests that loss of GluA2/3/4 losses may be a neurochemical 
marker of motor disability in Lewy body dementias. In contrast, no 
change was observed in the AMPA receptor status of in BA20. There are 
also no NMDA receptor changes observed in BA36 and BA20.   
 
Cerebrovascular–associated dementias was discussed in Chapter 4. In 
this study, we measured the various AMPA and NMDA receptor subunits 
levels in the post-mortem neocortex of a longitudinally assessed cohort of 
VaD (SIVD) and MIX, together with age-matched controls. These 
measurements were carried out on temporal (BA22) and frontal (BA9) 
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brain regions. In the temporal region, the GluA2 immunoreactivity and 
mRNA were up regulated in the SIVD, but remained unchanged in MIX. 
Higher GluA2 immunoreactivity was associated with milder cognitive 
impairment and lower concentrations of Aβ42 peptide and 
phosphorylated tau. Our study suggests that GluA2 upregulation may be 
an adaptive process in SIVD and the process is repressed in the presence 
of concomitant AD in mixed dementia. There was a significant reduction 
of GluN1 only in MIX, significant increases of GluN2A and GluN2B were 
found only in SIVD. Furthermore, GluN1 loss and GluN2A/GluN2B 
upregulation was associated with higher Braak stages and lacunar infarct 
score. In contrast, no AMPA and NMDA receptor change was observed in 
the BA9. These data suggest that the differential alterations of GluN 
subunits in SIVD and MIX may result from separate, interacting disease 
processes, and point to the potential utility of glutamatergic approaches 
for pharmacotherapy.  
These major findings are   summarised in Table 5.1 and have been 
discussed in various chapters. In the sections below, I will address the 
usefulness of using post-mortem tissue samples, the limitations of this 
study and the measures utilised to overcome them. Lastly, I will discuss 
the insight gained and provide suggestion for further studies.  
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GluA2 immunoreactivity and 
mRNA were up regulated in 
SIVD, but remained 
unchanged in MIX 
Higher GluA2 
immunoreactivity in SIVD 
was associated with milder 
cognitive impairment and 
lower concentrations of 
Aβ42 peptide and 
phosphorylated tau 
GluA2 upregulation may 
be an adaptive process 
in SIVD, and the process 
is repressed in the 
presence of concomitant 
AD in mixed dementia 
NMDAR 
Significant reduction of 
GluN1 only in MIX, significant 
increases of GluN2A and 
GluN2B in SIVD 
GluN1 loss and 
GluN2A/GluN2B upregulation 
associated with higher braak 
stages and lacunar infarct score 
respectively 
Differential alteractions 
of GluN subunits in SIVD 











Down regulation of 
GluA2/3/4 
immunoreactivities in LBD 
Lower GluA2/3/4 
immunoreactivities in LDB 
correlated with higher 
predeath Hoehn and Yahr 
scores and with longer 
Parkinson disease duration 
before dementia onset, but 
not with dementia severity, 
cortical lewy body burden or 
amyloid plaque and 
neurofibrillary tangle 
burden  
GluA2/3/4 losses may 
be a neurochemical 
marker of motor 
disability in LBD 





Table 5.1  A summary of the results obtained from thesis work  
Abbreviation: BA22,brodmann22(superior temporal cortex); BA9;brodmann9(prefrontal cortex); 
BA36(parahippocampal gyrus); BA20,Brodmann20(inferior temporal cortex) 
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5.2 Usefulness of using post-mortem tissue this study 
To understand any disease pathogenesis better, it is important to study 
the RNA and protein expression of the normal and diseased state.  In 
order to understand the brain changes towards the end of life of dementia 
patients, the usage of the human post mortem tissue in research is 
essential. Improvements in proteomic as well as genomics techniques 
through the years allowed such usage of human autopsy tissue in 
neurobiology studies. Doubts regarding the biochemical, molecular and 
structural integrity of the  post mortem delay were addressed by those  
who found that neither post-mortem interval nor the time in storage has 
been found to affect the integrity of the autopsy tissue (Barton et al., 
1993; Leonard et al., 1993). In this study, to control for sample selection 
biasness, all available samples were used at the time of the study with no 
selection bias for dementia severity, Braak stages or neuropsychiatric 
status. The studies are also carried out blinded to the clinical information. 
 
5.3 Limitations in the study and measures taken 
However, the usage of post mortem in research study comes with their 
inherent set of limitations.  
Post-mortem artefact All post mortem brain samples which was used 
have an average age of death of 80 years at the time of death, therefore 
the data obtained in this study is applicable only to the late stage of the 
diseases. Confounding factors such as post-mortem delay, agonal state 
(Barton et al., 1993) of the patients, tissue preparation and medication 
may affect the data.  Measures to control these include using age-matched 
controls and studying the effects of these confounding factors (if any) 
using statistical tools.  Effort is also made during tissue preparation and 
storage to maximise the post mortem yield of nucleic acids and proteins 
ante-mortem period.  
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Cohort effects  The post mortem brain samples used in the different 
studies were from the same cohort (SIVD/MIX are from OPTIMA cohort, 
and the LBD patients are Stavanger community cohort or the UK 
Dementia Case Register series, Newcastle upon Tyne) which will reduce 
the variability from study to study . That being said, this also means the 
generalisability of this data to other populations is limited.  Finally, due to 
tissue shortage, only a limited number of assays could be performed 
Correlation versus causation Data obtained in this study correlates the 
glutamatergic status of the diseased patients and with neuropathological 
presentation such as cognitive score. These correlations do not provide 
evidence for causation. In vivo animal model studies will be necessary to 
prove receptor changes lead to disease.  
 
5.4 Insights into my findings 
My findings provided insight to the glutamatergic status of other 
dementias other than widely studied AD, such as SIVD, MIX, PDD and DLB. 
These dementias are increasingly diagnosed in the elderly and more 
research is needed so as to provide information for the development of 
potential therapeutic drugs  
Lewy body dementia (Chapter 3) 
In this study, using a clinically well-characterized cohort of patients with 
Lewy body dementias (DLB and PDD), it was reported that moderate 
losses of AMPA receptor GluA2/3/4 subunits in parahippocampal gyrus 
region (BA36) correlated with pre-death Hoehn and Yahr scores and PD 
to dementia interval.  In this cohort, GluA2/3/4 immunoreactivities did 
not correlate with pre-death MMSE scores or cortical LB scores; and also 
did not seem to be affected by senile plaque or neurofibrillary tangle 
burden (though it maybe because of a small cohort). This suggests that 
GluA subunit changes in LBD which may lead to corticostriatal dopamine–
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glutamate imbalances may be a neurochemical marker of severity or 
chronicity of parkinsonism. This findings also suggest that although 
clinically defined PDD and DLB are two aspects of the same entity (LBD) 
and share similar brain changes (e.g., GluA deficits), PDD appears to be 
characterized by higher GluA2/ 3/4 losses, and also manifests more 
severe motor disability and longer duration of parkinsonism.  This data 
suggest both caution in extending such PD therapeutic rationales such as 
AMPA receptor antagonist (levodopa-induced dyskinesia) to LBD in view 
of altered levels of receptor drug targets. Further studies to elucidate the 
relationships between Parkinsonism, dementia and GluA neurochemical 
alterations are needed.  
No significant glutamatergic changes were observed in PDD and DLB in 
the inferior temporal cortex (BA20) unlike those observed in the 
parahippocampal gyrus (BA 36) suggesting differential glutamatergic 
changes in the same temporal region of the brain. More studies is needed 
to provide an explanation for these findings. 
The NMDA receptor was also found not affected in both the 
parahippocampal gyrus (BA36) and temporal region (BA20), but further 
work which includes increasing sample size, is needed to study these 
results  
 
Cerebrovascular-associated dementia (Chapter 4) 
The upregulation of GluA2 in the temporal cortex (BA22) of SIVD and not 
MIX may be a result of increased production or decreased breakdown of 
the mRNA. Previous studies has shown a decrease in the GluA2 mRNA in 
vulnerable region of  CA1 pyramidal neurons in animal models before 
delayed cell death  (Pellegrini-Giampietro et al., 1992; Pollard et al., 
1993). This reduction  in GluA2 mRNA  leads to a change in the RNA 
editing mechanism (Peng et al., 2006), thus forming new calcium-
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permeable GluA2 and allowing more AMPA receptor-mediated Ca2+ entry 
(Pellegrini-Giampietro et al., 1997). Animal studies have shown a 
decrease in GluA2 expression rather than increase two days after 
ischemia (Montori et al., 2010) suggesting that a difference in gene 
regulation in acute and long-term phases or the involvement of other 
SIVD factors. Our current data suggest that this clinical feature of SIVD 
may be associated with GluA changes and also be an adaptive process, 
perhaps by reducing Ca2+ permeability, and thereby limiting its 
excitotoxic effects, thus resulting in relatively mild cognitive impairment. 
This upregulation of GluA2 may be ameliorated in MIX due presence of 
AD pathology. In AD, GluA2 is well recognized to be reduced (Carter et al., 
2004; Gong et al., 2009; Ikonomovic et al., 1997) although one recent 
study showed an increase of GluA2 at incipient stages of disease 
(Williams et al., 2009). This indicates that a similar adaptive process 
leading to increased GluA2 may occur in early AD, but becomes 
compromised as the disease progresses. Therefore, the relative 
preservation of GluA2 in MIX may be a manifestation of opposing disease 
processes on the brain (i.e., decreases due to AD process ameliorated by 
up-regulation due to the SIVD process). Animal studies also have shown 
that exposure to amyloidogenic Aβ42 leads to the loss of surface GluA2 
expression as well as depression of AMPA receptor-mediated synaptic 
transmission (Hsieh et al., 2006; Liu et al., 2010). Taken together, the data 
from various studies including this one suggest that GluA2 alteration in 
dementia to be a complex, dynamic process which requires further 
investigation. 
The GluN1 subunit, of the NMDA receptor was found to be significantly 
increased in the MIX and not SIVD. This reduction of GluN1 correlated to 
worsening cognitive score which suggest an AD driven process which may 
underlie memory and learning impairment in MIX.  NMDA receptor 
reduction is well-recognized in AD (Bi and Sze, 2002; Hynd et al., 2004a; 
Sze et al., 2001; Ulas and Cotman, 1997). 
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GluN1 is expressed in abundance in the ER and will be degraded if not 
assembled with GluN2 subunits to form functional NMDA receptor. The 
presence of GluN1 is also required for the trafficking of NMDA receptor 
out of the ER.  A reduction of GluN1 in MIX, thus, can mean there are 
fewer functional NMDA receptors to participate in the generation of long 
term potentiation and synaptic plasticity. These findings may suggest that 
care should be excised in treating SIVD and SIVD/MIX patients. While 
AMPA and NMDA agonist maybe beneficial to MIX, it may not be the case 
for the SIVD.  
Futhermore, GluN1 loss and GluN2A/GluN2B upregulation was associated 
respectively with higher Braak stages and lacunar infarct score. These 
interesting findings of AMPA and NMDA receptor changes was however 
not found in the frontal cortex (BA9) suggesting brain specific 
glutamatergic changes.  This was not expected in MIX as the frontal cortex 
is known to be affected in AD. The differential changes observed in 
different region of the brain suggest that VaD affect different parts of the 
brain in differentially.  Further work should be done to explore these 
results. This includes increasing the sample size.  
 
5.5 Further studies 
Lewy body dementias (Chapter 3)  
The number of patients used in cohort was quite small with narrow range 
of cortical LB scores and is limited to two brain region (BA36 and BA20). 
To understand better and give further insight to the pathogenesis of LBD, 
further studies should include larger cohort as well as multiple brain 
regions. More comprehensive motor disability measurements should  
used such as the Parkinson’s Disease Rating Scale (Goetz et al., 2007) to 
provide better accuracy and sensitivity to the clinico-neurochemical 
correlations.  It will also be interesting to compare the glutamatergic 
status of LBD with non-demented PD. To understand the mechanism of 
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the down regulation of the GluA2 in LBD, in vivo animals  model such as 
the 26S proteasome knock-out mouse model (Tag) which has features of 
Dementia with Lewy bodies (Bedford et al., 2008a) can be used. These 
models may be able to explain the correlation of GluA2 down regulation 
with worsening motor dysfunction. The GluA2 levels (mRNA and 
protein)of these models can measured and correlated with the 
measurement of AMPA receptor-mediated rise in cytoplasmic free Ca2+ 
level (eg. by using optical imaging with the Ca indicator dye fura-2 and by 
intracellular recording) together severity of motor dysfunction of the 
mice. 
Cerebrovascular-associated dementia (Chapter 4) 
 In this study, the cohort was limited to SIVD and SIVD/AD patients and 
also two brain regions (BA9 and BA22). To understand better the 
pathogenesis of the diseases, follow-up studies should include other types 
of vascular dementia and other brain regions. It is of interest to perform 
this as vascular dementia is a heterogeneous disease, affecting different 
parts of the brain differentially depending on the location of lesions. To 
further study the mechanism of observed increase of GluA2, in vivo 
animal models of the diseased should be used such as SIVD model (Ihara 
and Tomimoto, 2011) and MIX model.  
To induce SIVD in rats, some groups often use a model of transient 
ligation of the bilateral common carotid arteries (BCCAs). This is not 
applicable to the transgenic or knockout mice due to poor development of 
the circle of Willis in C57BL/6 strains (Yang et al., 1997). Further 
development resulted in development of a mouse model stenosis of the 
BCCA using micro coils, which also resulted in the both white matter 
rarefaction and delayed memory impairment. These micro coils allows 
varying degree of stenosis by adjusting the internal diameter of the micro 
coils (Shibata et al., 2007, 2004). rUCCAO model  is a recent advancement 
in SIVD model which is simpler and more convenient with low mortality 
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rate which can induce WM impairment and nonspatial memory in 
C57BL/6 (Yoshizaki et al., 2008) It is also found that the rUCCAO mice 
showed a significant damage in learning and memory which is evaluated 
by the passive avoidance task as well as the Morris water maze (Ma et al., 
2012) reflecting fear memory and spatial working memory. 
The use of such animal model will allow us to investigate further the 
AMPA receptor changes observed in the various neurodegenerative 
diseases. Currently, the findings of my thesis do not lead to the causation 
of the disease. Animal models have the capacity to show that GluA2 
upregulation may be an adaptive process in SIVD, and the process is 
repressed in the presence of concomitant AD in mixed dementia. The 
GluA2 levels (mRNA and protein) as well as the RNA editing levels of the 
SIVD and MIX model can measured and correlated with the measurement 
of AMPA receptor-mediated rise in cytoplasmic free Ca2+ level (eg. by 
using optical imaging with the Ca indicator dye fura-2 and by intracellular 
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